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ACQUIRED DEMYELINATING SYNDROMES OF THE 
CENTRAL NERVOUS SYSTEM 
Acquired demyelinating syndromes (ADS) of the central nervous system (CNS) include a broad 
spectrum of phenotypes and are mainly classified by the clinical localization of symptoms and 
signs. Neurological deficits are caused by inflammation and the subsequent damage to the 
myelin sheet 1,2 A first attack of ADS may occur as a transient illness or may represent the 
first attack of a chronic demyelinating disorder, such as multiple sclerosis (MS).3 In earlier 
years, ADS patients were diagnosed with MS when they had a relapsing disease course during 
follow-up. However, due to the ongoing elucidation of the ADS spectrum, it became clear that 
not all patients with relapsing disease have MS. This clarification has important therapeutic 
implications. 
The ADS spectrum includes patients with a monophasic disease course, such as clinically 
isolated syndromes (CIS) with monofocal (single) or polyfocal (multiple) localizations, 
monophasic neuromyelitis optica spectrum disorders (NMOSD) and acute disseminated 
encephalomyelitis (ADEM). 1,2,4 Yet, the ADS spectrum also includes relapsing (and chronic) 
variants of ADS, such as MS, multiphasic ADEM (MDEM), ADEM followed by recurrent optic 
neuritis (ADEM-ON) and relapsing NMOSD. 3–6
The term ‘ADS’ has been introduced to cover the overlapping presenting phenotypes of 
these demyelinating syndromes. For example, optic neuritis (ON) can be a monophasic 
event (idiopathic ON) but can also be the first presentation of MS, NMOSD, recurrent ON, or 
even in context of other autoimmune diseases with CNS involvement.7 One can envision that 
at incident presentation, distinction between monophasic and relapsing syndromes can be 
challenging despite a detailed patient history, neurological examination and additional relevant 
diagnostic tools. However, accurate and early distinction between ADS subtypes is of utmost 
importance for counselling and prognosis, and also for initiation of appropriate treatment in 
chronic demyelinating disorders. Moreover, accurate identification of monophasic patients may 
prevent overtreatment and therewith the potential side effects of immunomodulatory drugs. 
ACQUIRED DEMYELINATING SYNDROMES IN CHILDHOOD
What are childhood-onset acquired demyelinating syndromes?
Acquired demyelinating syndromes in childhood are a rare group of disorders which can 
overlap in presenting phenotypes, as explained in the first paragraph of this chapter. At first 
presentation, the diagnostic process of these rare disorders can be challenging, as physicians 
are often dependent on the medical history by the caregivers because of the young age of the 
patient. A medical delay is not uncommon in this group. The National Pediatric MS center has 
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its outpatient clinic in the pediatric hospital of Erasmus MC-Sophia, where we try to assess 
patients as soon as possible after the first attack. This is made possible by the participation 
of pediatric neurologists and pediatricians in our national prospective study for children with 
ADS. The main goal of this study is to predict the outcome of a first demyelinating syndrome 
(PROUD-kids study). 
The diagnostic work-up consists of a carefully taken history of the patient and caregivers, 
neurological examination, magnetic resonance imaging (MRI) scans of the brain (and spinal 
cord), cerebrospinal fluid analysis (CSF) and blood analysis. Due to the overlap in clinical and 
radiological phenotypes, additional biomarkers are needed to shorten the time to accurate 
diagnosis and therefore also shorten the time that parents and patients are being kept in 
uncertainty. Considering several subtypes of ADS have life-long therapeutic implications, 
adequate counselling and initiating treatment in the right group of patients is highly important. 
The first presentation of ADS in children encompasses a wider spectrum than in adults and 
includes a more extensive list of differential diagnoses, which makes the diagnostic process 
even more difficult.8 The international pediatric MS study group proposed diagnostic criteria for 
ADS in children in 2007, and revised these in 2012, to aid the diagnostic process.9 
The first attack of demyelination can be a monofocal or polyfocal presentation with and 
without encephalopathy. Every subtype can potentially be a first attack of an underlying 
chronic demyelinating syndrome such as MS. Up to one-third of ADS patients will eventually 
be diagnosed with MS during follow-up.1,2,10 These estimates differ between studies because 
of different study designs. The same variation is found in incidence estimates of ADS, varying 
between 0.66 to 1.66 per 100.000 persons due to study designs.1,2,10–12 Our previous work reported 
on the distribution of the clinical ADS phenotypes of Dutch patients, including polyfocal ADS 
without encephalopathy (ADEM, 30%), polyfocal ADS without encephalopathy (24%), ON (22%) 
and other monofocal ADS (19%).10 
Clinically isolated syndromes (CIS) are a first episode of demyelination and can be monofocal 
or polyfocal without encephalopathy.9 Examples of monofocal CIS are ON, transverse myelitis 
(TM), brainstem or cerebellar syndromes and CIS with hemispherical symptoms. 
Acute disseminated encephalomyelitis (ADEM) is a relatively common subtype of ADS, where 
patients have a polyfocal presentation and encephalopathy.13 Encephalopathy is defined as 
behavioral changes and altered consciousness which cannot be explained by fever, and is a 
feature not typically seen in MS.1,9 ADEM is usually considered as a monophasic and benign 
illness that occurs mainly in young children with preceding infections.5,13,14 However, the 
presentation of ADEM can be severe, leading to ICU admissions and sometimes death.13 The 
MRI can show bilateral large hazy and poorly demarcated T2 hyperintense lesions in both the 
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white and the grey matter (cortical grey matter and deep gray matter like the basal ganglia 
and thalami).15 The proportion of patients with relapsing disease after a first attack varies from 
6-25%.10 13,14,16,17 The relapsing disease can still be transient, like in multiphasic ADEM (MDEM), 
but can also be a chronic disorder such as MS, NMOSD or ADEM-ON.6 Early distinction between 
patients who remain monophasic and who will relapse is important for counselling and  follow-
up. 
Pediatric onset NMOSD accounts for 3-5% of all NMOSD cases with a mean age of 10 years old. 
10,18 The proposed international criteria for adult NMOSD apply well in children with NMOSD 
and aid in quickly initiating immunosuppressive drugs with as little delay as possible.4,19 The 
presentation can be diverse, including an ADEM-like presentation, and more often includes 
intracerebral lesions than in adult patients.18–21 Therefore NMOSD antibody testing in patients 
with an ADEM-like presentation with (simultaneous) ON and spinal cord involvement should be 
considered. NMOSD will be discussed in more detail later in this chapter.
MS in childhood
Up to 10% of all MS patients have the first symptoms before age 18.22 Pediatric onset MS has 
a relapsing remitting disease course in about 97% of the cases; an initial progressive disease 
course is extremely rare and should raise a red flag prompting for extensive assessment for 
other diagnosis.23,24 
How is childhood-onset MS diagnosed?
Prognostic factors for MS diagnosis in childhood are age at onset >11 years, female gender, 
clinical presentation without encephalopathy, unique oligoclonal bands in cerebrospinal fluid 
(CSF), and MRI abnormalities.15,25,26 In children, the presence of T1 hypointense lesions together 
with periventricular lesions on baseline MRI are highly predictive for future MS diagnosis in 
children.15,27 Despite these predictive factors, physicians are at times unable to provide enough 
clarity on the diagnosis at time of first attack. Prediction of the subsequent course is even more 
difficult. Therefore the search for additional predictive biomarkers is necessary. 
As in adults, children with a first event of CNS demyelination may be diagnosed with MS, if 
clinical or radiological evidence is present of dissemination in time (DIT) and space (DIS).9,28 
MS diagnosis can only be established ‘per exclusionem’, so alternative diagnoses need to be 
excluded first. The differential diagnosis of pediatric MS includes CNS infection, neoplasm, 
leukodystrophy, and systemic inflammatory diseases.8 The McDonald 2010 criteria gave adult 
physicians the ability to establish MS diagnosis at time of a first attack of demyelination.29 
MRI abnormalities in MS patients typically show periventricular, juxtacortical, infratentorial, 
and spinal cord T2 weighted lesions.29 Examples of the MS predilection sites are shown in 
Figure 1.1. 
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Figure 1.1: MRI predilection sites for multiple sclerosis
Figure 1.1A: periventricular lesions, typically perpendicular on the corpus callosum. Figure 1.1B: 
extensive infratentorial lesions (midbrain/pons and right cerebellum). Figure 1.1C: a typical juxtacortical 
‘U-fiber’ lesion in the left parietal lobe. Figure 1.1D: cervical spinal cord lesion with a typical oval 
configuration.
Applicability of the adult 2010 criteria in children was supported by several studies.30–34 The 
International Pediatric MS study group (IPMSSG) implemented the McDonald 2010 criteria in 
the international consensus diagnostic criteria for pediatric MS, with provisions for children 
<12 years and patients with ADEM.9 
Recently, the international panel on diagnosis of MS proposed the McDonald 2017 criteria, after 
revision of the prior 2010 McDonald criteria. 29,35 These revised criteria include modifications 
to make the criteria easier to apply and to facilitate earlier MS diagnosis, while attempting 
to preserve the diagnostic accuracy of the criteria. Important modifications included re-
introducing CSF oligoclonal bands (OCB) into the criteria and allowing symptomatic lesions 
to contribute to DIS and DIT.3,35 Furthermore, cortical lesions have been added to demonstrate 
DIS. The performance of the McDonald 2017 criteria need to be validated in clinical practice. 
The McDonald 2010 and revised McDonald 2017 criteria are displayed in Table 1.1. 
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Table 1.1: McDonald 2010 and McDonald 2017 criteria
McDonald 2010 criteria Revised McDonald 2017 criteria
DIS Clinical
a) Objective clinical evidence of ≥2 lesions, or 
objective clinical evidence of 1 lesion with reasonable 
historical evidence of a prior attack involving a 
different CNS site
Clinical
a) Objective clinical evidence of ≥2 lesions, or 
objective clinical evidence of 1 lesion with reasonable 
historical evidence of a prior attack involving a 
different CNS site
MRI 
b) ≥ 1 T2 lesion in at least 2 out of 4 typical 
regions: periventricular lesion, juxtacortical lesion, 
infratentorial lesion, spinal cord lesion.
(symptomatic brain stem syndromes or spinal cord 
lesions are excluded)
MRI 
b) ≥ 1 T2 lesion in at least 2 out of 4 typical regions: 
periventricular lesion, juxtacortical and/or cortical 
lesion, infratentorial lesion, spinal cord lesion.
(brain stem syndromes or spinal cord lesions are 
included irrespective of clinical symptoms)
DIT Clinical
a) ≥2 attacks separated by a period of at least month
Clinical 
a) ≥2 attacks separated by a period of at least month
MRI 
b) Simultaneous presence of gadolinium-enhancing 
and non-enhancing lesions at any time
c) A new T2 and/or gadolinium-enhancing lesion 
on follow-up MRI, irrespective of its timing with 
reference to a baseline scan
(symptomatic brain stem syndromes or spinal cord 
lesions are excluded)
MRI 
b) Simultaneous presence of gadolinium-enhancing 
and non-enhancing lesions at any time
c) A new T2 and/or gadolinium-enhancing lesion 
on follow-up MRI, irrespective of its timing with 
reference to a baseline scan
OR
d) Demonstration of CSF-specific OCBs (as 
substitute for demonstration of DIT)
(brain stem syndromes or spinal cord lesions are 
included irrespective of clinical symptoms)
Overview of the McDonald 2010 and revised 2017 diagnostic criteria for DIS and DIT. Based on the 2017 
revisions to the McDonald 2010 criteria.35 DIS = dissemination in space, DIT = dissemination in time, OCB 
= oligoclonal bands. Changes compared to the 2010 criteria are made bold. 
What are the disease course and outcome of pediatric MS? 
Although pediatric onset relapsing remitting MS (RRMS) resembles adult-onset RRMS in 
clinical symptoms, a few differences in features of the disease in children should be noted: 
Children have a more inflammatory disease course than adults as observed in the higher 
annualized relapse rate (2–3 times more frequent and more severe relapses than adults early 
in the disease course) and a higher MRI lesion burden at baseline.36,37 Notably, a high proportion 
of children with a future MS diagnosis has T1 hypointense lesions on baseline MRI.15 In addition, 
pediatric onset MS patients show a reduced head and brain size for age, have disproportionally 
smaller thalami, and fail to reach their age-expected brain growth over serial MRI scans.38,39 
These data imply the presence of a prominent neurodegenerative aspect in pediatric onset 
MS, but additional exploration is needed.38 One biomarker of interest for axonal damage is 
neurofilament light chain (NfL).40 NfL can be tested in CSF and serum, but are not explored 
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earlier in pediatric ADS. In contrast to the implications of axonal damage, compensatory 
mechanisms seem to play a role considering the overall well recovery of relapses, and the 
delayed progression to secondary progressive MS.41–44
Considering pediatric MS manifests in the key formative years of education and brain 
maturation, cognitive function cannot be neglected. While knowing that children have a more 
inflammatory disease than adults and have signs of neurodegeneration early in the disease 
course, this population is at risk of cognitive and physical sequelae. Significant cognitive 
deficits are detected in approximately 30% of the children early in the disease course, but the 
outcome is heterogeneous.45–47 Also fatigue is a disabling complaint that is frequently reported 
by pediatric and adult patients with MS, and is associated with a reduced quality of life.48–50 The 
cause of fatigue in MS remains unclear. In a Canadian study, pediatric MS patients were less 
physically active and scored higher on fatigue scales than patients with monophasic ADS.51 One 
hypothesis is that due to fatigue, patients become less physically active and this may lead to 
decreased exercise capacity. On top of this, accrual of motor disabilities can also affect motor 
performance. The Expanded Disability Status Scale (EDSS), which was designed for adult 
patients, is widely used to evaluate disease severity and monitor disease progression.52 Despite 
the longer disease duration in pediatric patients to the secondary progressive disease phase 
of MS, these patients will reach disability milestones at younger ages than their adult-onset 
counterparts.42–44 Whether EDSS is an optimal metric to determine disabilities in the daily life 
of these children and whether there is a correlation between fatigue, exercise capacity, motor 
performance and quality of life are yet to be investigated. 
What are risk factors for pediatric MS? 
MS has been identified as a complex and multifactorial auto-inflammatory disease, with 
involvement of genetic susceptibility and environmental exposure.53 However the exact cause 
is unknown. 
The greatest contribution to genetic risk in both children and adults is conferred by HLA-
DRB1*15 allele.54 In addition, in large-scale genome wide association studies, up to 200 non-
HLA MS risk loci, which are mainly located in genes with immunological functions, are identified 
that increase MS susceptibility.55,56 In children, 57 of these risk loci have been validated to 
contribute to MS risk in pediatric patients.57 
Migration studies have shown that children who were born in high MS prevalence countries and 
who migrated to countries with low MS prevalence before age 15, adapt to the low risk of the 
country where they live.58–60 For example, if a 13-year old child born in The Netherlands (with 
high prevalence of MS) moves to Africa (with low prevalence of MS), the child will have a low 
risk of MS adapting to the African population. On the contrary, if the child migrates at age 17, 
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the child will keep the risk of the country of origin (in this case the high Dutch risk of MS). The 
place of residence during childhood, rather than ancestry, influences MS risk.61 This supports 
the hypothesis that exposure to environmental risk factors for MS occur for the most part 
before age 15.60 As such, studying risk factors in pediatric MS during the putative window of 
disease susceptibility is highly relevant, considering the shorter time between time of exposure 
and time of disease onset compared to adults. This hypothesis is displayed in Figure 1.2. 
Whether these risk factors purely play a role in immune mechanisms, or whether they also 
influence the target tissue (brain and spinal cord) to become more vulnerable to damage and 
have reduced repair possibilities, remains unknown. 
Figure 1.2: Putative window of disease susceptibility and the age of onset. 
As indicated before, MS patients have a genetic susceptibility but environmental risk factors also convey 
a risk, leading to disease onset. The time from exposure to risk factors and disease onset is shorter in 
childhood onset MS than in adult onset MS. Therefore the chances to identify these pivotal environmental 
factor are better in patients with childhood onset than in patients with adult onset.
Several environmental risk factors are identified. Epidemiological studies have shown a 
relationship between latitude and MS prevalence, and low vitamin D has been shown as a risk 
factor for MS in children 25,59,62,63 and increased risk of relapses.25,64 An increased BMI is also 
associated with a higher MS risk.65–67 Recently a causal and independent association between 
low serum vitamin D concentration, increased BMI and increased risk of pediatric MS is 
reported, after adjusting for sex, ancestry and HLA-DRB1*15.68 Other risk factors for MS include 
a remote infection of Epstein-Barr virus (EBV)25,69–72 and the exposure to parental smoking 
and the duration of this exposure.73,74 Whereas a remote infection of EBV increases MS risk, 
exposure to cytomegalovirus decreases the risk of MS.75 Earlier menarche in girls increases 
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MS risk and leads to an earlier age of onset, particularly in association with obesity.67,76 Also, 
the gender distribution is equal in pre-pubertal pediatric MS patients, whereas females are 
more often affected after puberty.42,69 This suggests that hormonal influences are correlated 
with disease onset. 
Several new potential risk factors are mentioned, for example high dietary salt intake. This 
may contribute in risk of MS diagnosis and a higher relapse rate.77–79 The effect on MS risk of 
delivery method, being breast fed and environmental quality (for example air pollution) during 
childhood needs further exploration.80,81 The latter also includes the relatively new concept of 
third-hand smoking (THS). Third-hand tobacco smoke contains residual tobacco smoke and 
particles that is left on indoor surfaces and dust, which might interact with environmental 
compounds to form new pollutants.82,83 Consequences on human health and the influence of 
THS on MS risk needs to be determined in the future. Another new field of pediatric ADS is the 
association of MS risk with the difference in gut colonization by non-pathogenic microflora: the 
gut microbiota.84 These findings need to be replicated. 
Growing evidence supporting the genetic and environmental interplay has implications on 
the pathophysiological insights and potential prevention strategies in children. The exact 
mechanisms need to be elucidated. 
How are pediatric ADS treated and managed?
Acute treatment
First choice of acute treatment in ADS is consensus based and contains high-dose intravenous 
corticosteroids (methylprednisolone for 3-5 consecutive days; IvMP).69,85–87 In case children 
do not respond to the first cycle of IvMP, a second cycle can be considered. Intravenous 
immunoglobulins (IvIG) or plasmapheresis could be considered in the acute phase when 
children do not tolerate or do not respond to corticosteroids. Severely affected children 
with a NMOSD-like phenotype who do not respond to IvMP are more likely to benefit from 
plasmapheresis than IvIG.88 
Chronic treatment of ADS subtypes 
The international pediatric MS study group made a consensus statement in 2012 about the 
initiation of immunomodulatory therapy in every child that is diagnosed with pediatric MS.89 
The evidence for treatment effects and potential side effects for first line injectable treatment 
with interferon beta and glatiramer acetate are well established in adults, but less evaluated 
in children.89 The number of the studies conducted in pediatric MS are retrospective or open-
label and there is a lack of randomized controlled trials. This is also the case for Natalizumab 
treatment (Tysabri), the only registered second-line option for pediatric MS. Despite this, a 
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similar (if not better) efficacy is observed as in adults.89–92 Limited information is available about 
the long term (adverse) effects of these drugs on the immune system, development and growth 
of the CNS and endocrine systems of children.93 
The lack of oral agents affects the adherence to currently available injectable therapy and also 
the limited second-line options for children are challenges in daily practice.94,95 In adults, oral 
first-line therapies (dimethylfumarate and teriflunomide) are now widely used.96,97 Recently, 
the first double-blinded randomized controlled trial in children (PARADIGMS study) was 
successfully completed. Fingolimod, an oral second line agent, was compared to interferon 
beta injections and showed superior efficacy on reduction of relapses and of inflammatory and 
neurodegenerative signs on MRI over a period of two years.98 The efficacy seemed even higher 
than in adult patients with a similar safety profile.98 This second-line drug will soon be available 
for pediatric MS patients. New clinical drug trials for children with MS have been launched, 
including oral teriflunomide (Terikids study) and alemtuzumab (Lemkids study).99 Chronic 
treatment of other ADS subtypes, including NMSOD and MOG-IgG associated disorders, are 
discussed later in this chapter. 
What is the Outcome of pediatric ADS 
Regarding recovery in ADS in general, it is reported that about 90% of the patients recovered 
physically from their initial event.100 However, monophasic illness, especially longitudinally 
extended transverse myelitis (LETM) and moderate/severe deficits at onset were associated 
with poor recovery.100 
ADEM is considered as a monophasic and benign illness that occurs mainly in young children 
who show good motor recovery.5,13,14 Despite this, a Canadian study showed the presence of 
lower brain volume, and impaired age-expected brain growth especially in ADEM patients 
compared to controls in longitudinal measurements.101 Moreover, these findings also applied 
for monophasic ADS with more CNS-region restricted presentations, like ON and TM. 101 This 
implies that, even in absence of chronic insults to the brain, one single demyelinating attack 
already causes permanent and irrevocable changes to the developing brain. Cognitive studies 
in ADEM are limited and show varying results.102 However, long-term deficits including affected 
attention, executive function, verbal processing and lower IQ scores are reported; especially in 
children with an early onset <5 years of age.103,104 
An American study with anti-aquaporin 4 antibodies (AQP4-IgG) seropositive NMOSD children 
reported that 94% of these children had a second attack and that residual deficits are 
seen frequently in >40% of the patients after a median follow-up of 1 year, including visual 
impairment and motor deficits.19 Long term follow-up of NMOSD children is necessary to gain 
more insight in their outcomes in this era with immunosuppressive drugs. 
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The potential cognitive and physical sequelae of pediatric MS are mentioned in the ‘Disease 
course and outcome of MS’ earlier in this chapter.1,2,10 Even though outcome studies of 
monophasic ADS and non-MS chronic disorders are emerging, the evidence is not as extensive 
as in pediatric MS patients. Additional studies on the outcomes and follow-up of pediatric ADS 
are needed.
NEUROMYELITIS OPTICA SPECTRUM DISORDERS 
Back in the 19th century, Eugene Devic and his pupil Fernand Gault described a case of a 
patient with simultaneous bilateral ON and TM, and subsequently provided a series of 16 
cases in literature.105–107 The presence of ON and TM in the absence of brain involvement were 
emphasized. Almost a century later, diagnostic criteria for neuromyelitis optica (NMO) were 
put forward with the same emphasis on ON, TM and absence of brain MRI lesions.108 Due to the 
overlap in affected localizations of the CNS, NMO was considered as a rare subtype of MS, with 
demyelinating, recurrent and often severe attacks.108
Antibody discovery
However, the pivotal discovery of the pathogenic serum AQP4-IgG in 2004 made the distinction 
between NMO and MS possible by laboratory findings.109 This led to an important change in 
perspective about NMO. NMO is now considered as a separate disease entity rather than 
a rare and severe subtype of MS.109 The identification of AQP4-IgG has brought insight in 
the pathophysiology of NMO as a primary B-cell mediated astrocytopathy with secondary 
demyelination. 4,110,111
After the discovery of serum AQP4-IgG, the diagnostic criteria for NMO were revised and 
included the use of the AQP4-IgG antibodies.112 Due to the clinical implications of AQP4-IgG 
antibodies, a lot of attention has been paid to the test characteristics of antibody detection.113,114 
In the Netherlands, already early in 2008, a highly specific cell-based assay (CBA) was 
developed at Sanquin Diagnostic Services in Amsterdam, together with the MS center ErasMS 
in Rotterdam.115 Sanquin has since this collaborative initiative been the Dutch centralized 
laboratory for AQP4-testing. 
Clinical spectrum and diagnosis
Thanks to the identification of APQ4-IgG in patients with demyelination, the clinical spectrum 
of NMO has broadened and is now rather called NMO spectrum disorders (NMOSD). NMOSD 
includes the classical involvement of the optic nerve(s) and spinal cord, but also limited forms 
such as isolated or recurrent ON, TM, acute brainstem syndromes,116 area postrema syndrome 
with intractable nausea, vomiting and/or hiccups,117 and cerebral syndromes (including 
diencephalic brain syndromes and symptomatic narcolepsy).4 Epidemiological estimates of 
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incidence and prevalence were not available till recently, mostly thanks to the identification 
of AQP4-IgG antibodies. NMOSD is a rare disorder with incidence figures in other countries 
ranging between 0.05-0.4 per 100.000 persons.118–121 The incidence figures of the Netherlands 
are yet to be investigated.
Diagnosis of NMOSD can be made based on clinical presentation, aided by the serological 
AQP4-IgG status and radiological features.4,122,123 AQP4-IgG positive patients are more often 
female, and have their initial presentation with a median in the late 30s, with a predominance 
for the African and Caribbean population.118,124,125 
In Table 1.2 the current diagnostic criteria for NMOSD are displayed. Some typical MRI features 
are presented in Figure 1.3. 
Table 1.2: Neuromyelitis optica spectrum disorders (NMOSD) diagnostic criteria (Wingerchuk et al., 2015)
NMOSD with AQP4-IgG 1. At least 1 core clinical characteristic 
2. Positive serological test for AQP4-IgG 
3. Exclusion of alternative diagnoses
NMOSD without AQP4-IgG 
Or 
NMOSD with unknown AQP4-IgG status
1.  At least 2 core clinical characteristics occurring as a result of one or 
more clinical attacks and meeting all of the following requirements 
a.  At least 1 core clinical characteristic must be optic neuritis, or 
acute myelitis with longitudinally extensive transverse myelitis 
(LETM), or area postrema syndrome 
b.  Dissemination in space (2 or more different core clinical 
characteristics 
c.  Fulfillment of additional MRI requirements, as applicable 
2.  Negative tests for AQP4-IgG, or testing unavailable 
3. Exclusion of alternative diagnoses
Core clinical characteristics 1. Optic neuritis (ON) 
2. Acute transverse myelitis (TM)
3.  Area postrema syndrome: episode of otherwise unexplained hiccups or 
nausea and vomiting 
4.  Acute brainstem syndrome 
5.  Symptomatic narcolepsy or acute diencephalic clinical syndrome with 
NMOSD-typical diencephalic MRI lesions 
6.  Symptomatic cerebral syndrome with NMOSD-typical brain lesions
Additional MRI requirements for NMOSD 
without AQP4-IgG and NMOSD with 
unknown AQP4-IgG status 
1.  Acute ON: requires brain MRI showing (a) normal findings or only 
non-specific white matter lesions, or (b) optic nerve MRI with T2-
hyperintense lesion or T1-weighted gadolinium enhancing lesion 
extending over >50% optic nerve length or involving the chiasm 
2.  Acute TM: requires associated intramedullary MRI lesion extending 
over ≥3 contiguous segments (LETM), or ≥3 contiguous segments of 
focal spinal cord atrophy in patients with history compatible with acute 
myelitis 
3.  Area postrema syndrome: requires associated dorsal medulla/area 
postrema lesions 
4.  Acute brainstem syndrome: requires associated periependymal 
brainstem lesions
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Figure 1.3: Radiological features in AQP4-IgG positive neuromyelitis optica patients
Figure 1.3A: severe and extensive cervical transverse myelitis with >3 contiguous segments. Figure 
1.3B: longitudinal involvement of the left optic nerve with swelling and gadolinium enhancement from 
intra-orbital area till the optic chiasm. Figure 1.3C: dorsal medulla lesion in a patient with area postrema 
syndrome. 
Despite the most recent diagnostic criteria for NMOSD, the diagnostic process remains 
challenging at times. Although 75%-90% of the patients with an NMOSD phenotype are tested 
seropositive for AQP4-IgG, the other patients still remain AQP4-IgG negative.126 Another 
relevant antibody in NMOSD is anti-myelin oligodendrocyte glycoprotein (MOG-IgG). Despite 
these two antibodies, a proportion of patients with an NMOSD phenotype remains seronegative 
for both. MOG-IgG positive NMOSD will be discussed further in ‘MOG-IgG spectrum diseases’ 
later in this chapter. 
Treatment
AQP4-IgG positive NMOSD are likely to have a relapsing disease course, with usually severe 
attacks.108 The accumulation of disability is associated with relapses.108,127 Yet, much of the 
neurological damage in NMOSD patients is caused during the first attack, often with a delayed 
diagnostic period. Therefore early identification of AQP4-IgG related disease and prompt 
initiation of acute treatment in these patients is important in order to minimize injury and 
accelerate recovery. Intravenous methylprednisolone is first choice in treatment of new 
relapses. However if insufficient improvement is seen during treatment, plasmapheresis is 
shown to be beneficial.88,128,129 The main goals of initiating chronic treatment is to reduce attack 
frequency and severity, in order to prevent progression of disability. Initiating MS treatment in 
NMOSD patients can worsen NMOSD disease activity and should therefore be avoided.130–135 
Azathioprine and mycophenolate mofetil are considered first-line treatment.88,128,129 In case 
the patient is refractory to the given chronic treatment, Rituximab should be considered and 
is currently the most effective for patients with NMOSD.136,137 Promising therapeutical agents 
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are under research in ongoing clinical trials (for example anti-CD19 agent Inebilizumab, 
complement inhibitor Eculizumab, anti-IL6 receptor agent SA237).128 
MOG-IGG SPECTRUM DISEASES 
In the recent years, new candidate biomarkers have gained attention in acquired CNS 
demyelination, especially anti-myelin oligodendrocyte glycoprotein IgG subtype antibodies 
(MOG-IgG). 
Antibody testing
MOG is a protein expressed on the outer surface of the myelin sheath and oligodendrocytes. 138–
140 The protein is a minor component of myelin (0.05%) and is found in the outermost lamella of 
the myelin sheath. In vivo studies demonstrated induction or contribution to CNS inflammation 
by MOG-IgG.141 MOG-IgG might mediate a complement-dependent immune reaction and 
therefore causing inflammation and demyelination.142 Serum cell-based assays (CBA) are most 
reliable for detection of MOG-IgG.138,143 These autoantibodies are highly specific for acquired 
CNS demyelination, since they are not detected in healthy controls or other neurological 
diseases.144–147 Epidemiological studies of MOG-IgG associated CNS demyelination are scarce 
and need further investigation. 
Clinical spectrum 
MOG-IgG are consistently identified in a spectrum of ADS in both adults and children. In 
both adults and children, these antibodies are predominantly found in ADEM and NMOSD-
like phenotypes, especially with involvement of the optic nerves, and in lesser degree LETM 
and brain stem syndromes.138,146–148 Multiple studies support that MOG-IgG demyelination is a 
separate entity from MS and the presence of MOG-IgG pleads against MS diagnosis.149,150 Even 
though the presence of MOG-IgG pleads against MS diagnosis, MOG-IgG seropositivity is found 
in adults with an MS phenotype, though very rare, and is associated only with low antibody 
titers.145,146 This can lead to diagnostic dilemmas. How to handle patients with persisting low 
MOG antibody titers and a clinical MS phenotype needs to be investigated. 
MOG-IgG associated demyelination has its own distinct clinical and radiological profile.149,150 
The lesions are often fluffy, poorly demarcated, and are often located infratentorially, in the 
brainstem or cerebellar peduncles.151,152 A few examples are shown in Figure 1.4.
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Figure 1.4: MOG-IgG associated MRI abnormalities. Figure 1.4A and 1.4B: supratentorial large confluent 
white matter abnormalities, some are poorly demarcated. 1.4C: white matter abnormalities in the 
bilateral cerebellar peduncles. 
Up to 39% of the AQP4-IgG negative NMOSD patients are seropositive for MOG-IgG.142,152–157 
Studies suggested that MOG-IgG positive NMOSD patients usually have a monophasic disease 
course and benign outcome compared to AQP4-IgG positive patients.142,152–155 A comparison 
between AQP4-IgG and MOG-IgG positive adult patients can be found later in this thesis.
In pediatric ADS patients, MOG-IgG are present in 18%-32% at first presentation.144,149,150 
Furthermore, age-dependent clinical phenotypes seem to be present, with ADEM-like 
presentation in childhood and NMOSD like phenotypes in adulthood.158 Several studies 
described the prognostic relevance of MOG-IgG. In children, MOG-IgG are found in 36%-40% 
of the ADEM patients.149,159 Children with monophasic ADEM often have transient serum MOG-
IgG: high serum antibodies are detected at onset and at serial samples titers often reduce to 
undetectable levels.146 In contrast, ADS patients with persisting MOG-IgG are at risk of a recurrent 
disease course160, including MDEM, ADEM-ON and recurrent NMOSD-like phenotypes.6,148,161,162 
In children, often widespread bilateral grey matter and white matter lesions in the brain and 
extensive involvement of the spinal cord (LETM) are seen.163,164 Compared to AQP4-IgG positive 
NMOSD children, MOG-IgG children less often present with area postrema syndrome, have 
lower disability, a longer time to relapse and more cerebellar peduncle lesions.165 
Treatment of MOG-IgG patients 
The high proportion of MOG-IgG patients with a monophasic disease course supports the 
decision against initiating immunosuppressive treatment after the first clinical event. Despite 
the seemingly benign course, a proportion still relapses and shows accumulation of disability, 
sometimes despite chronic immunosuppressive treatment. This raises the question how 
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relapsing MOG-IgG associated diseases need to be treated. The current treatment of MOG-
IgG associated disorders has been influenced by AQP4-IgG positive NMOSD treatment 
guidelines.88,128 However, evaluation of treatment responses in different subtypes of relapsing 
MOG-IgG disorders is lacking and is urgently needed. 
MS CENTER IN ROTTERDAM
The National pediatric MS center and NMO expert center are both part of the Academic Center 
of Excellence (ACE) ErasMS Center Rotterdam. 
As mentioned in the previous sections, pediatric MS is a highly heterogeneous disease and 
affects multiple functional domains, including both cognitive and physical functions of a 
developing child or adolescent. This requires a multidisciplinary approach in the treatment of 
pediatric MS patients.166 The Dutch National Pediatric MS center in Rotterdam operates with a 
multidisciplinary team (Figure 1.5). 
Figure 1.5: Multidisciplinary team of the National pediatric MS center.
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The Dutch NMO expert center (ErasMS Rotterdam and Sanquin Diagnostic Services) aims to 
combine clinical care with scientific research in order to further delineate the spectrum of 
NMOSD and its pathophysiology. 
Towards colleagues in the Netherlands and beyond, both centers have an advisory role in 
diagnostic and therapeutic decisions. Patients are referred by (pediatric) neurologists and 
pediatricians: some patients will be treated primarily in the our ErasMS center, whereas others 
are followed in collaboration with the referring center (executing the ‘shared care’ concept). In 
addition, due to the rarity of pediatric MS, ADS and NMOSD, apart from coordinating care 
and providing accurate counselling to patients and parents, raising awareness and providing 
opportunities for patients and parents to connect with each other via a specialized center is 
essential. 
SCOPE
This thesis focuses on two groups of patients in the ADS spectrum: NMOSD in adults and 
the spectrum of childhood onset ADS. The NMO expert center and the National pediatric MS 
center, as part of the ACE ErasMS Center Rotterdam, render us the unique opportunity to 
collect data from both groups. We aimed to further delineate the spectrum of ADS in children 
and NMOSD in adults by keeping two questions in mind: 
1. Can we improve on the early identification ADS subtypes?
2.  Can we shed more light on the disease course and outcome of ADS subtypes in adults and 
children?
The first part of this thesis focuses on NMOSD in adults (chapter 2). In chapter 2.1 we compared 
the clinical phenotypes of AQP4-IgG positive patients with MOG-IgG positive and seronegative 
patients with NMOSD. In chapter 2.2 and 2.3 the incidence estimates of AQP4-IgG and MOG-IgG 
seropositive NMOSD in the Netherlands are presented respectively. Moreover, the distribution 
of clinical phenotypes of MOG-IgG seropositive adults and children is described in chapter 2.3. 
The second part of this thesis focuses on childhood onset ADS (chapter 3) and is divided in two 
sections:
Section TWO-A focuses on finding biomarkers for early and accurate diagnosis of pediatric 
onset MS (chapter 3.1-3.4). The recently proposed McDonald 2017 criteria are validated in the 
spectrum of childhood onset ADS in chapter 3.1. In chapter 3.2 we investigated and validated 
the predictive value of the  immunological biomarker soluble CD27 for CDMS diagnosis at first 
attack of childhood demyelination. Another promising biomarker is neurofilament light chain 
(NfL), a marker for axonal damage. NfL in CSF predicts MS diagnosis in adults, but the predictive 
value in children is unknown. We studied the difference CSF NfL levels and predictive value for 
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MS diagnosis in in adults and children with ADS in chapter 3.3. Subsequently in chapter 3.4, 
we tested NfL levels in serum of our pediatric patients to investigate the correlation with CSF 
NfL levels and the predictive value of these serological levels for CDMS diagnosis. 
Section TWO-B of this thesis focuses on the disease course and outcome of childhood onset 
ADS (chapter 3.5-3.10). In order to investigate the clinical spectrum of relapsing MOG-IgG 
associated disorders, we collaborated with the European pediatric demyelination consortium. 
The results are presented in chapter 3.5 and 3.6. In chapter 3.5 we describe the disease course 
and outcome of children with ADEM followed by optic neuritis, one of the relapsing subtypes 
with relapsing MOG-IgG disorders. In chapter 3.6 we investigated the clinical phenotypes, 
treatment responses and outcomes of children with relapsing MOG-IgG associated disease.  In 
chapter 3.7 we provide an update on the incidence estimates of ADS subtypes in the Netherlands 
and give an overview of the long-term outcome of ADS patients. Fatigue and motor function 
of children with MS and ADEM are studied in chapter 3.8. In addition, chapter 3.9 shows the 
assessment of urological dysfunction early in the disease course in children with MS. Patients 
with ADEM usually have quick clinical recovery, however, the evolution of MRI lesions during 
follow-up is rarely investigated. The results are presented in chapter 3.10.
 
The main findings of thesis, the interpretation and the potential clinical implications of these 
results are discussed in chapter 4. In this chapter suggestions for future directions are 
provided.
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PART ONE
NEUROMYELITIS OPTICA 
SPECTRUM DISORDERS 
IN ADULTS

2.1
Neuromyelitis optica spectrum disorders: 
comparison of clinical and MRI characteristics 
of AQP4-IgG versus  MOG-IgG seropositive 
cases in the Netherlands
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ABSTRACT
Background 
Neuromyelitis optica spectrum disorders (NMOSD) are a group of rare inflammatory 
demyelinating disorders of the CNS. The identification of specific antibodies directed to 
aquaporin 4 (AQP4-IgG) led to the distinction from multiple sclerosis (MS). However, up to 
25% of the clinically diagnosed NMO patients are seronegative for AQP4-IgG. A subgroup of 
these patients might be identified by antibodies directed to myelin oligodendrocyte glycoprotein 
(MOG-IgG). We investigated whether the clinical characteristics of these patients differ. 
Methods 
Using a cell based assay, we analysed serum of 61 AQP4-IgG seronegative patients and 41 
AQP4-IgG seropositive patients with clinically NMOSD. Clinical characteristics of the AQP4-
IgG, MOG-IgG seropositive and double seronegative NMOSD patients were compared. 
Results 
Twenty of the 61 AQP4-IgG seronegative patients tested MOG-IgG seropositive (33%). MOG-
IgG seropositive patients were more frequently males in contrast to AQP4-IgG seropositive 
patients (55% versus 15%, p <0.01) and Caucasians (90% versus 63%, p =0.03). They more 
frequently presented with coincident optic neuritis (ON) and transverse myelitis (TM) (40% 
versus 12%, p =0.02) and have a monophasic disease course (70% vs 29%, p <0.01). AQP4-IgG 
seropositive patients were 2.4 times more likely to suffer from relapses as compared with 
MOG-IgG seropositive patients (RR 2.4, 95% CI 1.2 – 4.7). AQP4-IgG seropositive patients had 
higher EDSS levels at last follow-up (p <0.01) and suffered more from residual complaints. 
Conclusion 
Antibodies directed to MOG identify a subgroup of AQP4-IgG seronegative NMO patients with 
generally a favourable monophasic disease course. 
 
MOG ANTIBODIES IN NMOSD
43
2.1
INTRODUCTION
Neuromyelitis optica spectrum disorders (NMOSD) are a group of rare inflammatory 
demyelinating disorders of the central nervous system (CNS), characterised by severe 
episodes of optic neuritis (ON) and/or longitudinally extensive transverse myelitis (LETM).1,2 
Antibodies directed to aquaporin 4 (AQP4-IgG) are specific for neuromyelitis optica (NMO) and 
distinguish NMO from multiple sclerosis (MS).3 Despite the development of highly sensitive 
cell based assays (CBA)4 10-25% of the patients clinically diagnosed with NMO are AQP4-IgG 
seronegative.1 In the Netherlands AQP4-IgG was found in 74% of the recurrent NMO cases.5 
The presence of antibodies directed to myelin oligodendrocyte glycoprotein (MOG-IgG) has been 
reported in a subgroup of patients with NMO and NMOSD6-13 and ON.14-16 These MOG antibodies 
are associated with CNS demyelinating syndromes, particularly with children with an ADEM 
like disease onset.17,18 In case of NMOSD MOG antibodies seem to be associated with a male 
predominance and relative mild disease course.7,9,10 Double seropositive (AQP4-IgG and MOG-
IgG) NMOSD patients seem to be rare and only a few cases have been described.6,10,16 In this 
study we investigated the presence of MOG-IgG in NMOSD patients referred to our clinic. Clinical 
characteristics of MOG-IgG seropositive patients were compared with AQP4-IgG seropositive 
patients, as well as MOG-IgG seropositive patients with double seronegative NMOSD patients. 
METHODS
Study participants
This study was conducted at the Dutch national NMO expert centre which includes Sanquin 
Diagnostic Services in Amsterdam and the NMO expert clinic at the Erasmus MC in Rotterdam. 
Patients with NMOSD referred to the Dutch NMO expert centre at Erasmus MC between 2000 
and 2015 were included retrospectively. Patients either presented primarily at Erasmus MC, 
or were referred by ophthalmologists and neurologists in (non-) academic hospitals in the 
Netherlands. All patients fulfilled the following inclusion criteria: 1) age at first presentation 
at Erasmus MC ≥ 18 years; 2) diagnosis of NMOSD according to current diagnostic criteria 
for NMO19, except for AQP4-IgG seropositive status, or limited forms of NMO defined as 
LETM ≥ 3 vertebral segments or bilateral ON or recurrent unilateral ON.1 Patients were not 
included in case they were diagnosed with MS, or a non-demyelinating inflammatory cause 
like other systemic autoimmune diseases (e.g. systemic lupus erythematous, sarcoidosis) 
or ophthalmologic diseases (e.g. Leber hereditary optic neuropathy, acute ischemic optic 
neuropathy). Additionally 41 AQP4-IgG seropositive NMOSD patients from the Dutch NMO 
expert centre of whom serum samples were available were included. Clinical characteristics 
were compared between MOG-IgG seropositive NMOSD patients and AQP-IgG seropositive and 
double negative patients respectively. Data on auto-immune comorbidity, defined as coexisting 
clinically diagnosed auto-immune disease(s), were collected. Relapses were defined as new 
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neurological symptoms lasting for at least 24 hours with objective findings at neurological 
examination. Patients without relapses were defined as monophasic during the current 
observation period, irrespective of its duration. In order to compare the disease severity for 
patients with ON, the nadir visual acuity was retrieved from medical records. For all patients 
the Expanded Disability Status scale (EDSS) was assessed.20 Cerebral and spinal cord magnetic 
resonance images (MRIs) were evaluated for NMO-like lesions.21 This study was approved by 
the Medical Ethical Committee of Erasmus MC in Rotterdam. All patients provided informed 
consent.
Cell culture and cell based assays
All samples were tested blindly at Sanquin, Amsterdam. We used cell based assays (CBA) for 
MOG-IgG and AQP4-IgG detection as has previously been described.5,17 Briefly, patient serum 
was incubated with HEK293 cells transiently transfected with AQP4-M23 (final serum dilution 
1:20) or LN18 cells stably transfected with full length MOG (final serum dilution 1:200). After 
washing, cells were subsequently incubated with goat anti-human IgG Allophycocyanin (APC) 
conjugated secondary antibody (Jackson ImmunoResearch Laboratories, Brunschwig Chemie 
B.V., Amsterdam, The Netherlands (specific for human IgG)) and analysed after washing 
using fluorescence-activated cell sorter (FACS). The cut-off was determined in every assay as 
average deltaMFI + 10 standard deviations of 8 individual negative control sera. Our assay has 
an anti-IgG specific detection antibody and thus no IgM anti-MOG or IgM anti-AQP4 is detected. 
STATISTICAL ANALYSIS 
Patients were divided into three groups: AQP4-IgG seropositive, MOG-IgG seropositive and 
double seronegative NMOSD. Statistical analyses were performed using SPSS 21.0. The chi-
square test and Fisher exact test were used in order to compare categorical data. Mann-
Whitney U test and Student’s t-test were used for continuous data when appropriate. In A 
P-value <0.05 was considered significant. 
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2.1
RESULTS 
Hundred and two NMOSD patients were included; 61 of them were AQP4-IgG seronegative and 41 
were AQP4-IgG seropositive. Twenty of the 61 AQP4-IgG seronegative patients tested MOG-IgG 
seropositive (33%). In none of the AQP4-IgG seropositive patients MOG-IgG was detected. An overview 
of the included patients is presented in Figure 2.1.1 The median time to sampling was 10.7 months 
(0 – 401.5). Thirteen patients (12.7%) received chronic treatment while the sample was collected. 
In table 2.1.1 clinical characteristics are presented for MOG-IgG seropositive (n=20), AQP4-IgG 
seropositive (n=41) and double seronegative (n=41) NMOSD patients. 
Figure 2.1.1: Overview of included patients.
Compared with AQP4-IgG seropositive patients, MOG-IgG seropositive patients were more 
frequently males (55% versus 15%, p <0.01) and Caucasians (90% versus 63%, p =0.03). They 
more frequently presented with coincident ON and transverse myelitis (TM) (40% versus 12%, 
p = 0.02). AQP4-IgG seropositive patient more often presented with longitudinally extensive 
transverse myelitis (LETM) (49% versus 20%, p = 0.03). In Table 2.1.2 MRI features are presented. 
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Table 2.1.2: MRI features of MOG-IgG and AQP4-IgG seropositive patients with NMOSD. 
MOG-IgG+ (n=20) AQP4-IgG+ (n=41) P-value
Brain
NMO specific brain lesions, n (%) 0 12/38 (32)* 0.01
Aspecific brain lesions, n (%) 4 (20) 12/37 (32) 0.32
Spinal cord 
Affected spinal cord segments 
Cervical
Thoracic 
Lumbar
Whole spinal cord
9/12 (75)
10/12 (83)
3/12 (25)
3/12(25)
31/36 (86)
30/36 (83)
5/36 (14)
5/36 (14)
0.66
1.00
0.66
0.66
Central grey matter 10/12 (83) 30/36 (83) 1.00
* Magnetic resonance imaging was reviewed for the presence of NMOSD specific brain lesions as recently 
described.21 
Five patients with diencephalic lesions surrounding the third ventricle and cerebral aquaduct, two patients 
with dorsal brainstem lesions, two patients with both diencephalic and dorsal brainstem lesions, one 
patient with a dorsal brainstem, diencephalic and periependymal lesion, one patient with a specific lesion 
of the internal capsule and one patient with an extensive confluent hemispheric lesion were detected.
Abbreviations: AQP4-IgG aquaporin-4 immunoglobulin, MOG-IgG myelin oligodendrocyte glycoprotein 
immunoglobulin, MRI magnetic resonance imaging, NMOSD neuromyelitis optica.
The cerebral MRI features as recently described in NMOSD patients21 were only found in het 
AQP4-IgG seropositive patients and not in the MOG-IgG seropositive patients (32% versus 0%, 
p <0.01). An example of typical NMO dorsal brainstem (A) and midbrain (B) lesions of one of 
our patients is presented in Figure 2.1.2. Spinal cord MRI features and cerebrospinal fluid 
(CSF) findings were similar in the AQP4-IgG versus MOG-IgG seropositive groups. MOG-IgG 
seropositive patients more frequently had a monophasic disease course (Table 2.1.1) (70% vs 
29%, p <0.01). AQP4-IgG seropositive patients were 2.4 times more likely to suffer from relapses 
as compared with MOG-IgG seropositive patients (RR 2.4, 95% CI 1.2 – 4.7). EDSS at last follow-
up was higher for AQP4-IgG seropositive patients (p <0.01) and they more often suffered from 
residual visual, motor and sensory complaints (Table 2.1.1). Presenting phenotype was not 
predictive for a relapsing disease course. Table 2.1.3 shows the clinical characteristics of the 
relapsing patients. TM relapses were more frequently seen in the AQP4-IgG group compared 
with the MOG-IgG seropositive patients (76% versus 17%, p=0.01). 
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Figure 2.1.2: Transversal MRI FLAIR images presenting typical NMO dorsal brainstem (A) and 
midbrain (B) lesions of one of our NMO patients with AQP4-IgG seropositivity.
DISCUSSION
Antibodies directed to MOG can be detected in a subgroup of children with acquired 
demyelinating syndromes.17,18 Recently it has been reported that MOG-IgG also can be found 
in adults with clinical NMOSD phenotypes and ON.6-16 In this study we confirm that MOG-IgG is 
present in approximately one third of the AQP4-IgG seronegative NMOSD cases. An overview 
of previous studies using a CBA for MOG-IgG testing in NMO(SD) and this study is presented 
in Table 2.1.4. 
In line with previous studies we found a male and Caucasian predominance, frequent 
coincident ON and TM, more often a monophasic disease course and lower EDSS levels at 
follow-up in MOG-IgG seropositive cases.7,9,10 Six out of 8 (75%) MOG-IgG seropositive patients 
with coincident ON and TM had a monophasic disease course as originally described as 
Devic’s syndrome.1 Follow-up periods between the MOG-IgG and AQP-IgG seropositive patients 
differed slightly, but not significantly. It cannot be excluded that upon further follow-up some 
of the monophasic MOG-IgG seropositive patients will have relapses.In our study a relatively 
high rate of a monophasic disease course was observed in the AQP4-IgG seropositive patients, 
which is a result of our protocol to start immunosuppressive treatment in this group as early 
as possible, often already after the first attack.
In addition to previous studies, cerebral MRIs from MOG-IgG and AQP4-IgG seropositive 
patients were assessed for presence of NMO specific brain lesions.21 These lesions were 
not present in MOG-IgG seropositive NMOSD patients, which might be explained by different 
underlying disease mechanisms. AQP4-IgG, MOG-IgG seropositive NMOSD and seronegative 
NMOSD seem to be similar in their clinical opticospinal phenotype, although there might be 
pathophysiological differences between these NMOSD subgroups.23,24 Further neuropathological 
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studies are needed in order to improve criteria for clinical NMOSD phenotype, since MOG-IgG 
seropositivity might reflect a separate demyelinating syndrome. 
The presence of MOG-IgG further expands the spectrum of NMOSD. Although the presence of 
MOG-IgG is rare, the detection it seems beneficial in clinical practice to differentiate patients 
with NMOSD from MS13 and may identify a subgroup of NMOSD patients with favourable 
outcome with lower EDSS levels at follow-up and less relapses. However it is still important 
to realise that some MOG IgG seropositive patients experience frequent relapses and have 
prominent residual neurological deficits. 
MOG-IgG was found in 33% of the clinical NMOSD AQP4-IgG seronegative cases. This is higher 
than has been described in some of the previous studies (Table 2.1.4).8-13,15,16However, it is 
difficult to compare these percentages considering the different study protocols and inclusion 
criteria. 
Our relative high percentage of MOG-IgG seropositivity is probably caused by the retrospective 
character of our study and selection bias of patients who have been referred to our NMO expert 
centre at Erasmus MC Rotterdam. The scope of the current study was to compare clinical 
characteristics of MOG-IgG versus AQP4-IgG seropositive NMOSD patients, rather than to 
determine the prevalence of MOG-IgG seropositive CNS demyelination. Further studies are 
needed in order to present epidemiological figures of AQP4-IgG and MOG-IgG seropositivity in 
the Netherlands. 
This study confirms MOG-IgG seropositivity in a subgroup of patients with clinically NMOSD 
in the Netherlands. The limitation of our study is a relatively small sample size and therefore 
statistical corrections could not be made. Also sequential samples were not collected. Even 
though AQP4-IgG and MOG-IgG represent a considerable amount of patients with the clinical 
profile of NMOSD, there is still a group of patients without antibodies. Future studies are 
needed to gain more insight in this group of seronegative NMOSD patients in order to possibly 
detect new autoantibodies, to better customise treatment for individual patients and to predict 
their prognosis. 
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ABSTRACT
Neuromyelitis optica (NMO) is a rare autoimmune disease affecting the optic nerves and spinal 
cord. In the majority of NMO patients anti-aquaporin-4 antibodies (AQP4-IgG) are detected. 
Here we assessed a nationwide incidence of AQP4-IgG seropositive NMO spectrum disorders 
(NMOSD) in the Netherlands based on results of one central laboratory. Data were collected 
since the introduction of the highly sensitive cell based assay for six consecutive years. 
Samples of 2,795 individual patients have been received, of them 94 (3.4%) were seropositive. 
Based on the Dutch population with 16,6 million inhabitants the mean incidence of AQP4-IgG 
seropositive NMOSD was calculated 0.09 per 100,000 people. 
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INTRODUCTION
Neuromyelitis optica (NMO) is a rare autoimmune disease classically affecting the optic nerves 
and spinal cord.1 Exact incidence figures of NMO in the Netherlands are currently unknown. 
The clinical spectrum of NMO has broadened in the past years and besides Devic’s syndrome 
it includes limited forms such as isolated or recurrent optic neuritis, transverse myelitis, 
brainstem syndromes and other cerebral presentations.2,3 In approximately 77% of the patients 
with NMO spectrum disorders (NMOSD) specific antibodies against aquaporin-4 (AQP4-IgG) 
are detected.2 In the Netherlands diagnostic testing of these antibodies is performed in one 
centralised NMO expert centre. This provides an unique chance to get insight in a nationwide 
incidence of AQP4-IgG seropositive NMOSD. Epidemiological figures of NMOSD are of interest 
for patient care and counseling and for the estimation of the socioeconomic burden of the 
disease. The purpose of this study is to estimate a nationwide incidence of NMOSD in the 
Netherlands. 
METHODS
Study participants
This study was conducted at the Dutch national NMO expert centre which includes Sanquin 
Diagnostic Services in Amsterdam and the NMO expert clinic at the Erasmus university 
Medical Centre (Erasmus MC) in Rotterdam. We collected demographic data (age and gender) 
from serum samples sent for routine AQP4-IgG diagnostics. Data were collected since the 
introduction of the highly sensitive cell based assay (CBA) for AQP4-IgG detection in May 2009 for 
six consecutive years. Samples sent in from abroad, mainly Belgium and the Dutch Caribbean, 
were excluded from this study (n=139 patients). Of these foreign patients 8 were AQP4-IgG 
seropositive. Incidence rates were calculated as the number of AQP4-IgG seropositive patients 
per year divided by the number of Dutch inhabitants per 100,000 people. Population figures 
were extracted from Statistics Netherlands.4 From the patients known at the Erasmus MC in 
Rotterdam clinical data were collected. Magnetic resonance images (MRIs) were evaluated 
for the presence of lesions, longitudinally extensive transverse myelitis (LETM)3 and cerebral 
NMO-like lesions.5 In five patients known at Erasmus MC the diagnosis of NMOSD was made 
prior to the time of the AQP4-IgG assay in 2009 based on their clinical characteristics and 
therefore they were not included in the incidence calculations. This study was approved by the 
Medical Ethical Committee of the Erasmus MC in Rotterdam. All patients from the Erasmus 
MC provided informed consent. 
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AQP4-IgG cell based assay
We used a CBA for AQP4-IgG detection as has previously been described.6 In short, patient 
serum was incubated with HEK293 cells transiently transfected with AQP4-M23 (final serum 
dilution 1:20). After washing, cells were subsequently incubated with goat anti-human IgG 
Allophycocyanin (APC) conjugated secondary antibody and analysed after washing using 
fluorescence-activated cell sorter (FACS). The cut-off was determined in every assay as 
average deltaMFI + 10 standard deviations of 8 individual negative control sera. 
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS 21.0. The Chi-Square test and Mann-Whitney U 
test were used to compare categorical and continuous data respectively. 
RESULTS
During six consecutive years, from May 2009 until May 2015, 3,207 samples of 2,795 individual 
Dutch patients have been received for AQP4-IgG testing. Samples were sent from 85 different 
hospitals including all 8 university hospitals. Of all included patients 94 (3.4%) were seropositive. 
Two hundred and forty children and adolescents less than 18 years old were included, of them 8 
(3.3%) were AQP4-IgG seropositive. The mean age of AQP4-IgG seropositive patients was 47.6 
years ± 18.2 compared with 41.0 years ± 16.1 in the seronegative group (p<0.01). Seventy-eight 
(83%) of the seropositive patients were female in contrast to 1,698 (63%) female patients in 
the seronegative group (p<0.01). The incidence rates of 6 consecutive years are presented in 
Table 2.2.1. 
Table 2.2.1: Incidence rates of 6 consecutive years of AQP4-IgG seropositive NMOSD in the 
Netherlands. Populations figures were extracted from Statistics Netherlands.4
Year
Number of AQP4-IgG 
seropositive NMOSD patients
Number of 
Dutch inhabitants
Incidence per 
100.000 people 
1: May 2009 – April 2010 15 16,486,000 0.09
2: May 2010 – April 2011 15 16,575,000 0.09
3: May 2011 – April 2012 12 16,656,000 0.07
4: May 2012 – April 2013 16 16,730,000 0.10
5: May 2013 – April 2014 18 16,778,000 0.11
6: May 2014 – April 2015 13 16,829,000 0.08
Mean/year 15* 16,676,000 0.09
* Results rounded to integer.  
AQP4-IgG aquaporin-4 immunoglobulin G, NMOSD neuromyelitis optica spectrum disorders.
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AQP4-IgG aquaporin-4 immunoglobulin G, NMOSD neuromyelitis optica spectrum 
disorders.
The mean incidence of NMOSD during the past six years in the Netherlands was calculated 
0.09 per 100,000 people. Considering that approximately 77% of NMOSD patients has 
antibodies directed to AQP42, the estimated incidence of NMOSD in general (including AQP4-
IgG seropositive and seronegative cases) is 0.12 per 100,000 people. Thirty-six of the 94 AQP4-
IgG seropositive NMOSD patients (38%) are known at the Erasmus MC and their clinical data 
are presented in Table 2.2.2 Seventy-eight percent of them were females. Twenty-four patients 
had LETM at some point during their disease course. Eventually at last follow-up 21 patients 
(58%) fulfilled classic NMO criteria with optic neuritis and transverse myelitis.3 
Table 2.2.2: Clinical characteristics of 36 AQP4-IgG seropositive NMOSD patients known at Erasmus MC. 
AQP4-IgG seropositive NMOSD patients, n = 36
Age at onset,  mean years (SD) 41.6 (18.9)
Females, n (%) 28 (78%)
Caucasians, n (%) 27 (75%)
AID comorbidity, n ( %) 8 (22%)
Time from first onset of symptoms to APQ4-IgG assay, 
median months (range)
7.9 (0.3 – 248.8¹)
Type of onset, n (%)
ON 
TM 
NMO
Brainstem and or cerebral syndromes
12 (33%) 
18 (50%) 
4 (11%) 
2 (6%)
CSF elevated IgG index >0.68 and/ or positive OCB, n (%) 11/31 (35%)
MRI cerebral lesions, n (%)*
NMO like5
Aspecific
17/34 (50%)
4 (12%)
13 (41%)
MRI spinal cord lesions, n (%)*
LETM
30/33 (91%)
24 (73%)
Relapse, n (%) 24 (67%)
Chronic treatment, n (%) 30 (83%)
Follow-up, mean years (SD) 5.4 (5.4)
Type at last Follow-up, n (%)
ON
TM
NMO 
Brainstem and or cerebral syndromes
 
3 (8%) 
11 (31%) 
21 (58%) 
1 (3%)
¹In our cohort we report a patient with an extraordinary time from onset to sampling of 248.8 months. 
This particular patient suffered from recurrent unilateral optic neuritis in 1988, 2004 and in several years 
afterwards. Using the current diagnostic criteria2 NMOSD diagnosis could not have been made in this 
unique case prior to the AQP4-IgG testing. 
*MRIs performed at onset and/or follow-up. 
AID autoimmune disease, AQP4-IgG aquaporin-4 immunoglobulin G,CSF cerebrospinal fluid, LETM 
longitudinally extensive transverse myelitis, NMO(SD) neuromyelitis optica (spectrum disorders), OCB 
oligoclonal bands, ON optic neuritis, TM transverse myelitis.
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DISCUSSION
Here we report the incidence of AQP4-IgG seropositive NMOSD in the Netherlands, derived 
from data of the Dutch national NMO expert centre, is nearly one in a million: 0.09 per 100,000 
people. Unique for this study is that we have a nationwide coverage given that the CBA is 
performed in one central laboratory. Our incidence figure is within the range of previous 
described incidence rates which range from 0.05 – 0.4 per 100,000 people.7 It has to be 
considered that epidemiological studies on NMOSD are difficult to compare since they are 
based on different selection and inclusion criteria. For example different clinical definitions 
and AQP4-IgG assays were used. Also the ethnicities of included patients and the geographic 
coverage differed. Two studies performed in comparable geographic areas in Denmark and the 
United Kingdom differed essentially from our study, as both studies also included AQP4-IgG 
seronegative NMOSD patients and did not have nationwide coverage.8,9
In a comparable Austrian study an incidence of 0.05 was calculated.10 The main difference with 
our study is that the patients they identified were all Caucasian. However there are indications 
that some ethnic groups are overrepresented in NMOSD.11 In the Netherlands we estimated 
the incidence of NMOSD is more than twice as high in non-Caucasians. Based on 25 percent 
of the patients known at Erasmus MC were non-Caucasian and 11.9 percent of the Dutch 
inhabitants are non-Caucasian4 we estimated a mean annual incidence rate of NMOSD for 
non-Caucasians of 0.19 per 100,000 people and for Caucasians of 0.08 per 100,000 people. 
We think our findings reflect the real incidence of AQP4-IgG seropositive NMOSD in 
the Netherlands. However, we cannot exclude that mild cases and forme fruste types 
of the disease2 have been missed. Fifty-eight percent of the NMOSD patients at the 
Erasmus MC fulfilled classic NMO criteria3. Unfortunately we did not have access to 
the clinical data of all patients and therefore we could not present this figure for all 
NMOSD patients in the Netherlands. Only the clinical data of patients known at the 
Erasmus MC are presented, however covering over one third of the study population. 
More awareness and better recognition of NMOSD might increase the incidence in the future. 
Further demographic studies and international collaboration in the NMO field would add to a 
better NMOSD understanding. 
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ABSTRACT 
Objective:
To compare the diagnostic accuracy of the McDonald 2017 vs the McDonald 2010 criteria to 
predict a second attack of multiple sclerosis (clinically definite multiple sclerosis, CDMS) at 
first attack of acquired demyelinating syndromes(ADS). 
Methods
Hundred and sixty-four children (<18 years) with an incident attack of ADS were included in 
a prospective multicenter study between June 2006 and December 2016. Brain (and spinal if 
available) MRI was performed  ≤3 months after symptom onset. Sensitivity, specificity, positive 
predictive value, negative predictive value, accuracy were compared at baseline between the 
2010 and 2017 criteria.
Results
Among the 164 patients,110 (67%) patients presented without encephalopathy (ADS-, female 
63%; median age 14.8 years, IQR 11.3-16.1) and 54 (33%) with encephalopathy (ADEM, female 
52%; median age 4.0, IQR 2.6-6.1). Of the 110 ADS- patients, 52 (47%) were diagnosed with 
CDMS within a median FU of 4.5 years (IQR 2.6-6.7). The sensitivity was higher for the 2017 
criteria than for the 2010 criteria (83%; 95% CI 67-92, vs 49%; 95% CI 33-65; p<0.001), but the 
specificity was lower (73%; 95% CI 59-84 vs 87%; 95% CI 74-94, p=0.02). At baseline, 48 patients 
fulfilled the 2017 criteria compared to 27 patients when using the 2010 criteria. The results 
for children without encephalopathy <12 years were similar. In ADEM patients, 8% fulfilled 
the 2010 criteria and 10% the 2017 criteria at baseline, but no patient fulfilled the criteria for 
CDMS. 
Conclusions:
The McDonald 2017 criteria are more sensitive than the McDonald 2010 criteria for 
predicting CDMS at baseline. These criteria can also be applied in children <12 years without 
encephalopathy, but not in children with ADEM.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system.1 
Up to 10% of all MS patients have their first symptoms before the age of 18.2,3 Recently, the 
international panel on diagnosis of MS proposed the McDonald 2017 criteria, by reviewing and 
revising the prior 2010 McDonald criteria.4,5 These revised criteria include modifications to 
facilitate earlier MS diagnosis, while attempting to preserve the diagnostic accuracy of the 
criteria.5 Important modifications included re-introducing CSF oligoclonal bands into the 
criteria as a substitute for dissemination in time (DIT), and allowing symptomatic lesions to 
contribute to dissemination in space(DIS) and DIT. Furthermore cortical lesions have been 
combined with the juxtacortical lesion component to demonstrate DIS. 
The applicability of the adult McDonald 2010 criteria in children was supported by several 
studies.6-12 These criteria were implemented in the revised 2012 diagnostic criteria for children 
with acquired demyelinating syndromes (ADS) proposed by the International pediatric MS 
study group(IPMSSG).13 ADS encompasses the first attack of demyelination in the central 
nervous system(CNS).13,14 According to the IPMSSG criteria, MS diagnosis based on the first 
baseline MRI in children with a first attack should be taken with caution for children aged 
<12 and patients presenting with acute disseminated encephalomyelitis(ADEM) due to a lower 
specificity and sensitivity of the McDonald 2010 criteria in these groups.13
A Canadian study reported that the revised McDonald 2017 criteria apply well in children 
with a first attack of ADS across the age-span.15 Validation of these criteria in different study 
populations is imperative because of the long-term administration of disease modifying 
treatment(DMT) after MS diagnosis. Overtreatment in patients must be prevented, as well as 
under-treatment due to delayed diagnosis. Early and accurate identification of MS patients is 
therefore essential. 
We aimed to evaluate the diagnostic accuracy of the revised 2017 MS criteria in children with 
ADS at time of first presentation. Extra attention is paid to children below the age of 12 years 
and to patients presenting with ADEM. 
METHODS
Patients and design
Children younger than 18 years with a first attack of demyelination were consecutively 
included in the nationwide, multicenter and prospective study for children with ADS between 
June 2006 and December 2016 (PROUD-kids study).16,17 Patients were assessed at baseline 
and were prospectively followed. MRI was performed within 3 months after symptom onset as 
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part of routine diagnostic process to rule out alternative diagnoses. Patients with alternative 
non-demyelinating disorders were excluded from our study. All patients had a follow-up(FU) 
duration of at least 1 year, as the interval between first and second attack in pediatric MS is 
typically less than one year.18-21
Patients were included for analysis when presenting with ADS without(ADS-) and with 
encephalopathy(ADEM).13 Patients with neuromyelitis optica spectrum disorders(NMOSD) 
or with relapsing disease other than MS were excluded from analyses (for example patients 
presenting with relapsing anti-MOG antibody related disorders), because there is emerging 
evidence that these patients have a distinct clinical phenotype.22,23
Standard protocol approvals and patient consents
The PROUD-kids study protocol was approved by the Ethics Committee Erasmus MC Rotterdam 
and by the other participating centers in the Netherlands. Written informed consent was 
obtained from all patients and/or their families.  
Definitions
Acquired demyelinating syndromes in children encompass the first attack of demyelination in 
the CNS, including patients presenting with (ADS+) and without encephalopathy (ADS-). ADEM 
was defined as a polyfocal onset with encephalopathy (ADS+).13 Clinically definite multiple 
sclerosis (CDMS) was defined as a second attack of MS, with two non-encephalopathic 
confirmed attacks with clinical evidence of two separate lesions.13 ADS- patients who remained 
monophasic were defined as monophasic ADS-.13 Patients were re-assessed annually. The 
patients were instructed to contact the outpatient clinic if new symptoms occurred in order to be 
clinically assessed. A relapse was defined as new neurological deficits or subacute worsening 
of existing symptoms after 30 days of improvement or stable disease, without evidence of an 
alternative diagnosis.24 
Procedures
Brain and spine MRI scans were performed at 1.5 Tesla scanners. Available T1-, axial T2-, 
axial and/or sagittal fluid attenuated inversion recovery(FLAIR)-, and T1-weighted images 
with gadolinium administration were evaluated centrally. The MRI scan closest to the date of 
symptom onset was evaluated as the baseline scan. 
For DIS, all baseline MRI scans were scored using the McDonald 2010 criteria, and the modified 
components as described in the revised McDonald 2017 criteria for the first MRI scan (Table 
3.1.1). MRI techniques which are required to reliably demonstrate cortical lesions, such as 
double inversion recovery, were not part of the routine MRI protocol. Therefore the cortical 
lesion component was not taken into account in our analyses. If a spinal MRI was performed 
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within 30 days after or before brain MRI, this scan was taken into account in scoring the DIS 
components. For DIT, all MRI scans with post-gadolinium T1 images were used, or scans that 
did not have gadolinium administered, but did not show any FLAIR/T2 hyperintense lesions 
either. CSF analyses for oligoclonal bands(OCB) were performed in local laboratories using 
isoelectric focusing.25 OCB status was considered as positive if there were ≥2 unique bands in 
CSF compared to serum. 
Table 3.1.1: Baseline MRI criteria for MS diagnosis derived from the McDonald 2010 and revised 2017 
criteria.
McDonald 2010 criteria for baseline MRI Revised McDonald 2017 for baseline MRI
DIS DIS
At least 2 out of 4 of: 
- ≥1 periventricular lesion 
- ≥1 juxtacortical lesion
- ≥1  infratentorial lesion
- ≥1 spinal cord lesion
(symptomatic brain stem syndromes or 
spinal cord lesions are excluded)
At least 2 out of 4 of: 
- ≥1 periventricular lesion
- ≥1 juxtacortical or cortical lesion
- ≥1  infratentorial lesion
- ≥1 spinal cord lesion
(asymptomatic and symptomatic brain stem 
syndromes or spinal cord lesions are included)
DIT DIT 
- Simultaneous presence of asymptomatic 
gadolinium-enhancing lesions
At least one: 
- Simultaneous presence of asymptomatic or 
symptomatic gadolinium-enhancing lesions
- Presence of unique CSF oligoclonal bands 
compared to serum as substitute for DIT 
Changes in the McDonald 2017 criteria compared the 2010 criteria are made bold.
Abbreviations: dissemination in space (DIS), dissemination in time (DIT), cerebrospinal fluid (CSF).
Rationale
We set out to analyze our data in a manner that is representative for clinical practice. As 
acknowledged by the International Panel on Diagnosis of MS, spinal cord MRI and/or lumbar 
puncture were not performed in every case depending on clinical presentation and were left to 
the decision of the local treating physician.5 We did not exclude patients without a spinal cord 
MRI or lumbar puncture, as this would probably introduce selection bias in our study. 
DIS was based on three parameters(periventricular, juxtacortical, infratentorial), or four 
including spinal localization if a spinal MRI was performed. We allowed OCB status to contribute 
to the fulfillment of DIT 2017 in patients with no gadolinium enhancement. 
STATISTICAL ANALYSIS
For statistical analyses we used SPSS software, version 24.0 (SPSS Inc.) and GraphPad Prism5. 
CDMS diagnosis was used as endpoint for all following analyses. For group comparisons, the 
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Chi-square test and Fisher Exact test were used for categorical data. The Mann-Whitney U test 
was used for continuous data. 
Diagnostic performance and accuracy
Patients fulfilling the diagnostic criteria at time of the first attack with a subsequent diagnosis 
of CDMS during FU were considered as true positives (TP). False positives (FP) did fulfil the 
diagnostic criteria for MS at baseline MRI, but were not diagnosed with CDMS during FU. 
Patients who did not fulfil the diagnostic criteria at baseline MRI and who were not diagnosed 
with CDMS during FU were considered as true negatives (TN). False negatives (FN) were 
patients who did not fulfil the diagnostic criteria on baseline MRI, but were diagnosed with 
CDMS during FU. 
The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and 
accuracy were calculated, including a 95% confidence interval(CI). 
Comparison between the sensitivity and specificity for the 2010 and 2017 criteria were made 
using the McNemar’s test. Kaplan Meier analysis was used to analyze the time to CDMS 
diagnosis using the 2010 and 2017 criteria(log-rank test). Patients who did not meet the 
criteria for CDMS diagnosis during FU were considered as censored observations. Cox hazard 
regression analyses were performed to calculate hazard ratios(HR) for time to MS diagnosis 
based on the McDonald 2010 criteria (applied at baseline), McDonald 2017 criteria (applied at 
baseline) and CDMS diagnosis. P-values <0.05 were considered significant. 
RESULTS
Patient characteristics
The inclusion and exclusion process of eligible ADS children is displayed in Figure 1. Among 
the 164 included patients with a first demyelinating event, 54 patients(33%) presented with 
encephalopathy (ADS+) and were diagnosed with ADEM. The other 110 (67%) were ADS- at 
time of inclusion. Of these, 52/110 (47%) were diagnosed with CDMS during FU (median FU 
time 4.5 years, IQR 2.6-6.6). Median time to CDMS diagnosis was 10.2 months(IQR 3.8-20.7). 
None of the ADEM patients had a second attack within a median FU of 5.1 years (IQR 2.7-7.8). 
Patient characteristics and statistical comparisons between monophasic ADS- and CDMS are 
displayed in Table 3.1.2.
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Figure 3.1.1: Flow chart for patient inclusion 
DIS and DIT performance on baseline MRI 
All test characteristics of analyses with and without children <12 years are presented in Table 
3.1.3.  
Dissemination in space 
Hundred and ten ADS- patients were included for this analysis, of whom 52 were diagnosed 
with CDMS during FU(47%). Spinal MRI was included when available. The 2010 DIS criteria 
were fulfilled in 54 patients(49%). Of these, 41 were diagnosed with CDMS(76%). Additional 16 
patients fulfilled the 2017 DIS criteria (n=70, 64%) and 48 of these 70 patients were diagnosed 
with CDMS(69%). The 2017 DIS criteria yield an increase in sensitivity of 13% compared to the 
2010 criteria(p=0.1), and a loss in specificity of 16%(p=0.008). 
A sub-analysis evaluating the fulfillment of DIS in patients who had T1 images with gadolinium 
administration (n=93) yielded no difference in the results.
Of the 110 ADS- patients, 61 patients (55%) had spinal cord imaging and spinal lesions were 
detected in 45/61 scans(74%). In a subgroup analysis we only included patients who underwent 
a spinal scan. The test characteristics for DIS were comparable with the results above.
Dissemination in Time 
To evaluate the DIT for both criteria we selected ADS- patients who had T1 images with 
gadolinium administration (n=93). Of these patients, 41 were diagnosed with CDMS during 
FU(44%). The 2010 DIT criteria were fulfilled in 35 patients(38%). Of these, 23 were diagnosed 
with CDMS(66%). Regarding the difference between symptomatic and asymptomatic lesions 
for the DIT-component, we observed that the 2017 DIT criteria (excluding OCB) yielded 3 more 
MCDONALD 2017 CRITERIA IN CHILDHOOD-ONSET ADS 
91
3.1
Ta
bl
e 
3.
1.
3:
 T
es
t c
ha
ra
ct
er
is
ti
cs
 o
f t
he
 M
cD
on
al
d 
20
10
 a
nd
 M
cD
on
al
d 
20
17
 c
ri
te
ri
a.
P
at
ie
nt
s 
w
it
h 
A
D
S-
 a
nd
 
C
D
M
S,
 e
xc
lu
di
ng
 A
D
EM
 
D
IS
 2
01
0 
 
 (n
=1
10
)
D
IS
 2
01
7 
 
 (n
=1
10
)
D
IT
 2
01
0 
 
 (n
=9
3)
D
IT
 2
01
7 
 
(O
C
B
 e
xc
lu
de
d)
  
(n
=9
3)
D
IT
 2
01
7 
 
(O
C
B
 in
cl
ud
ed
) 
(n
=9
3)
M
cD
on
al
d 
 
(D
IS
+D
IT
) 2
01
0 
 
(n
=9
3)
M
cD
on
al
d 
(D
IS
+D
IT
) 
20
17
 (O
C
B
 e
xc
lu
de
d)
 
(n
=9
3)
M
cD
on
al
d 
(D
IS
+D
IT
) 
20
17
 (O
C
B
 in
cl
ud
ed
) 
(n
=9
3)
Se
ns
iti
vi
ty
 %
, (
95
%
C
I)
Sp
ec
ifi
ci
ty
 %
, (
95
%
C
I)
P
P
V 
%
, (
95
%
C
I)
N
P
V 
%
, (
95
%
C
I)
Ac
cu
ra
cy
 %
, (
95
%
C
I)
79
 (6
5-
89
)
78
 (6
4-
87
)
76
 (6
2-
86
)
80
 (6
7-
89
)
78
 (7
1-
86
)
92
 (8
1-
98
)
62
 (4
8-
74
)
69
 (5
6-
79
)
90
 (7
5-
97
)
76
 (6
9-
84
)
56
 (4
0-
71
)
77
 (6
3-
87
)
66
 (4
8-
80
)
69
 (5
5-
80
)
68
 (5
8-
77
)
63
 (4
7-
77
)
77
 (6
3-
87
)
68
 (5
1-
82
)
73
 (5
9-
84
)
71
 (6
2-
80
)
90
 (7
6-
97
)
60
 (4
5-
73
)
64
 (5
0-
76
)
89
 (7
2-
96
)
73
 (6
4-
82
)
49
 (3
3-
65
)
87
 (7
4-
94
)
74
 (5
3-
88
)
68
 (5
5-
79
)
70
 (6
1-
79
)
61
 (4
5-
75
)
83
 (6
9-
91
)
74
 (5
5-
87
)
73
 (6
0-
83
)
73
 (6
4-
82
)
83
 (6
7-
92
)
73
 (5
9-
84
)
71
 (5
6-
83
)
84
 (7
0-
93
)
77
 (6
9-
86
)
P
at
ie
nt
s 
w
it
h 
A
D
S-
 a
nd
 
C
D
M
S 
 <
12
 y
ea
rs
  
(e
xc
lu
di
ng
 A
D
EM
)
n=
30
n=
30
n=
28
n=
28
n=
28
n=
28
n=
28
n=
28
Se
ns
iti
vi
ty
 %
, (
95
%
C
I)
Sp
ec
ifi
ci
ty
 %
, (
95
%
C
I)
P
P
V 
%
, (
95
%
C
I)
N
P
V 
%
, (
95
%
C
I)
Ac
cu
ra
cy
 %
, (
95
%
C
I)
86
 (4
2-
99
)
87
 (6
5-
97
)
67
 (3
1-
91
)
95
 (7
4-
10
0)
87
 (7
5-
99
)
10
0 
(5
6-
10
0)
78
 (5
6-
92
)
58
 (2
9-
84
)
10
0 
(7
8-
10
0)
83
 (7
0-
96
)
71
 (3
0-
95
)
90
 (6
8-
98
)
71
 (3
0-
95
)
90
 (6
8-
98
)
86
 (7
3-
99
)
71
 (3
0-
95
)
90
 (6
8-
98
)
71
 (3
0-
95
)
90
 (6
8-
98
)
86
 (7
3-
99
)
10
0 
(5
6-
10
0)
81
 (5
7-
94
)
64
 (3
2-
88
)
10
0 
(7
7-
10
0)
86
 (7
3-
99
)
57
 (2
0-
88
)
95
 (7
4-
10
0)
80
 (3
0-
99
)
87
 (6
5-
97
)
86
 (7
3-
99
)
71
 (3
0-
95
)
95
 (7
4-
10
0)
83
 (3
7-
99
)
91
 (6
9-
98
)
89
 (7
8-
10
0)
10
0 
(5
6-
10
0)
91
 (6
8-
98
)
78
 (4
0-
96
)
10
0 
(7
9-
10
0)
93
 (8
3-
10
0)
Te
st
 c
ha
ra
ct
er
is
tic
s 
of
 d
is
se
m
in
at
io
n 
in
 s
pa
ce
 (D
IS
) c
ri
te
ri
a,
 d
is
se
m
in
at
io
n 
in
 t
im
e 
(D
IT
) c
ri
te
ri
a,
 f
ul
l M
cD
on
al
d 
20
10
 a
nd
 M
cD
on
al
d 
20
17
 c
ri
te
ri
a 
(D
IS
+D
IT
) 
fo
r 
C
D
M
S 
di
ag
no
si
s 
in
 p
at
ie
nt
s 
w
ith
ou
t e
nc
ep
ha
lo
pa
th
y 
(A
D
S-
). 
D
IT
 a
nd
 D
IS
+D
IT
: p
at
ie
nt
s 
w
er
e 
in
cl
ud
ed
 fo
r 
an
al
ys
is
 if
 g
ad
ol
in
iu
m
 w
as
 a
dm
in
is
te
re
d 
or
 w
he
n 
no
 T
2 
le
si
on
s 
w
er
e 
pr
es
en
t 
at
 b
as
el
in
e 
M
R
I. 
Sp
in
al
 M
R
I w
as
 u
se
d 
in
 t
he
 e
va
lu
at
io
n 
of
 D
IS
 a
nd
 D
IS
+D
IT
 if
 a
va
ila
bl
e.
 S
ub
-a
na
ly
se
s 
ar
e 
pr
es
en
te
d 
of
 p
at
ie
nt
s 
in
cl
ud
in
g 
ac
ut
e 
di
ss
em
in
at
ed
 e
nc
ep
ha
lo
m
ye
lit
is
 (A
D
EM
), 
an
d 
pa
tie
nt
s 
yo
un
ge
r 
th
an
 1
2 
ye
ar
s 
ol
d 
(e
xc
lu
di
ng
 A
D
EM
)
CHAPTER 3.1
92
patients fulfilling DIT criteria (n=38, 41%), of whom 26/38 were diagnosed with CDMS(68%). 
A major increase in patients fulfilling DIT with the 2017 criteria is caused by allowing OCB to 
contribute to DIT when no gadolinium enhancement was present: an additional 20 patients 
fulfilled 2017 DIT at baseline(n=58 patients, 62%). Thirty-seven(64%) of these 58 patients were 
diagnosed with CDMS.
The test characteristics for 2010 and 2017 DIT criteria, excluding OCB status, were similar. 
When adding OCB status, the DIT criteria yield 27% in sensitivity (p<0.001), but lost 17% in 
specificity(p=0.004).(Table 3.1.3)
McDonald 2010 vs McDonald 2017 criteria
To evaluate the McDonald 2010 and 2017 criteria we selected ADS- patients who had T1 images 
with gadolinium administration (n=93). The McDonald 2010 DIS+DIT criteria were fulfilled in 
27/93 patients at baseline (29%), of whom 20 were diagnosed with CDMS (74%) after a median 
FU of 4.5 years (IQR 2.6-7.1). 
The McDonald 2017 criteria identified 21 additional patients who fulfilled the criteria at 
baseline (n=48, 52%) compared to the 2010 criteria, and 34/48 patients (71%) were diagnosed 
with CDMS. The sensitivity was higher in the McDonalds 2017 criteria (83% vs 49%; p<0.001) 
and the specificity was lower (73% vs 87%; p=0.02)(Table 3.1.3). 
The seven patients who caused the loss in specificity were identified (fulfilling the 2017 criteria 
and not the 2010 criteria at baseline, but not having a second attack during a FU of median 2.7 
years (IQR: 1.2-6.5)). New lesions on subsequent MRI were observed in 4 out of these 7 patients 
during FU. The other 3 patients did not undergo a second MRI. 
Of the 41 patients diagnosed with CDMS, the McDonald 2010 criteria led to the identification of 
20 patients (49%) at baseline. A second attack occurred in 17/20 (85%) within 3 years of FU and 
19/20 (95%) within 5 years. With the McDonald 2017 criteria 34/41 (83%) CDMS patients were 
identified at baseline. At 3 and 5 years of FU, 31/34 (91%) and 33/34 (97%) had a second attack 
within 3 and 5 years. 
Only one patient who fulfilled the 2010 and 2017 diagnostic criteria at baseline did not have a 
second attack (CDMS) within 5 years of FU, yet this patient showed new MRI lesions on FU scans.
The survival curves for CDMS diagnosis, the McDonald 2010 criteria and the revised McDonald 
2017 criteria on baseline MRI are presented in Figure 2. MS diagnosis could be made earlier in 
ADS patients using the 2017 than the 2010 criteria. For both criteria the hazard ratios for the 
DIS, DIT and full criteria at baseline are displayed in Table 3.1.4.  
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Figure 3.1.2: Time from incident ADS event to MS diagnosis
Survival curves for time from incident ADS event to MS diagnosis according to the McDonald 2010 (at 
baseline), McDonald 2017 (at baseline) criteria and CDMS. Abbreviations: acquired demyelinating 
syndromes (ADS), clinically definite multiple sclerosis (CDMS).
Contribution of symptomatic enhancing lesions, OCB and spinal cord imaging
As described before, the McDonald 2017 criteria identified 21 additional patients(n=48) 
compared to the 2010 criteria (n=27). 
These 21 patients were identified with the contribution of two major changes in the criteria. 
First, symptomatic lesions can be included to demonstrate DIS and DIT for the McDonald 2017 
criteria. This led to 7 more MS diagnoses (n=34) at baseline compared to the 2010 criteria 
(n=27). Of these 34 patients, 25 were diagnosed with CDMS (74%).
Table 3.1.4: Hazard ratios for CDMS diagnosis after applying DIS, DIT and full criteria (DIS+DIT) for 
McDonald 2010 and 2017 on baseline MRI.
McDonald 2010 p-value McDonald 2017 p-value 
DIS
(n=110)
HR 5.8
(95% CI 3.0-11.4) 
p<.001 HR 11.3 
(95% CI 4.0-31.6) 
p<.001
DIT
(n=93)
HR 2.9 
(95% CI 1.5-5.4) 
p=.001 HR 8.3 
(95% CI 3.0-23.4) 
p<.001
DIS+DIT (n=93) HR 3.1 
(95% CI 1.7-5.8)
p<.001 HR 8.5 
(95% CI 3.5-20.4) 
p<.001
Abbreviations: clinically definite multiple sclerosis (CDMS), dissemination in space (DIS), dissemination in 
time (DIT)
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Second, OCB are allowed to be taken into account when assessing DIT. This led to the other 14 
patients who fulfilled the McDonald 2017 criteria at baseline (total n=48) and caused the major 
increase in sensitivity of the criteria. Among these 48 patients, 34 (71%) were diagnosed with CDMS.
No additional patients fulfilled the McDonald 2010 criteria depending on spinal imaging. 
In contrast, the presence of a spinal cord lesion contributed to fulfilling McDonald 2017 at 
baseline in 6 patients. Three of these patients were eventually diagnosed with CDMS. Thus, 
3/41 (7%) patients with future CDMS fulfilled the DIS component at baseline by performing 
spinal cord imaging. 
Relevant subgroup analyses
DMT use before CDMS
DMTs have the potency to postpone a second attack, and could therefore influence CDMS 
diagnosis. We performed a subgroup analysis after excluding patients who received DMT 
before CDMS diagnosis (exclusion n=12). In the included patients (n=81), test characteristics 
for the full criteria (DIS+DIT) remained comparable with the total group (including DMT use 
before CDMS) for both the 2010 (sensitivity 41% vs 49%; specificity 87% for both selections) and 
2017 criteria (sensitivity 83% and specificity 73% for both selections). 
Analysis in ADS- patients <12 years old
The IPMSSG recommended that the McDonald 2010 criteria at baseline should not be used 
in patients <12 years. We applied the novel 2017 criteria to the group of patients below age 12 
only, after exclusion of ADEM cases. 
Seven of 28 ADS- patients (25%) were diagnosed with CDMS. Five patients (18%) fulfilled 
baseline criteria for 2010, 4 of them (80%) fulfilled the criteria for CDMS. Nine patients fulfilled 
the 2017 criteria (32%), and 7 (78%) were diagnosed with CDMS. 
The test characteristics were even better in children <12 years old than in the total group, 
for both McDonald 2010 criteria (sensitivity 57% vs 49%; specificity 95% vs 87%) and 2017 
criteria(sensitivity 100% vs 83%; specificity 91% vs 73%).  
Analysis in ADEM subgroup 
Only ADEM patients are included in this analysis (n=54). DIS was fulfilled for the 2010 criteria 
and 2017 criteria in respectively 24 (44%) vs 28 ADEM patients (52%). 
Regarding DIT, 7/49 (14%) ADEM patients fulfilled the 2010 DIT criteria and 9/49 (18%) fulfilled 
the 2017 DIT criteria, including OCB status. 4/49 (8%) of the patients would have fulfilled the 
McDonald 2010 criteria, and 5/49 (10%) the McDonald 2017 criteria(gain of 1 patient due to 
OCB). None of the patients fulfilled the criteria for CDMS during FU. 
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DISCUSSION
We investigated the application of the novel McDonald 2017 criteria for pediatric MS in clinical 
practice. We show that the McDonald 2017 criteria have a higher sensitivity than the previous 
2010 criteria for CDMS diagnosis for pediatric patients (83% vs 49%, p<0.001). However, the 
specificity was lower (73% vs 87%, p=0.02). Overall the diagnostic accuracy of the 2017 criteria 
was higher than for the 2010 criteria (77% vs 70%). The revised criteria are easier to apply 
than the McDonald 2010 criteria, mainly because of the major change of accepting all lesions 
to contribute to DIS and DIT, without taking the clinical symptoms into account. Moreover, we 
show that the 2017 McDonald criteria lead to more MS diagnosis at baseline, therefore MS 
diagnosis can be made earlier using the 2017 criteria. 
A high sensitivity is important to start DMT as soon as possible.26 which might lead to 
overtreatment in the group of patients who have a less active clinical disease course. Our 
main findings are supported by a recent extensive study in a cohort of ADS patients that also 
included evaluation of the applicability of the McDonald 2017 criteria.15 We validate their 
finding that the sensitivity is increased and specificity is decreased mainly by including OCB 
status into the 2017 criteria. However, specificity of the McDonald 2017 criteria in our study 
is somewhat lower. This is probably due to our study design by taking CDMS, a more clinical 
primary endpoint instead of new T2 lesions on a second MRI. We identified a minor subgroup 
of 7 patients that was responsible for the loss in specificity, who had a FU duration of 2.3 years. 
New lesions on subsequent MRI were observed in 4 of these patients. The other 3 patients did 
not undergo a second MRI. However, given the presence of typical MS lesions at baseline and 
OCB positivity in these 3 patients, it is quite likely that these patients would also have developed 
new MRI lesions after a longer FU. Taken together, we believe that initiation of DMT based on 
the novel criteria is warranted. Yet, clinicians should be aware that with the McDonald 2017 
criteria, more patients will be identified at baseline, and that a proportion of these patients will 
clinically have a less active disease course.
Performing spinal MRI led to fulfillment of the McDonald 2017 criteria at baseline in 3/41 
(7%) CDMS patients, but did not have additional value in the McDonald 2010 criteria, in line 
with another study that indicated limited value of spinal cord imaging in the McDonald 2010 
criteria in children.6 Fadda et al argued whether spinal cord acquisition would meaningfully 
add to the performance of the McDonald 2017 criteria, as only a real small proportion of their 
patients fulfilled the criteria based on spinal cord MRI. 15 However, in our cohort 7% of the 
CDMS patients could have been identified at baseline, which could significantly reduce the 
time to diagnosis in these patients. The exact place of spinal cord imaging as part of the MS 
diagnostic procedure deserves further investigation. 
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Our data shows that about 10% of the ADEM patients fulfill the McDonald 2010 and 2017 
criteria at baseline. However, no ADEM patient was diagnosed with CDMS in our cohort. The 
IPMSSG 2012 criteria explicitly mention not to apply the McDonald 2010 criteria to patients with 
ADEM. Our data supports this view for the McDonald 2017 criteria, in order to prevent incorrect 
initiation of treatment in these monophasic patients. 
Regarding age, ADS- patients <12 years seemed to have better accuracy for the McDonald 2017 
criteria than the total group (sensitivity 100% vs 90%, specificity 81% vs 60%, PPV both 64%, 
NPV 100% vs 89%), despite the small sample size for this analysis. This implies that both the 
McDonald 2010 criteria and McDonald 2017 criteria can be used across the age span, including 
children <12 years old with ADS, excluding patients with ADEM, in keeping with results from 
previous studies. 12,15,27 
Our study has several limitations. The choice of brain and/or spinal MRI, inclusion of contrast 
or not, and the decision to include testing for CSF oligoclonal bands, were left to the discretion 
of the treating physician. For example, spinal imaging is not always justified (sedation may be 
needed), CSF is not always tested in isolated optic neuritis and a paired serum sample is not 
always available with CSF (e.g. in case of exclusion of suspected infection). Therefore, like in 
other studies on the diagnostic criteria for pediatric MS, there was not complete coverage of 
all potentially relevant parameters. However, our main goal was to evaluate the revised 2017 
criteria in real world data, therefore we did not exclude patients from the analyses. Instead a 
few sub analyses have been performed. Despite our considerable FU duration of median 4.6 
years, it is possible that some patients are going to develop a second attack in the future. DMT 
could have postponed CDMS diagnosis, however our sub analysis excluding these patients 
showed no differences in test characteristics. Second, the PROUD-kids study did not have a 
standardized MRI follow-up, therefore we did not take FU MRIs into account for the analysis 
of the 2010 and 2017 criteria. However, the scope of this article was to analyze the diagnostic 
accuracy for CDMS at first attack of ADS. 
In conclusion, our data suggests that the McDonald 2017 criteria perform well in children. MS 
diagnosis can be made earlier and leads to a higher number of MS patients at baseline. Both 
the McDonald 2010 and 2017 criteria show similar results for the patients <12 years presenting 
with ADS, and can therefore be applied in this population as well. As proposed by the IPMSSG 
for the McDonald 2010 criteria, application of both 2010 and 2017 criteria in ADEM patients 
should be avoided.
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T-cell activation marker sCD27 is 
associated with clinically definite 
multiple sclerosis in childhood acquired 
demyelinating syndromes
Y.Y.M. Wong, R.M. van der Vuurst de Vries, E.D.van Pelt, I.A. Ketelslegers, M.J. Melief, 
A.F. Wierenga-Wolf, C.E. Catsman-Berrevoets, R.F. Neuteboom, R.Q. Hintzen, on behalf of the 
Dutch paediatric MS and ADEM study group. 
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ABSTRACT 
Background
Cerebrospinal fluid (CSF) levels of T-cell activation marker soluble CD27 (sCD27) are associated 
with subsequent disease activity after a first attack of suspected MS in adults. The predictive 
value for disease course in children with acquired demyelinating syndromes (ADS) is unknown.
Objectives
To assess the predictive value of sCD27 levels for clinically definite MS (CDMS) diagnosis in 
childhood ADS.
Methods
Children <18 years with a first demyelinating event were prospectively included and followed. 
sCD27 was determined in CSF using an enzyme-linked immunosorbent assay (ELISA). Cox 
regression analyses were used to calculate hazard ratios (HR) for CDMS. 
Results
Ninety-four ADS children were included (ADS with encephalopathy (ADS+) n=33 and ADS 
without encephalopathy (ADS-) n=61). Twenty-nine of 61 ADS- children(48%) were diagnosed 
with CDMS during follow-up. At baseline, sCD27 levels were higher in patients with a future 
CDMS diagnosis (n=29) than in monophasic ADS+(n=30), monophasic ADS- (n=28) and relapsing 
non-MS patients (n=7)(p<0.001). In ADS- patients, sCD27 was associated with CDMS (HR 1.8 
per 100 U/mL increase in sCD27 levels, p=0.031), after adjustments for age, oligoclonal bands 
and presence of dissemination in space on baseline MRI.
Conclusion
CSF sCD27 levels at first attack of demyelination is associated with CDMS diagnosis in children. 
This makes sCD27 a potential clinically relevant quantitative marker when performing routine 
CSF diagnostics.
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INTRODUCTION
Clinical manifestations of acute onset inflammatory demyelinating disease of the central 
nervous system (CNS) in children are termed acquired demyelinating syndromes (ADS).1,2 
ADS encompasses for example optic neuritis (ON), transverse myelitis (TM) as well as other 
presentations that localise to monofocal or polyfocal locations in the CNS, such as acute 
disseminated encephalomyelitis (ADEM). Up to one third of the children with ADS receive a 
later diagnosis of multiple sclerosis (MS).1,3,4 5 At the time of a first attack, it can be a challenge 
to determine the disease course of these patients. Early identification of children who will have 
an active disease course is important and can have therapeutic implications.6 
Soluble CD27 (sCD27) is a soluble form of CD27 secreted by activated T-cells after activation 
via the T-cell receptor, and is introduced as a potential biomarker for T-cell mediated 
inflammation.7 CD27 and sCD27 have a role in maturation, activation and proliferation of T- and 
B-cells.8,9 High sCD27 levels are reported in autoimmune diseases like rheumatoid arthritis, 
systemic lupus erythematosus and MS.10-12 Komori et al, validated CSF sCD27 as a biomarker 
for intrathecal T-cell activation in MS, using an extensive and validated battery of biomarkers 
for CNS inflammation.13 Serum sCD27 does not discriminate between healthy individuals and 
MS patients.14 In a recent study, high sCD27 levels in CSF associate with MS diagnosis and 
disease course in adult patients with clinically isolated syndromes.15 
These observations in adults have not yet been validated in the paediatric population with CNS 
demyelination. It is shown that children with MS tend to have a more inflammatory disease 
course than adults.16,17 Therefore we hypothesized that the predictive value of sCD27 levels for 
a second attack of MS will be equal or even higher in children than in adults. Furthermore, ADS 
with encephalopathy (ADEM) are known to have extensive intracerebral inflammation on MRI 
scans and may have severe clinical presentations.18 The levels of sCD27 might therefore differ 
between ADS subtypes. 
Here we examined whether sCD27 levels at first attack in children differ between ADS subtypes 
and assessed the predictive value of sCD27 for a second attack of MS in paediatric ADS patients. 
METHODS
Study participants 
Patients <18 years were included in the Dutch prospective and multicentre study for children 
with acquired demyelinating syndromes (ADS) (PROUD-kids study). 2 All patients with a lumbar 
puncture and baseline MRI, performed for routine diagnostics <6 months after onset of first 
symptoms, were included between June 2006 and February 2017. Patients with alternative 
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diagnosis were excluded. Patients were assessed at baseline and reassessed regularly. 
Patients were instructed to contact the hospital in case of suspected exacerbation. 
Definitions
Acquired demyelinating syndromes in children encompass the first attack of demyelination 
in the central nervous system, including patients presenting with encephalopathy (ADEM, 
defined as ADS+) and ADS without encephalopathy (defined as ADS-).2 3 CDMS was defined as 
two non-encephalopathic attacks, based on the clinical criteria proposed by the International 
Pediatric MS study group for paediatric MS diagnosis.3 Relapsing patients who have a distinct 
clinical phenotype other than CDMS were also included in this study, such as ADEM followed 
by relapsing optic neuritis (ADEM-ON)19, anti-aquaporin 4 antibody (AQP4-IgG) positive and 
negative relapsing disease.3,20,21 
A relapse was defined as acute worsening of existing symptoms or new symptoms after 
30 days of improvement or stable disease and no evidence of an alternative diagnosis. The 
symptoms should exist for more than 24 hours and not be preceded by fever.22 Exacerbations 
were confirmed by neurological examination. 
Follow-up (FU) duration was calculated by subtracting the date of first symptoms from the last 
visit date. Disability was expressed by the Expanded Disability Status Scale (EDSS).23 
CSF samples and sCD27 ELISA
CSF samples were centrifuged for 10 minutes at 3000 rpm to separate the supernatant from 
cells and cellular components. After centrifugation, all samples were stored in -80 degrees 
Celsius until use.24 Routine diagnostics of CSF included OCB, IgG index, cell count and total 
protein. Soluble CD27 levels were measured in duplo using the available commercial ELISA kit 
(Pelikine compact human sCD27 kit) manufactured by Sanquin in Amsterdam, the Netherlands.7 
The manufacturer’s instructions were followed when performing the sCD27 ELISA. Levels of 
sCD27 were expressed by units/mL by reference to a standard curve supplied with the ELISA 
kit. The clinical diagnosis was blinded for the analysts who performed the ELISA. The detection 
limit of the ELISA was 6 units/mL.
Standard protocol approvals, registrations and patient consents
The PROUD-kids study was approved by the Erasmus MC ethical committee and by the ethical 
committees of the other participating centres. Written informed consent was obtained from 
patients and/or their families. 
SOLUBLE CD27 IN PEDIATRIC ADS
105
3.2
STATISTICAL ANALYSIS 
Statistical analyses were performed using SPSS 24.0. Kolmogorov-Smirnov test was used 
to assess the normality of the data. Figures are made in Graphpad Prism5. Soluble CD27 
levels were not normally distributed, and were therefore log transformed to attain normally 
distributed data. Due to log-transformation, geometric means were calculated. For group 
comparisons, Student’s t-test and Mann-Whitney U test were used for continuous variables 
when appropriate. Student’s t-test was performed to compare the sCD27 levels in different 
ADS subgroups. Chi-square and Fisher exact test were used for categorical data. Correlation 
analyses were done for two continuous variables. 
Cox proportional hazard regression models were used to calculate univariate and multivariable 
hazard ratios (HR) in the ADS- group, with CDMS set as endpoint. The Cox proportional 
hazard assumption was tested by including a time dependent covariate in the model. Known 
predictors for MS diagnosis such as age of onset, OCB and fulfilling dissemination in space 
(DIS) at baseline MRI are used for adjustments in the multivariable analysis for sCD27 levels. 
Annualised relapse rate (ARR) for CDMS patients was compared between groups with high and 
low levels of sCD27 using a binomial regression model with the natural logarithm of number 
of FU years after a second clinical attack as offset. This offset corrects for the difference in FU 
duration between patients. The data were overdispersed and therefore the Poisson regression 
model was not suitable for our data set. P-value of <0.05 was considered significant. 
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RESULTS
Patients characteristics
A total of 94 children with a first attack of ADS were included in this study. Of these children, 33 
presented with ADS+ and 61 with ADS-. The median age for ADS+ was 4.5 years (IQR 2.6-6.3) 
and for ADS- patients 14.5 years (IQR 11.3-16.0). During follow-up, 30/33 (91%) of the ADS+ 
patients remained monophasic. Three ADS+ patients (9%) had a relapsing disease and fulfilled 
the criteria for ADEM-ON. No patient presenting with ADS+ was diagnosed with CDMS. Within 
the ADS- patients, 33/61 (54%) had a second attack. Of these 33 relapsing patients, 29/33 (88%) 
children were diagnosed with a second attack fulfilling the criteria for CDMS and the other 
4/33 (12%) were diagnosed with a relapsing demyelinating disorder other than MS (2 AQP4-IgG 
positive and 2 AQP4-IgG negative patients). The median time to CDMS was 10.3 months (IQR 
4.3-15.7). The median FU duration for all included patients was 2.5 years (IQR 1.4-4.9).
The following flowchart (Figure 3.2.1) illustrates the presenting phenotypes (ADS+ and ADS-) 
and diagnoses during follow-up. 
Figure 3.2.1: Flowchart of included ADS patients. 
Patients presented as ADS without encephalopathy (ADS-) and ADS with encephalopathy (ADS+; ADEM). 
The disease course during follow-up are shown dividing patients in monophasic ADS-, monophasic 
ADS+, CDMS and relapsing non-MS. The relapsing non-MS patients included 3 ADEM followed by optic 
neuritis, 2 AQP4 positive NMOSD and 2 patients with AQP4 negative NMOSD. Abbreviations: acquired 
demyelinating syndromes (ADS), ADS without encephalopathy (ADS-), ADS with encephalopathy (ADS+), 
acute disseminated encephalomyelitis (ADEM), anti-aquaporin 4 antibodies (AQP4), clinically definite MS 
(CDMS). 
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The median time between onset of symptoms and CSF sampling was 2.2 weeks (IQR 0.7-
5.9). No correlation was found between the levels of sCD27 and time between first symptoms 
and CSF sampling in the total group and in all groups separately. Twenty-four out of the 94 
patients (26%) received acute treatment (intravenous corticosteroids) before CSF sampling. No 
difference in sCD27 was found in patients who did or did not receive intravenous corticosteroids. 
No patients were on disease modifying therapy (DMT) or oral steroids before CSF sampling. 
Patient characteristics are shown in Table 3.2.1.
Soluble CD27 levels in subgroups of ADS 
Soluble CD27 levels at first attack of ADS were higher in patients with a future second attack 
of MS (n=29) than in ADS-patients who remained monophasic (n=28) (geometric means 65 U/
mL; 95% CI 47-89 vs 13 U/mL; 95% CI 9-18, p<0.001). Patients with monophasic ADS+ (n=30) 
did not differ in sCD27 levels from monophasic ADS- patients (n=28) (geometric mean 18 U/
mL; 95% CI 11-30 vs 13 U/mL; 95% CI 9-18), but did differ from ADS- patients with future CDMS 
diagnosis (geometric mean 13 U/mL; 95% CI 9-18 vs 65 U/mL; 95% CI 48-89; p<0.001). Patients 
with a relapsing non-MS disease course (n=7; 4 patients with ADS- onset and 3 with ADS+ 
onset) had lower sCD27 levels at onset than patients with a future CDMS diagnosis (geometric 
mean 18 U/mL; 95% CI 8-42 vs 65 U/mL; 95% CI 48-89 U/mL; p=0.001), but did not differ from 
monophasic ADS+ and monophasic ADS- patients. These results are displayed in Figure 3.2.2. 
No differences were found in sCD27 levels between anti-MOG positive (n=13) and anti-MOG 
negative (n=81) patients (data not shown). 
Fourteen of the 59 ADS- patients (24%) (after excluding the 2 AQP4 positive patients) fulfilled MS 
diagnosis at baseline by fulfilling the IPMSSG 2012 criteria for MS on first MRI.3 The sCD27 levels 
of these 14 children are significantly higher than ADS- patients who did not fulfil the criteria at 
baseline (geometric mean 78 U/mL; 95% CI 53-115 vs 20 U/mL; 95% CI 15-30, p<0.001). 
Ten out of the 28 monophasic ADS- patients showed sCD27 levels that exceed the upper bound 
of the 95% confidence interval of the geometric mean (13 U/mL; 95% CI 9-18), as shown in 
Figure 3.2.2. Of these patients, 8/10 fulfilled the diagnosis of MS by follow-up MRI scans, but 
did not experience a second attack during FU. The sCD27 geometric mean of these 8 patients 
was higher than the other 20 monophasic ADS- patients (geometric mean 35 U/mL; 95% CI 
27-45 vs 9 u/mL; 95% CI 6-12; p<0.001), but lower than the patients with future CDMS diagnosis 
(geometric mean 35 U/mL; 95% CI 27-45 vs 65 U/mL; 95% CI 48-89 U/mL; p=0.04). 
A subgroup analysis (n=59) was performed after excluding patients with <2 years of FU (patients 
with CDMS n=20). This did not change our observation that sCD27 levels are elevated in patients 
with a future second attack of MS compared to the three other subgroups (geometric mean 61 
U/mL, 95% CI 42-89 vs 15 U/mL, 95% CI 10-22; p<0.001). 
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Figure 3.2.2: Comparison of CSF sCD27 levels in ADS at time of first demyelinating event
Comparison of CSF soluble CD27 levels between patients with ADS+ (ADEM), monophasic ADS-, CDMS 
and relapsing non-MS patients. The relapsing non-MS patients included 3 ADEM followed by optic 
neuritis, 2 AQP4 positive NMOSD and 2 patients with AQP4 negative NMOSD. Horizontal lines with 
error bars indicate geometric means with 95% CI. Abbreviations: acquired demyelinating syndromes 
(ADS), ADS without encephalopathy (ADS-), ADS with encephalopathy (ADS+), acute disseminated 
encephalomyelitis (ADEM), clinically definite MS (CDMS).
Soluble CD27 correlates with CSF and MRI parameters
Patients with OCB (n=39) had higher sCD27 levels compared to patients without OCB (geometric 
means 42 U/mL; 95% CI 30-60 vs 17 U/mL; 95% CI 12-23, p<0.001). Soluble CD27 levels were 
positively correlated with IgG index (Spearman rho 0.695, p<0.001) as well as white blood cell 
count (Spearman rho 0.444, p<0.001). 
Patients fulfilling DIS on baseline MRI (n=50) showed higher sCD27 levels than patients without 
DIS (geometric mean 35 u/mL; 95% CI 26-46 vs 16 u/mL; 95% CI 11-24, p=0.003). 
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Figure 3.2.3: Comparison of sCD27 levels with CSF and MRI parameters 
Comparing CSF and MRI parameters with the levels of sCD27 in ADS patients. Horizontal lines with error 
bars indicate geometric means with 95% CI. Abbreviations: acquired demyelinating syndromes (ADS), 
oligoclonal bands (OCB), dissemination in space (DIS)
Seventy-two patients (77%) received gadolinium when the first MRI was performed. The sCD27 
levels were significantly higher in children who showed enhancement (n=31, 58%) than patients 
without enhancement (geometric mean 49 U/mL; 95% CI 34-71 vs 19 U/mL; 95% CI 12-28, 
p=0.001). 
For the analyses depicted above, all patients were analysed. Exclusion of patients with ADS+ 
(ADEM) and relapsing non-MS from the analysis (thus only including patients with monophasic 
ADS- and CDMS), did not alter the results. Results are shown in Figure 3.2.3. 
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Figure 3.2.4: Kaplan Meier curve for time to CDMS diagnosis in ADS without encephalopathy 
Kaplan Meier curve for time to CDMS diagnosis. All ADS- patients were stratified into two groups by the 
median CSF sCD27 level of all CIS patients; median 36 u/mL. Abbreviations: acquired demyelinating 
syndromes (ADS), ADS without encephalopathy (ADS-), clinically definite MS (CDMS).
High levels of sCD27 at first attack in ADS- patients are independently associated with a 
shorter time to CDMS. 
As described above, all patients with a second attack of MS had an ADS- presentation. No 
patient with ADS+ was diagnosed with CDMS. Therefore, in the following analyses ADS+ 
patients were excluded as well as the relapsing non-MS patients with AQP4-IgG. 
A Kaplan Meier curve was obtained after dichotomizing the sCD27 levels, using the median of 
the included ADS- patients (n=59); median sCD27 36.0 U/ml. Six out of 29 patients in the low 
sCD27 group were diagnosed with CDMS (21%) versus 23/30 (79%) in the high level group. In 
Figure 3.2.4 shows the Kaplan Meier curve for time to CDMS diagnosis (Log rank test, p=0.006). 
The univariate HR for CDMS was 2.8 (95% CI 1.7-4.6) per 100 U/mL increase in sCD27 levels 
(p<0.001). In the multivariable COX regression analyses, we corrected for age of onset, OCB 
and dissemination in space (DIS). After these corrections, sCD27 was independently associated 
with time to CDMS diagnosis with an HR of 1.8 (95% CI 1.0-3.3) per 100 U/mL increase in sCD27 
levels (p=0.031).
Eight out of 29 patients (28%) who received MS diagnosis based on MRI received DMT before 
CDMS and this might have postponed the second attack. We performed a sub-analysis using 
the COX-regression analysis where we excluded these patients, resulting in the same HR for 
the univariate (2.8, 95% CI 1.7-4.9; p<0.001) and multivariable analyses after adjusting for age 
of onset, OCB and DIS (1.8, 95% CI 0.96-3.4; p=0.061).
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Annualised relapse rate and disability
In patients who were diagnosed with CDMS, we used a negative binomial regression model for 
analyzing the ARR. The median of sCD27 levels in CDMS patients (n=29; 71 U/mL) was used to 
stratify patients into two groups with either high or low sCD27 levels. There was no difference 
found in ARR between high and low level group after correcting for follow-up duration. No 
correlation was found between sCD27 levels and EDSS score during follow-up.
DISCUSSION
Here we show that the T-cell activation marker sCD27 in CSF at first attack in paediatric ADS 
differs among ADS subtypes. Soluble CD27 levels in patients with a future diagnosis of CDMS 
were higher than in monophasic ADS+, monophasic ADS- and relapsing non-MS patients. There 
was no difference between the latter three groups. We analyzed ADS+ patients separately from 
ADS- patients as MS diagnoses after ADS+ is extremely low and also in our cohort no patients 
with ADS+ were diagnosed with CDMS during follow-up. Soluble CD27 was associated with a 
shorter time to CDMS diagnosis independently of known relevant clinical parameters such as 
MRI and CSF characteristics. 
An interesting observation was that 80% of the monophasic ADS- patients, whose sCD27 levels 
exceeded the 95% CI intervals of the whole monophasic ADS- group, fulfilled the IPMSSG 
diagnostic criteria for MS based on FU MRI. The sCD27 levels of this group were higher than 
monophasic ADS- and somewhat lower than patients with CDMS diagnosis. This may be 
related to the fact that these patients (who are diagnosed with MS by MRI alone) have a less 
active clinical disease course, compared to CDMS patients with higher levels of sCD27.
In line with Van der Vuurst de Vries et al, we observed higher soluble CD27 levels in patients with 
a future CDMS diagnosis than in monophasic ADS patients without encephalopathy (including 
clinically isolated syndromes).15 The levels were even higher in children than in adults with MS 
(geometric mean 65 U/ml; 95% CI 48-89 versus 42 U/mL; 95% CI 29-51 respectively).15 Our data 
not only validates the conclusion of Van der Vuurst et al, but is also congruent with previous 
observations that paediatric MS patients have a more inflammatory disease course compared 
to adults. 16,25-30 
The higher levels in patients with a future CDMS diagnosis most likely correspond to a higher 
intrathecal T-cell activation and higher inflammatory activity. The correlation we found between 
sCD27, OCB and IgG index is in line with previous adult studies. 13-15 In vitro, a functional role of 
sCD27 on stimulation and differentiation of B-cells is described earlier. 31,32 However the exact 
role for sCD27 on IgG production remains to be investigated.
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In adult MS patients, a higher ARR was found in patients with high sCD27 levels at time of 
clinically isolated syndrome.15 One would expect also a higher relapse rate in paediatric MS 
patients with high sCD27 levels at time of the first attack, however, no association with ARR 
was found. This finding might be explained by a ceiling effect, as the overall relapse rate in our 
paediatric MS cohort is high.16 
No association was found with EDSS, which is little surprising given the slower disease 
progression in paediatric MS.27,33 Longer follow-up duration will be needed to investigate a 
possible relationship between sCD27 levels and chronic disease progression. 
There were a few limitations of this study. First, the FU duration varied between patients. 
We addressed this problem by correcting for FU duration in the survival analyses. We also 
performed a sub-analysis in which we excluded patients with less than two years of follow-up. 
This did not alter the conclusions. Second, we did not perform a follow-up MRI on a regular 
basis. However, we aimed to assess the value of sCD27 levels on the clinical disease course 
and therefore chose CDMS as a study endpoint instead of the McDonald criteria. In addition, 
the use of DMTs may have delayed a second attack and could have influenced the results 
of the survival analyses. Therefore we performed sub-analyses after excluding patients with 
ADS- who used DMT before CDMS diagnosis. After excluding these patients, the multivariable 
analysis was not significant (p=0.061), however there was still a clear trend and the univariate 
analysis remained significant. Lastly, patients who remained monophasic had a shorter time to 
CSF sampling compared to patients who were diagnosed with CDMS during follow-up. This may 
have been caused by the difference in severity of the presenting symptoms and the differential 
diagnosis at onset, for example in ADEM, where acute non-demyelinating pathology needs to 
be ruled out. Yet, we found no correlation between the time to CSF sampling and the levels of 
sCD27, making it unlikely that this influenced our results. 
In summary, we show that CSF sCD27 in children with ADS at time of the first attack is 
associated with a future CDMS diagnosis, independently of MRI and CSF parameters. This 
result is in line with the earlier finding in adult CIS patients that higher sCD27 was associated 
with subsequent MS diagnosis.14 Therefore we can conclude that sCD27 is a potential clinically 
relevant quantitative marker when performing routine CSF diagnostics not only in adults but 
also in children with ADS. The next step will be validation of these findings in international 
cohorts. 
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ABSTRACT 
Background
A promising biomarker for axonal damage early in the disease course of MS is neurofilament 
light chain (NfL). It is unknown whether NfL has the same predictive value for MS diagnosis in 
children as in adults. 
Objective
To explore the predictive value of NfL levels in CSF for MS diagnosis in paediatric and adult CIS 
patients.
Methods
88 adult and 65 paediatric patients with a first attack of demyelination were included and 
followed (mean follow up-time in adults: 62.8 months (SD±38.7) and 43.8 months (SD±27.1) 
in children). Thirty control patients were also included. Lumbar puncture was done within 6 
months after onset of symptoms. NfL was determined in CSF using ELISA. COX regression 
analyses were used to calculate hazard ratios (HR) for clinically definite MS (CDMS) diagnosis. 
Results
After adjustments for age, oligoclonal bands, and asymptomatic T2-lesions on baseline MRI, 
increased NfL levels in both paediatric and adult CIS patients were associated with a shorter 
time to CDMS diagnosis (children HR 3.7; p=0.007, adults HR 2.1; p=0.032). For CIS patients 
with a future CDMS diagnosis, children showed higher NfL levels than adults (geometric mean 
4888 vs 2156 pg/mL; p=0.007).
Conclusion
CSF NfL levels are associated with CDMS diagnosis in children and adults with CIS. This makes 
NfL a promising predictive marker for disease course with potential value in clinical practice. 
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INTRODUCTION
Childhood-onset multiple sclerosis (MS) occurs in 3-5% of all MS patients. 1,2 Although children 
with MS have a more inflammatory disease course with a higher relapse rate than adult 
patients, 3-5 clinical follow-up studies suggest that disability progression is slower in children 
than in adults. 4,6,7 However, impairment of age-expected brain growth was seen early in the 
disease course of paediatric MS patients. 8 This indicates that not only neuroinflammation but 
also neurodegeneration occurs early in childhood-onset MS. 
Axonal damage is considered one of the major causes for persisting neurological disability in 
MS. 9 A promising biomarker for axonal damage is neurofilament light chain (NfL). 
Neurofilament light chain is an element of the neuron cytoskeleton, and is released in the 
extracellular space after neuronal cell death. 10 In healthy individuals, NfL levels increase with 
age, which reflects neurodegeneration and is part of the physiological aging process. 11 
High NfL levels in CSF in adults with clinically isolated syndrome (CIS) have been reported as 
an independent risk factor for MS diagnosis. 12 Furthermore, NfL levels have been associated 
with brain volume changes in adult CIS patients. 12 However, whether NfL is also increased at 
disease onset in children is still unknown.
The primary purpose of this prospective study was to investigate whether NfL levels can predict 
diagnosis of clinically definite MS (CDMS) in children with CIS. Our second aim was to compare 
NfL levels in CSF at time of a first demyelinating event between children and adults. Finally, we 
examined the association between NfL and signs of axonal loss on MRI. 
METHODS
Study participants 
Children and adults were included in either our prospective cohort of adult patients with CIS 
(PRedicting the OUtcome of a Demyelinating event, PROUD study) or in our prospective cohort 
of children with acquired demyelinating syndromes (ADS) (PROUD-kids study). 13,14 Both studies 
are ongoing multicentre studies initiated by Erasmus MC in Rotterdam, The Netherlands, 
which is a tertiary referral centre for adult and paediatric MS patients (MS Centre ErasMS, and 
National Paediatric MS Centre). 
All patients were included between February 2002 and December 2015 within 6 months after a 
first event of demyelination of the CNS. Adult patients were younger than 50 years of age, and 
paediatric patients were younger than 18. No patients had a history of previous neurological 
CHAPTER 3.3
120
symptoms suggestive for CNS demyelination. Patients with alternative diagnoses were 
excluded from analyses. 
The included patients underwent a baseline brain MRI and routine laboratory tests to rule out 
other possible diagnoses. A lumbar puncture was performed and extra CSF was collected and 
stored at −80°C until use. 
Patients were assessed at baseline and were reassessed regularly. At baseline instructions 
were given to the patients to contact the hospital in case of suspected exacerbation. 
Cerebrospinal fluid of adult control samples (n=30) was obtained in the Erasmus MC from 
patients with neurological symptoms but no objective clinical or paraclinical findings to define 
a specific neurological disease (symptomatic controls). 15 
Standard protocol approvals and patient consents
The study protocol was approved by the Medical Ethics Committee of Erasmus MC Rotterdam 
and of the other participating centres. Written informed consent was obtained from all patients 
and/or their families. 
Definitions
Clinically isolated syndrome (CIS) was defined as a first attack of demyelination in the CNS 
without encephalopathy. 16 Clinically definite MS (CDMS) was defined by the Poser criteria as 
two non-encephalopathic attacks with clinical evidence of two separate lesions. 17 Acquired 
demyelinating syndromes (ADS) in children encompass the first attack of demyelination, 
including CIS and acute disseminated encephalomyelitis (ADEM).14 Patients presenting with 
other ADS subtypes than CIS or ADEM were excluded from the analyses. Children were 
diagnosed with CIS, ADEM and CDMS according to the diagnostic criteria proposed by the 
International Paediatric Multiple Sclerosis Study Group. 13 CDMS was used as the primary 
outcome. Patients who remained CIS during follow-up are referred to as CIS-CIS and patients 
who were diagnosed with CDMS during follow-up are referred to as CIS-CDMS. In both children 
and adults an exacerbation is defined as sub-acute worsening of existing symptoms, or new 
symptoms after at least 30 days of improvement or stable disease. Symptoms should exist for 
more than 24 hours, not be preceded by fever, and not be caused by an alternative diagnosis.18 
All exacerbations were confirmed by neurological examination. 
Expanded Disability Status Scale (EDSS) was used to assess disability. 19 When patients were 
diagnosed with CDMS an EDSS was done annually. EDSS scores performed within 3 months 
after an exacerbation were not considered. Follow-up was calculated by subtracting the date of 
first symptoms from the last visit date. Baseline MRI scans were performed at 1.5 Tesla scanners 
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and reviewed blindly. Available T1-, axial T2-, axial and/or sagittal fluid attenuated inversion 
recovery (FLAIR)- images were used. The MRIs were scored on ≥9 T2 lesions, dissemination 
in space and time, and asymptomatic T2 lesions. The presence of T1-hypointense lesions on 
baseline MRI were assessed in CDMS patients. T1-hypointense lesions were defined as non-
enhancing lesions being hypointense relative to cortical grey matter. 20 Patients who did not 
receive gadolinium were excluded for the analysis of T1-hypointense lesions.
CSF sampling and NfL ELISA
Routine CSF diagnostics including IgG index, oligoclonal bands (OCB), cell count and total 
protein were performed. The remaining CSF was immediately centrifuged for 10 minutes at 
3000 rpm to separate the supernatant from cells and cellular elements. After centrifugation, 
samples were aliquoted and stored at −80°C until use.
CSF analyses for oligoclonal bands (OCB) were performed in local laboratories using isoelectric 
focusing. 21 OCB status was regarded as positive if there were ≥2 unique bands in CSF compared 
to serum. IgG index above 0.66 was considered as elevated. 
Neurofilament light chain levels in CSF were measured batch-wise in two rounds, according to 
the manufacturer’s instructions, using a stable commercially available solid phase sandwich 
ELISA (UmanDiagnostics, Umea, Sweden). 22 NfL concentrations (picogram per millilitre (pg/
mL)) were calculated using a standard curve according to manufacturer’s instructions. All 
samples were tested double blind and measured in duplicate. The detection limit of the ELISA 
was 150 pg/ml. 
Data analysis
We used SPSS software, version 21.0 (SPSS Inc) and GraphPad Prism5 to perform statistical 
analyses. After log transformation, NfL levels showed a parametric distribution in both 
children and adult samples. Therefore we calculated geometric means for NFL levels. Group 
comparisons for continuous data were performed using 2-tailed t test for normally distributed 
variables (NfL, age at onset, follow-up time) and Mann-Whitney U test was used for non-
parametric data (time between CIS and lumbar puncture). We used one-way ANOVA and post-
hoc Bonferroni correction for parametric data to analyse differences between multiple groups. 
Chi-square or Fisher exact test were performed for categorical variables (gender, type of 
clinical onset, OCB, elevated IgG-index, asymptomatic T2 lesions, ≥9 T2-lesions, and disease 
modifying therapies (DMT) after CIS and before CDMS). Spearman rank correlation was used 
for correlation analyses between non-parametric continues variables. Time to CDMS diagnosis 
was determined by subtracting the date of the first symptoms from the date of diagnosis. COX 
proportional hazard regression analyses were used to calculate univariate and multivariable 
hazard ratios (HR) for time to CDMS diagnosis. Known predictors for MS diagnosis were used in 
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the multivariable analyses (OCB, asymptomatic T2-lesions). Patients who were not diagnosed 
with CDMS during follow-up were considered as censored observations. We used the median 
of NfL levels to establish cut-off values for high and low levels of NfL in children and adults 
separately. P-values less than 0.05 were considered significant. 
RESULTS
Patients characteristics
Sixty-five children with a first demyelinating event of the CNS, 88 adult patients with CIS, and 
30 age and gender matched adult control individuals were included in this study. 
Of the 65 children, 24 presented with ADEM and 41 with CIS. Twenty-five out of 41 (61%) children 
with CIS were diagnosed with CDMS during a mean follow-up time of 38.4 months (SD: 21.0). 
The mean follow-up time in adult CIS patients was 68.2 months (SD: 39.3) in this period 43 
(49%) patients were diagnosed with CDMS. 
The median time from CIS to CDMS in adult patients was 36.4 months (IQR 14.4-48.9) and in 
children 10.8 months (IQR 5.0-15.7). 
The time between CIS and lumbar puncture was not significantly different between children 
and adult patients. No patients were receiving disease modifying therapies (DMTs) at time of 
lumbar puncture.
Sixteen adult patients (18%) and 14 (34%) children who were not yet diagnosed with CDMS 
received DMT (glatiramer acetate (n=11), interferon (n=19), natalizumab (n=1)). 
The patient characteristics for adults and children are shown in Table 3.3.1 and Table 3.3.2.
NfL levels at time of the first demyelinating event per clinical subgroup 
Patients (children and adults) at time of a first attack of demyelination showed higher NfL 
levels than control individuals; geometric mean 2040 vs 444 pg/mL; p<0.001. In Figure 3.3.1, 
NfL levels from controls, adult, and paediatric patients are shown.
In adult patients, NfL levels at time of CIS were higher in the group that was diagnosed with 
CDMS (CIS-CDMS, n=43 (49%)) compared to the group that remained CIS during follow-up 
(CIS-CIS); geometric mean 2156 vs 1342 pg/mL; p=0.012. (Figure 3.3.2)
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Figure 3.3.1: CSF NfL levels in Controls vs Adults vs Children 
CIS and ADEM patients are included in children. 
Horizontal lines with error bars indicate geometric mean with 95% CI. 
Abbreviations: NfL = Neurofilament light chain; pg/mL = picogram/millilitre
In children, we compared NfL levels between CIS-CIS, CIS-CDMS, and ADEM patients. NfL 
levels at time of CIS in paediatric CIS-CDMS patients (n=25; 61%) were higher than in paediatric 
CIS-CIS patients; geometric mean 4888 vs 967 pg/mL; p=0.01. Children with ADEM did not 
differ in NfL levels from CIS-CIS and CIS-CDMS children; geometric mean 2683 pg/mL (Figure 
3.3.2). There was no correlation between time from onset of symptoms to lumbar puncture and 
NfL levels in both children and adults. 
NfL levels compared between children and adults
Next, we compared NfL levels between children and adult patients at time of CIS. In the CIS-
CDMS group, NfL levels were higher in children compared to adults; geometric mean 4888 vs 
2156 pg/mL; p=0.007. NfL levels were not different between adults and children in the CIS-CIS 
groups (Figure 3.3.2).
Association of NfL levels with time to CDMS diagnosis in children and adults with CIS
To analyse time to CDMS diagnosis, we used median CSF NfL levels in CIS patients as cut-off. 
This resulted in a cut-off of 1802 pg/mL for adults and 2537 pg/mL for children. These cut-offs 
were used to divide CIS patients (ADEM excluded) into groups with high and low NfL levels, and 
were subsequently used in the COX regression analysis.
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The univariate COX regression analysis showed a HR for CDMS diagnosis of 2.1; p=0.024 in 
adults and 3.8 in children with CIS; p=0.003. Kaplan-Meier curves are shown in Figure 3.3.3A/B. 
In a multivariable COX regression analysis, we corrected for clinically relevant parameters; 
the presence of asymptomatic T2 lesions on the baseline MRI and OCB. We also corrected for 
age at onset, based on correlation with NfL levels in control individuals (spearman rho 0.59, 
p=0.001). The HR in the multivariable COX regression analysis for high NfL levels was 2.1 in 
adults (p=0.032) and 3.7 in children (p=0.007). (Table 3.3.3)
Figure 3.3.2: NfL levels in clinical subgroups of adults and children 
Horizontal lines with error bars indicate geometric mean with 95% CI. 
Abbreviations: NfL = Neurofilament light chain; ns = not significant; pg/mL = picogram/millilitre
A total of 16 (18%) adult CIS patients and 14 (34%) children received DMT before CDMS 
diagnosis. This could have postponed the second attack. The HR in children increased after 
excluding patients who received DMT before CDMS diagnosis. In adults the univariate HR did 
not change, and the HR in the multivariable analysis showed a trend towards significance.
When we add DMT before CDMS diagnosis into the COX regression model, the HRs did not change. 
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Thirteen (11%) adults and nine (22%) children were treated with methylprednisolone within 
three months before LP. When we corrected for this in the COX regression model, the results 
did not change. 
In another subanalysis, we excluded CIS-CIS patients who had less than 2 years follow-up 
(children: n=5, adults: n=10). After this exclusion, HRs were not altered in adults and increased 
in children. Table 3.3.3 shows the univariate and multivariable HRs including those of the 
subanalyses. 
Figure 3.3.3: Time from CIS to CDMS in CIS patients with high and low CSF NfL levels 
A. Adults (log-rank test p=0.02). 
B. Children (log-rank test p=0.001). Kaplan-Meier curves showing time to CDMS diagnosis for CIS 
patients (ADEM excluded) with either high or low CSF NfL levels. 
Abbreviations: CDMS = Clinically definite multiple sclerosis; NfL = Neurofilament light chain; pg/mL = 
picogram/millilitre
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Association of CSF NfL levels with disability 
We did not find a correlation between CSF NfL levels and EDSS scores after CDMS diagnosis. 
We collected EDSS data from 55/68 (81%) patients who were diagnosed with CDMS. Only 6 
patients (4 adults and 2 children) reached an EDSS of 3.0 or more. 
Association of CSF NfL levels with signs of axonal damage on MRI
CSF NfL levels were increased in CDMS patients showing T1-hypointense lesions on baseline 
MRI (adults 20/39, 51%; children 15/23, 65%). We found this in adults (geometric mean 3188 vs 
1588 pg/mL; p=0.001) and in children (geometric mean 8920 vs 1668; p=0.001). (Figure 3.3.4A/B) 
Figure 3.3.4: CSF NfL levels in CIS-CDMS adults and children with and without T1-hypointense lesions 
on baseline MRI 
A. Adults: T1-hypointense lesions vs no T1-hypointense lesions on baseline MRI. 
B. Children: T1-hypointense lesions vs no T1-hypointense lesions on baseline MRI. 
Horizontal lines with error bars indicate geometric mean with 95% CI. 
Abbreviations: NfL = Neurofilament light chain; pg/mL = picogram/millilitre; CDMS = Clinically definite 
multiple sclerosis
DISCUSSION
In this prospective study, we demonstrate that CSF NfL levels in children and adults with a 
first attack of suspected MS are predictive for CDMS diagnosis. Furthermore at time of CIS, 
CSF NfL levels in patients with a future CDMS diagnosis are higher in children than in adult 
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patients. This underlines that not only inflammation is more severe in children 3-5 but that 
children also have more axonal damage early in the disease course of MS than adult patients. 8 
To our knowledge, we are the first to show that CSF NfL levels are associated with a subsequent 
diagnosis of CDMS in children with CIS. In addition, the results validate the predictive value of 
CSF NfL levels for CDMS diagnosis in adult CIS patients. 12,23 Both in adults and children, these 
findings were independent of known predictive factors for CDMS, i.e. asymptomatic T2 lesions 
on baseline MRI and unique OCBs in CSF. Moreover, CSF NfL levels predicted a second attack 
even better than these currently used markers. 
It is essential to improve currently available routes to prediction to prevent unnecessary treatment 
of patients with low clinical disease activity, especially because these immunomodulatory 
therapies can have serious side effects. Recently, other potential CSF biomarkers for a future 
MS diagnosis have been identified. 24,25 Our findings draw further attention to the relevance of 
including CSF analyses as part of routine diagnostics.
Since NfL is considered a biomarker for axonal damage, neurodegeneration, and brain atrophy, 
26,27 we reasoned that its presence in CSF could be associated with T1-hypointense lesions on 
MRI, which are signs of axonal loss. 28 In children with CIS, these T1-hypointense lesions have 
been reported to be highly predictive for MS diagnosis. 20 Here, we demonstrate that children 
and adult CIS patients with T1-hypointense lesions on baseline MRI have higher NfL levels than 
patients without these lesions. 
CSF NfL levels in children with ADEM were not significantly different from levels in patients who 
remained CIS or who were eventually diagnosed with CDMS. Nevertheless, these levels were 
high in ADEM patients (geometric mean 2683 pg/ml), indicating considerable axonal damage. 
Studies have reported cognitive impairment and persistent motor dysfunction in children with 
ADEM. 29,30 Moreover, it has been shown that subsequent white matter maturation and age-
expected brain growth is disturbed not only in paediatric MS, but also in monophasic ADS, 
including ADEM. 31,32 These findings support the occurrence of damage during the acute phase 
with a lasting impact. Which stresses the importance of adequate follow-up and support after 
the acute event.
NfL levels have been reported to be also increased in serum of adult CIS and MS patients , 33,34 
but the predictive value in CIS patients for MS diagnosis of this marker seems limited to CSF.12 
As we here aimed to assess and compare prediction in both children and adults with CIS, we 
restricted in this study to CSF samples.
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There are some limitations in this study. First, the range of follow-up is rather wide. We did 
correct for this in the COX regression analyses, and we also performed a subanalysis after 
excluding CIS-CIS patients with a follow-up less than 2 years, which did not change our findings. 
Second, in both the adult and paediatric study, we did not perform a follow-up MRI on a regular 
basis. Therefore, the Poser criteria were used instead of the McDonald 2010 criteria. In this 
way, we could show an effect on clinical disease activity (second attack) instead of disease 
activity measured with MRI. Third, in order to prove an association of CSF NfL levels with 
EDSS, we will need a longer follow-up period since disability occurs later in the disease course 
especially in children. 6 Fourth, we did not have access to advanced imaging techniques for 
quantification of neurodegeneration (e.g. T1-hypointense lesion volumes, total brain volume 
and brain tissue integrity). However, we used the presence of T1-hypointense lesions as an MRI 
marker for axonal damage, 28 because it is easily assessable. Furthermore, we did not include 
paediatric controls since we did not receive ethical permission to collect paediatric control CSF 
samples, which made the collection of this rare material not possible. Yet, control groups in 
other paediatric studies indicate low physiological levels of NfL, in the same range as the adult 
controls in the present study.35,36 
Last, although our sample size was relatively small due to limited availability of CSF, we were 
still able to correct our results for other predictive factors for MS diagnosis. Our findings 
in children were also compatible to those in adults, further stressing the robustness of the 
observations.
In conclusion, we show that high levels of CSF NfL are associated with CDMS diagnosis 
independently of known predictive factors (i.e. asymptomatic T2 lesions and OCB) in both 
children and adults. CSF NfL levels at time of a first demyelinating event are higher in children 
than in adults with a future CDMS diagnosis. In addition, this marker for axonal damage, 
is associated with MRI signs of neurodegeneration in both groups. Given that therapeutic 
interventions might delay disease progression and accumulation of disability, 37,38 it is essential 
to accurately predict MS diagnosis, not the least in the paediatric population. Hence, NfL in 
CSF is a promising predictive marker for the disease course in both adults and children with a 
first demyelinating event, with a potential value in future clinical practice. 
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ABSTRACT
Background
Acute disseminated encephalomyelitis, followed by optic neuritis (ADEM-ON) is a rare 
demyelinating syndrome different than MS and neuromyelitis optica spectrum disorder. We 
aim to describe the disease course, treatment response and outcome of these children. 
Methods
Children <18 years were identified from 6 countries of the EU Paediatric Demyelinating Disease 
Consortium. Patients fulfilled the diagnostic criteria for ADEM, followed by at least one ON. 
Anti-MOG antibodies (MOG-IgG) were tested in all patients. 
Results
In this study of 17 patients (9 boys) with ADEM-ON, MOG-IgG were identified in 16/17. Age 
at onset was 6.1 years (IQR 5.1-9.2). Twelve patients received oral prednisolone and 10 
received maintenance immunosuppression (e.g. azathioprine, intravenous immunoglobulins, 
Rituximab). During a follow-up of 5.3 years (IQR 1.8-10.2), 54 relapses occurred with a median 
3 relapses/patient (range 1-9). Patients relapsed on all treatments but no relapses occurred 
on a prednisolone dose >10mg/day. Visual and cognitive residual deficits were common in this 
group. 
Conclusion
ADEM-ON is a MOG-IgG associated relapsing disorder and can have a heterogeneous disease 
course. Patients were refractory for maintenance immunosuppression and appeared to be 
corticosteroid-dependent. Further international collaborations are now required to unify 
guidelines in this difficult to manage group of patients.
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INTRODUCTION
Acute disseminated encephalomyelitis (ADEM) is a well-recognized acquired demyelinating 
syndrome (ADS) characterized by a polyfocal onset and encephalopathy. It is most commonly seen 
in young children.1 Although predominantly monophasic, some children relapse and may fulfill the 
diagnostic criteria of multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD).1 
More recently, a distinct clinical phenotype has been recognized, different than MS and NMOSD, 
with patients relapsing with single or recurrent episode of ON following ADEM.2 The majority 
of these children have myelin oligodendrocyte glycoprotein antibodies (MOG-IgG). 3-5 In a Dutch 
paediatric cohort of acquired demyelinating syndrome (ADS) only 1.2% of children were diagnosed 
with ADEM-ON.6 Despite the rarity of ADEM-ON in ADS, ADEM-ON has been the final diagnosis in 
about 40% of MOG-IgG positive relapsing patients who initially presented with ADEM.7,8 
As no treatment guidelines are currently available for patients with ADEM-ON the aim of this 
European collaboration study was to describe the disease course, treatment response and 
outcome of ADEM-ON patients in a multinational approach. 
METHODS
Patients and design
We collected demographic, clinical, radiological and serological data of 17 patients under age 
18 from 6 countries of the EU Paediatric Demyelinating Disease Consortium (The Netherlands 
n=7, United Kingdom n=6, Germany n=1, France n=1, Spain n=1, Belgium n=1). This consortium 
was initiated as a component of the ERN-RITA (European Reference Network for Rare 
Immunodeficiency, Autoinflammatory and Autoimmune Disease). Patients were identified 
by reviewing local or national paediatric demyelination registries and included after fulfilling 
the following criteria: i) presenting with ADEM as a first demyelinating event in accordance 
with the IPMSSG criteria ii) experiencing ≥1 subsequent attack of optic neuritis (ON) without 
encephalopathy ≥3 months after ADEM onset, with or without additional episodes of ADEM in 
between (MDEM-ON).1 
A unified case reporting form was distributed to all participating sites to collect de-identified 
patient data. Assessments of visual function were carried out by ophthalmology departments 
at the respective centres, including high contrast visual acuity measured by the logarithm of 
the minimum angle of resolution (logMAR) and colour vision measured by Ishihara plates. 
All patients were tested locally in the respective reference laboratories of the referring countries 
for serum MOG and AQP4 antibodies, using live cell-based assays, as part of standard clinical 
care while clinically symptomatic.3,4,9-11 
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Institutional review board and/or national research ethics approval was obtained at individual 
centers or national programs respectively. 
STATISTICAL ANALYSIS
Chi square and Mann-Whitney U test were used for group comparison. Time to first ON-relapse 
(TTFR) was calculated by subtracting the date of ON-relapse from the onset date of the last 
ADEM attack. ARR after the first ON was analyzed with a negative binomial regression, with 
the natural logarithm of follow-up years after the first ON as offset. This offset was used to 
correct for the different follow-up durations between patients. Statistical significance was set 
at p-value of 0.05. 
RESULTS
Seventeen ADEM-ON patients were included in this study. Clinical, paraclinical features, 
treatment response and outcome are summarised in Table 3.5.1 and Figure 3.5.1. MOG-IgG 
were identified in 16/17 (94%). This seronegative patient had a typical ADEM-ON disease 
course and serum was tested in the acute phase at onset and re-tested during relapses. MOG-
ab were persistently positive in all patients who were retested at follow-up (n=8) irrespective of 
the presence of disease activity. All patients were AQP4-IgG negative. Brain MRI at follow-up 
showed improvement or complete resolution of ADEM brain lesions in all patients. 
A total of 54 relapses were reported in the cohort (median 3 relapses per patient, range 1-9), 
during a median follow-up of 5.3 years (IQR 1.8-10.2). Of which 51/54(94.4%) were ON (10/51 
bilateral) and 3/54(5.6%) ADEM-relapses (Figure 3.5.1). Nadir visual acuity (VA) at relapses 
(n=32) was median 0.08 (IQR <1/300 – 0.38). No differences in nadir VA or residual deficits 
was observed between treated and untreated patients. Oral prednisolone taper was used in 
12/17 (71%) patients (starting dose 1-2 mg/kg/day). Twenty-seven of the 54 relapses occurred 
when oral corticosteroids were tapered off to a low dose (median 8.5 mg, range 1-10 mg) 
or in the four weeks following discontinuation (median 1.1 weeks; range 0.5-5 weeks). Oral 
corticosteroid was re-introduced using a higher dose when relapse occurred (median 20 mg, 
range 10-60 mg), resulting in prolonged corticosteroid exposure (median 6 months, IQR 1.7-
14.8 months). No relapses occurred while using a dose>10mg.
Maintenance immunotherapy was commenced in 10/17(59%); Azathioprine 2-3 mg/kg/
day (n=6), Mycophenolate 1200 mg/m2/day (n=1), regular IVIG 0.4-1.0 g/kg/dosis (n=2) and 
Cyclophosphamide 750 mg/m2/month for 6 months (n=1). Median time from acute treatment 
to initiating maintenance therapy was 3 days (range 0-42 days). Treatment response was 
evaluated at least 6 months after initiation (time of treatment range 6-61 months). Six patients 
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relapsed on maintenance treatment (total 13 relapses) and were switched to another therapy 
or another agent was added to the treatment regime, including Rituximab (500 mg/m2/dosis, 
2 dosis per cycle; every 6 months) and IviG (Figure 3.5.1). Of these 6/13 relapses occurred 
when the oral corticosteroids were tapered off to a low dose (≤10 mg/day) despite ≥6 months 
of treatment with maintenance therapy. Seven relapses occurred in patients on maintenance 
treatment only. The disease course differed between patients in the number of relapses and the 
length of disease-free intervals, up to many years (median 5.7 months, range 3-247 months), in 
both treated and untreated patients (Figure 3.5.1).
Figure 3.5.1 ADEM-ON disease course and treatment (n=17). 
Disease course of acute disseminated encephalomyelitis followed by optic neuritis (ADEM-ON) and 
treatments given per patient. Magnetic resonance imaging from patient 12. Onset: bilateral multiple large 
and hazy lesions on fluid-attenuated inversion recovery (FLAIR) imaging sequence. Relapse 1: resolution of 
white matter lesions on FLAIR imaging and a thickened left optic nerve on T1 sequence without gadolinium 
enhancement. Relapse 3: relapse of ON without new T2 lesions. AZA, azathioprine; CYC, cyclophosphamide; 
IVIG, intravenous immunoglobulins; MMF, mycophenolate mofetil; RTX, Rituximab. °, ADEM; , ON.
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Table 3.5.1: Patient characteristics 
Clinical parameters Patients n=17
Male, n (%) 9 (56)
Age of onset, years, median (IQR) 6.1 (5.1-9.2)
Caucasian, n (%) 13 (81)
Other autoimmune diseases, n (%) 0 
Admission to ICU, n (%) 7 (41)
Preceding event <4 weeks before onset, n (%)
- Vaccination 
- Infection/fever
- 5 (29)
- 11 (65)
CSF oligoclonal bands, n (%) 0/14 
MOG-IgG 16/17
MRI brain at baseline*
ADEM-likea
Unspecific lesionsb
Unavailablec
15
1
1
MRI Spine at baseline 12/15 (80%)
Presenting symptoms
Seizures, n (%) 7 (41)
Vision disturbances, n (%) 6 (35)
Autonomic features, n (%) 7 (41)
Cranial nerves, n (%) 3 (18)
Bulbar dysfunction, n (%) 1 (6)
Sensory, n (%) 3/15 (20)
Motor dysfunction, n (%) 9 (53)
Cerebellar symptoms, n (%) 9 (53)
Headache, n (%) 10 (59)
Acute treatment, n (%)
- IvMP 3-5 days
- Dexamethasone
- IvIG 5 days 
- Additional treatment 
o 2nd IvMP 3-5 days
o 2nd IvIG 5 days
13 (77)
- 10/13 (77)
- 2/13 (15)
- 1/13 (8)
- 7/13 (54)
o 4/7 
o 3/7
Outcome, n (%)
- Residual deficits 
- Visual impairment
- Visual acuity impairment 
- Visual field impairment
- Colour vision
- Cognitive impairment 
- Seizures
12 (71) 
8 (47)
7 (41)
7 (41)
4 (24)
8 (47)
2 (12)
Definitions. IQR: interquartile range. ICU: intensive care unit. CSF: cerebral spinal fluid. ADEM: 
acute disseminated encephalomyelitis. IvMP: intravenous methylprednisolone. IvIG: intravenous 
immunoglobulins. MOG-IgG: myelin oligodendrocyte glycoprotein antibodies (IgG subtype). 
* Baseline MRI brain performed within 3 months after onset of symptoms. aADEM-like MRI: predominantly 
confluent, hazy and poorly demarcated involving both grey and white matter.bUnspecific lesions: non-
specific white matter lesions not fulfilling MAGNIMS criteria for MS specific lesions. cUnavailable: patient 
was retrospectively identified. MRI was not assessable. However, the patient had encephalopathy at 
presentation and patient charts mentioned lesions fitting the diagnosis of ADEM.
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A shorter TTFR was associated with more relapses after the first ON during follow-up 
(spearman rho -0.531,p=0.028). The median TTFR was 7 months(IQR 4-85). There was a trend 
to have higher ARR in patients who relapsed within 7months (mean ARR 1.24 vs 0.35,p=0.061). 
At last follow-up, residual deficits were reported in 12/17(71%) patients and included visual 
impairments (n=8), cognitive impairments (n=8), seizures (n=2), behavioural problems (n=3), 
weakness in extremities (n=1) and bladder/bowel dysfunction (n=1) were less common. The 
median EDSS score at last follow-up was 1.0 (IQR 0-3.0). 
Residual deficits did not correlate with number of relapses or TTFR. 
DISCUSSION
Here we report the disease course, treatment and outcome of ADEM-ON patients identified 
from six European countries. MOG-IgG were identified in 16/17. This rare group of patients was 
characterized by large heterogeneity in disease course and applied treatment regimens. By 
contrast to the reported literature in adults with MOG-IgG associated disease, residual deficits 
such as visual and cognitive impairments were common.11-15 
Despite heterogeneity in treatment we observed that relapses occurred on all treatments even 
under more potent therapies such as Rituximab and/or IVIG. Oral prednisone, on the contrary, 
was effective if given in doses >10mg daily. This indicates a certain degree of corticosteroid 
dependence in these children, although the worrisome side effects and unpredictable disease 
course of ADEM-ON patients warrant against long-term use of high doses (>10mg) prednisone. 
Corticosteroid dependence may be typical for relapsing MOG-IgG relapsing ON.16 
We observed a prolonged interattack intervals (>5 years) which is not typically seen in 
children with RRMS and may result in potential overtreatment and exposure to long-term 
immunosuppression. This stresses the importance of identifying early predictors for future 
disease course. TTFR may be good marker, as children with a short TTFR tended to have a 
higher ARR. Monitoring of MOG-IgG during the course of disease may aid in predicting the 
future disease course and guiding treatment.17 
Although this study was the result of a multinational EU collaboration, the sample size 
remained relatively small due to the extreme rarity of ADEM-ON. Some patients with solely one 
ON-relapse within the first three months of ADEM were excluded as we followed the IPMSSG 
2012 criteria1. However this three months duration merits further study as it is arbitrary. 
International collaborations are now required to unify treatment guidelines to inform on early 
prognostic markers and treatment effect in this rare demyelinating syndrome. 
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ABSTRACT 
Importance
Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) are consistently identified in a range 
of demyelinating disorders in adults and children. Current therapeutic strategies are largely 
center-specific and no treatments have been formally evaluated. 
Objective
To examine the clinical phenotypes, treatment response and outcome of children with relapsing 
MOG-IgG associated disease.
Design, Setting, and Participants
We prospectively collected demographic, clinical, and radiological data of 102 patients from 
8 countries of the EU Paediatric Demyelinating Disease Consortium. Patients were treated 
according to local protocols. 
Main outcomes and measures
Annualised relapse rate (ARR) and Expanded Disability Status Scale (EDSS) score before and 
during treatment with disease-modifying therapies (DMT). 
Results
102 children were identified (median age 7.0, range 1.5-7.9 years; male to female ratio 1.0:1.8; 
white to other race/ethnicity ratio 3.6/1.0). Original diagnoses were neuromyelitis optica 
spectrum disorder (NMOSD, 43.1%), acute disseminated encephalomyelitis followed by optic 
neuritis (ADEM-ON, 19.6%), multiphasic disseminated encephalomyelitis (MDEM, 19.6%), and 
relapsing optic neuritis (RON, 17.6%). A total of 464 demyelinating events were reported. Treated 
patients had more relapses (median, 3.0; range, 1.0-17.0) than untreated patients (median, 1.0; 
range 1.0-7.0) (P = 0.009) and higher EDSS scores (median, 1.5; interquartile range, 0-2.5) 
than untreated patients (median, 1.0; interquartile range, 0-1.5) (P < 0.001). Fifty-two children 
(51.0%) received DMT: 28 (53.8%) were treated with 1 DMT, 17 (32.7%) with 2, and 7 (13.5%) with 
3 or more sequential DMT. Patients relapsed during all treatments, with a total of 127 relapses 
on treatment reported. No changes in median ARR and EDSS score were observed between the 
pre-initiation and post-initiation phases of interferon beta and glatiramer acetate treatment (n 
= 11). The median ARR was reduced from 1.84 to 1.0 with azathioprine (n = 20, P < 0.001), 1.79 
to 0.52 with mycophenolate mofetil (n = 15, P = 0.003), and 2.12 to 0.67 with rituximab (n = 9, 
P < 0.001), although the median EDSS score remained unchanged. An improvement in ARR 
(from 2.16 to 0.51, P < 0.001) and EDSS score (from 2.2 to 1.2, P = 0.01) was observed in the 12 
patients treated with regular intravenous immunoglobulins.
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Conclusions
Although commonly used to treat patients with multiple sclerosis, DMT were not associated 
with clinical improvement in children with MOG-IgG associated disease, whereas azathioprine, 
mycophenolate mofetil, rituximab, and particularly intravenous immunoglobulins were 
associated with a reduction in relapse frequency. A correct diagnosis of relapsing MOG-IgG 
associated disorders is therefore important to optimize immune treatment.
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INTRODUCTION
Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) are consistently identified in a range 
of acquired demyelinating syndromes (ADSs) in adults and children1 and in up to 50% of children 
at first presentation of ADSs.2-4 Although MOG-IgGs were initially reported in predominantly 
monophasic disease, a recent report5 of 210 children with ADS who were followed up for at least 
2 years observed that 22 of 65 MOG-IgG positive children (33.8%) experienced clinical relapse 
and were diagnosed with multiphasic disseminated encephalomyelitis (MDEM),6 recurrent 
optic neuritis (RON),7 acute disseminated encephalomyelitis followed by optic neuritis (ADEM-
ON),8 or neuromyelitis optica spectrum disorder (NMOSD).9-11 Two recent reports identified 
MOG-IgGs in 22 of 35 children (62.8%)5 and 26 of 48 children (54%) 12 with non–multiple 
sclerosis (MS) relapsing demyelination, which is more than 3 times more common than the 
aquaporin 4 antibody (AQP4-IgG) (4 of 35 patients5 and 8 of 48 patients12).The MOG-IgG positive 
children had distinctive clinical and magnetic resonance imaging (MRI) features different from 
MS and AQP4-IgG NMOSD.12 Treatment of MOG-IgG associated disease has been influenced 
by protocols used for NMOSD with AQP4-IgG,13 although these 2 disorders are thought to be 
clinically and biologically different.14,15 
The high proportion of monophasic courses in patients with MOG-IgGs5 supports the decision 
against commencing maintenance immunosuppression after the first clinical event of MOG-
IgG associated disease. Furthermore, because some patients with MOG-IgGs seem to have 
a milder NMOSD phenotype than patients with AQP4-IgG,16 with good short-term response 
to corticosteroids, many of the relapsing cases were also not treated with maintenance 
immunosuppression. Recent reports1,17 also highlight that patients with MOG-IgGs continue 
to relapse and accrue disability, sometimes despite maintenance treatment, raising important 
questions about how patients with relapsing MOG-IgG associated disease should be treated. 
Current therapeutic strategies are largely center specific, formal consensus guidelines are 
yet to be formulated, and no clinical trials have been performed. We therefore conducted 
this retrospective, multicenter study to describe the first attack features, paraclinical 
characteristics, disease course, and responses to different treatment strategies in children 
with MOG-IgG associated relapsing demyelinating syndromes.
METHODS
Study participants
From January 1, 2014, through December 31, 2016, we collected demographic, clinical, and 
radiologic data from102 patients from 8 countries of the EU Paediatric Demyelinating Disease 
Consortium (United Kingdom [n = 57],Germany/Austria [n = 18], the Netherlands [n = 12], 
France [n = 10], Turkey [n = 3], Switzerland [n = 1], and Israel [n = 1]), a component of the 
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European Reference Network for Rare Immunodeficiency, Autoinflammatory, and Autoimmune 
Disease. Participants were retrospectively identified from those prospectively recruited into the 
respective national demyelination programs or centers and fulfilled the following inclusion 
criteria: (1) a diagnosis of relapsing demyelination syndrome, (2) presence of MOG-IgGs 
detected at onset or at the time of a clinical relapse, and (3) age younger than 18 years at first 
presentation. 
Institutional review board and/or national research ethics approval was obtained at individual 
centers or national programs, respectively. Patients included in this study had been enrolled 
in national programs with respective review board/ethical committee approvals (France 
[Hopital Bicetre, Paris], the Netherlands[Medische ethische toetsings commissie Erasmus 
Medical Centre, Rotterdam], Germany and Austria [University of Innsbruck Ethics Committee], 
United Kingdom [West Midlands–South Birmingham Research Ethics Committee],and Turkey 
[Hacettepe University, Ankara]) or provided verbal and/or written informed consent to the 
respective referring physician. All data were de-identified.
Procedure
Clinical data were de-identified and entered by each participating investigator onto a unified 
case reporting form (CRF), detailing selected demographics, clinical findings, and laboratory 
results (MOG-IgG and AQP4-IgG, cerebrospinal fluid white blood cell count, protein level, 
number of oligoclonal bands, virologic test results, erythrocyte sedimentation rate, and 
Epstein-Barr virus serologic test results), first and subsequent attacks characteristics, and 
treatment information. All CRFs were initially reviewed by the respective national leads (5 
of us, M.B., K.R., R.N., K.D., and M.L.) and subsequently analyzed by 2 of our investigators 
(Y.H., M.L.). Demyelinating phenotype at onset was determined from the patient’s clinical 
features, according to established criteria.18 All patients had undergone brain and spinal cord 
MRI according to local MRI protocols (which do not routinely include orbital MRI). Cases were 
assigned by participating investigator and subsequently confirmed by national leads based 
on clinical and radiologic information provided on the CRF to one of the following diagnostic 
categories: (1) MS, fulfilling the 2013 International Pediatric Multiple Sclerosis Study Group 
consensus criteria18; (2) NMOSD, fulfilling the 2015 International Panel for NMO diagnosis 
criteria19; (3) MDEM and ADEM-ON, fulfilling the 2013 International Pediatric Multiple Sclerosis 
Study Group consensus criteria18;and (4) recurrent demyelination in a single central nervous 
system area without evidence of clinically silent disease,18 such as RON.
Annualized relapse rates (ARRs) were calculated as the number of relapses per year before 
treatment (excluding index event) and during treatment only in patients with at least 6 months 
of follow-up after initiation of treatment.20 Relapses were analyzed for up to 2 years before 
initiation of therapy and for the duration of the time undergoing therapy.
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Outcomes at last follow-up were retrieved from the patient’s medical records to represent 
the most contemporary assessment of disability. If unavailable, this assessment was obtained 
directly from the patient’s primary treating physician. The Expanded Disability Status Scale 
(EDSS) scores were documented at point of disease stability at least 3 months from acute or 
relapsing events.
MOG-IgG testing
Within 1 month of an acute event (onset or relapse), clinically symptomatic children underwent 
testing for serum MOG-IgGs, using a live cell-based assay optimized to reduce IgM cross-
reactivity5,21 in the respective reference laboratories (detailed in the supplemental file) of the 
referring countries, as part of routine assessments of children with demyelinating diseases 
(antibody testing in the cerebrospinal fluid was not routinely performed).
STATISTICAL ANALYSIS 
Parametric or nonparametric statistical tests (Mann-Whitney and Kruskal-Wallis tests) were 
used for continuous distributions, as appropriate, and χ2 or Fisher exact tests for nominal data 
to compare the demographics, presenting symptoms, demyelinating phenotypes, and radiologic 
and serologic characteristics across the different groups and between those who received or 
did not receive maintenance immunotherapy. Receiver operating characteristic analysis was 
used to identify the cutoff age associated with phenotype change. A paired 2-tailed t test was 
used to compare ARRs and EDSS scores before and during treatment. A 2-sided P < 0.05 was 
considered to be significant. Data were analyzed using GraphPad Prism 5 (GraphPad Software).
RESULTS
Patients group
A total of 102 children with relapsing MOG-IgG associated disease were studied (median 
[range] age, 7.0[1.5-7.9] years; male to female ratio, 1.0:1.8; white to other race/ethnicity ratio, 
3.6:1.0). All patients were tested for AQP4-IgG, and none were double positive. The median 
length of follow-up (from first clinical presentation) was 5 years (interquartile range [IQR], 
3-9 years). The original diagnoses were NMOSD in 44 children (43.1%), MDEM in 20 (19.6%), 
ADEM-ON in 20 (19.6%), and RON in 18 (17.6%). None of the patients had a final diagnosis of 
relapsing-remitting MS. Patients presenting with ADEM were younger than patients presenting 
with other ADS (mean [SD] age, 5.6 [0.4] years vs 10.7 [0.6] years; P < 0.001). Mean (SD) age at 
onset was 3.8 (1.7) years in patients with MDEM, 6.9 (2.6) in patients with ADEM-ON, 9.1 (4.5) 
years in patients with NMOSD, and 11.7 (4.0) years in patients with RON. Clinical events and 
radiologic changes in patients 9 years or younger were more likely to affect the brain, whereas 
events in patients older than 9 years were more likely to affect the optic nerve (Figure 3.6.1). 
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Patients’ demographic, clinical, and paraclinical features and EDSS scores according to each 
relapsing demyelination syndrome phenotype are summarized in Table 3.6.1.
First Attack Features
The most frequent demyelinating phenotype at onset was ADEM (53 [52.0%]) followed by optic 
neuritis (41 [40.2%]). Of the children presenting with optic neuritis, 18 (43.9%) had bilateral 
optic neuritis, 15 (36.6%) had unilateral optic neuritis, and 8 (19.5%) had simultaneous optic 
neuritis and transverse myelitis. Visual symptoms were reported in 55 patients (53.9%) and 
encephalopathy in 53 (52.0%). Of the 58 patients with abnormal brain MRI findings at onset, 
cerebellar symptoms were found in 29 (50.0%) and seizures in 19 (32.8%).
Paraclinical Features
Cerebrospinal fluid lymphocytosis was reported in 43 of 73 tested patients (58.9%) (lymphocyte 
count, 10-624/μL; to convert to×109/L, multiply by 0.001). Intrathecal oligoclonal bands were 
seen in only 6 of 54 tested patients (11.1%) across the phenotypes (Table 3.6.1). Erythrocyte 
sedimentation rate was increased in 21 of 36 patients (58.3%), and evidence of remote Epstein-
Barr virus infection was seen in 11 of 43 (25.6%).
Disease Course
A total of 464 demyelinating events were reported in the cohort (Figure 3.6.1). No differences 
were found in time to first relapse, total number of relapses, and EDSS scores among the 
different original diagnoses. Despite no differences in EDSS scores detected in the different 
phenotypes, cognitive problems were seen more frequently in patients with MDEM and ADEM-
ON
(16 of 40 patients [40.0%]) vs NMOSD and RON (4 of 62 patients [6.5%], P < 0.001). Similarly, 
patients with abnormal intracranial MRI findings (18 of 65 patients [27.7%]) were more likely to 
have cognitive problems than patients with normal intracranial MRI findings (2 of 37 patients 
[5.4%], P = 0.008).
Patients receiving immunotherapy had more clinical relapses and worse EDSSs than untreated 
patients (Table 3.6.2). One patient died. Good recovery, defined as an ARR of 0 at last follow- up 
(>6 months) and having no neurologic sequelae (EDSS score of 0), was reported in 32 of the 102 
patients (31.3%; of these 10 were treated patients).
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Figure 3.6.1: Demyelinating phenotypes of the first attack and subsequent relapses. 
A total of A total of 464 demyelinating events were reported in 102 patients presenting with MOG-IgG 
associated relapsing demyelination syndrome. Receiver operating characteristic analysis identified age 
9 to be the best cut off age associated with phenotype change. Clinical events in patients of 9 years or 
younger were more likely to affect the brain, whereas events in patients older than 9 years were more 
likely to affect the optic nerve (p<0.001). Brain MRI abnormalities were also more common in the younger 
group (p<0.001). There was no sex predisposition of differences (female:male ratio in patients under or 
over the age of 9 years was 1:1.64 vs 1:1.6, p>0.99).
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Table 3.6.2: Comparison between patients who were treated and not treated with disease modifying 
drugs.a 
Treated (n=52) Untreated (n=50) p-value
Age median (IQR), years 6.0 (5.0-9.2) 7.0 (5.0-13.0) 0.22
Female to male ratio 2:1 1.5:1 0.84
White to other race/ethnicity ratio 1.9:1 1.4:1 0.54
Demyelinating phenotype at onset: 
- ADEM 29 (55.8) 23 (46.0) 0.32
- Optic neuritis 14 (26.9) 19 (38.0) 0.40
- Transverse myelitis 3 (5.8) 3 (6.0) >0.99
- Optic neuritis and transverse myelitis 3 (5.8) 5 (10.0) 0.72
- Brainstem syndrome 2 (3.8) 0 0.24
Original RDS diagnoses:
- MDEM 10 (19.2) 10 (20.0) >0.99
- ADEM-ON 10 (19.2) 10 (20.0) >0.99
- NMOSD 25 (48.1) 19 (38.0) 0.32
- RON 6 (11.5) 12 (240.) 0.19
Follow-up time, Median (IQR), years 5.0 (3.0-9.0) 5.0 (3.0-8.0) 0.78
EDSS at last follow-up, median (IQR) 1.5 (0-2.5) 1.0 (0-1.5) 0.009
Total number of relapses throughout the follow-up, 
median (range)
3 (1-19) 1(1-7) <0.001
Abbreviations: ADEM, acute disseminated encephalomyelitis; ADEM-ON, ADEM followed by optic neuritis; 
EDSS, Expanded Disability Status Scale; IQR, interquartile range; MDEM, multiphasic disseminated 
encephalomyelitis; NMOSD, neuromyelitis optica spectrum disorder; RDS, relapsing demyelination 
syndrome; RON, relapsing optic neuritis. a Data are presented as number (percentage) of patients unless 
otherwise indicated
CHAPTER 3.6
174
Figure 3.6.2: Disease course in relation to respective therapies. 
Each solid marker denotes a demyelinating event, with the color in the figure key denoting respective 
treatment, whereas an open marker denotes initiation of therapy. Patient relapsed while undergoing all 
treatments, with a total of 127 relapses during treatment reported in the cohort. All patients treated with 
first-line injectable multiple sclerosis treatment continued to relapse. Twenty-eight patients remained 
relapse free while receiving treatment; 7 of 15 (46.7%) treated withmycophenolate mofetil, 10 of 20 
(50.0%) treated with azathioprine, 1 of 7 (14.2%) treated with rituximab alone, 6 of 10 (60.0%) treated with 
intravenous immunoglobulin (IVIG), and 2 of 2 (100%) treated with rituximab and IVIG together. Patient 52 
presented initially with bilateral optic neuritis, relapsed 2 years later with transversemyelitis, experienced 
cognitive and psychiatric problems, and died at 20 years of age of progressive encephalopathy and 
respiratory failure.
Response to Immunotherapy
The short-term treatment for each of these patients at presentation and during subsequent 
episodes of relapses was directed by the treating pediatricians based on protocols influenced 
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by their regional and/or national reference center for central nervous system demyelination, 
guided by severity and persistence of symptoms. Disease-modifying drugs (i.e., all forms of 
maintenance immunomodulation or immunosuppression therapies) were given in 52 children 
(51.0%): 28 patients (53.8%) were treated with 1 DMT, 16 (30.7%) with 2, and 7 (13.5%) with 3 
or more sequential DMT, with only 2 patients receiving combinational treatment (intravenous 
immunoglobulin [IVIG] and rituximab) at any time point. All treatments were optimized at 
their respective regional or tertiary treating center. The clinical course and disease activity 
in patients who underwent therapy with maintenance treatment are illustrated in Figure 
3.6.2. Median time from disease onset to DMT treatment was 1.64 years (IQR, 0.50-3.60 
years). Patient relapsed while receiving various treatments, with a total of 127 relapses while 
receiving treatment reported in the cohort (Figure 3.6.2); Interferon beta and glatiramer 
acetate (total relapses, 71; 2.1 relapses during treatment), azathioprine (total relapses, 20.0; 
0.5 relapse during treatment), mycophenolate mofetil (total relapses, 13.0; 0.5 relapse during 
treatment), rituximab (total relapses, 10.0;0.7 relapse during treatment), IVIG (total relapses, 
6.0; 0.1 relapse during treatment), cyclophosphamide (total relapses, 3.0; 2.0 relapses during 
treatment), cyclosporine (total relapses, 2.0; 2.0relapses during treatment), and natalizumab 
(total relapses, 2.0; 0.3 relapse during treatment). The ARRs and EDSS scores before and 
during treatment are depicted in Figure 3.6.3. 
Conventional MS treatment (interferon beta and glatiramer) was given as first-line treatment 
in 10 children and as a second-line treatment in 1 child and was discontinued in all in view of 
lack of response and ongoing treatment adverse effects. Two patients were initially switched 
to an alternative interferon preparation before changing treatment. All patients relapsed while 
receiving treatment. There was no change in the ARRs before and during treatment, with a mean 
difference of 0.02 (mean ARR before treatment, 2.40; mean ARR during treatment, 2.38; P > 
.99). There was no change in EDSS score (mean EDSS score before treatment, 2.2; mean EDSS 
during treatment, 3.0; P = 0.23). No severe or life-threatening relapses have been reported with 
conventional MS treatment. Three patients received natalizumab (2 with good response and 1 
who continued to relapse), and no patients received fingolimod or alemtuzumab. 
Eleven patients began therapy with mycophenolate mofetil of whom 3 were switched in view 
of treatment failure, with 1 having additional adverse effects. Four patients were switched to 
mycophenolate mofetil after cyclophosphamide (n = 2), azathioprine (n = 1), rituximab (n = 1), 
and cyclosporine treatment followed by interferon beta-1a (n = 1). Eight of 15 patients (53.5%) 
relapsed while receiving treatment. Mycophenolate mofetil treatment was associated with 
a mean reduction in the ARR of 1.27 (mean ARR before treatment, 1.79; mean ARR during 
treatment, 0.52; P = 0.003), with no change in EDSS score (mean EDSS score before treatment, 
1.7; mean EDSS score during treatment, 1.9; P = 0.59). 
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Figure 3.6.3: Efficacy of various disease-modifying therapies in patients with MOG-IgG associated 
relapsing demyelination
Only 2 patients receiving combinational treatment (IVIG and Rituximab) and were included for both 
treatment analysis. No differences were detected in the pre-treatment EDSS and ARR between the 
different treatment groups
Twelve patients began therapy with azathioprine of whom 2 were switched in view of treatment 
failure and 2 stopped treatment (1 because of treatment failure and 1 because of adverse 
effects). Eight patients received azathioprine as second line treatment; first-line MS treatment 
failed in 5 (1 receiving mycophenolate mofetil and 2 after 1 year of corticosteroid treatment). 
Ten of 20 patients (50.0%) relapsed while receiving treatment. Azathioprine treatment was 
associated with a mean reduction in the ARR of 0.84 (mean ARR before treatment, 1.84; mean 
ARR during treatment, 1.0; P < 0.001), with no change in EDSS score (mean EDSS score before 
treatment, 2.5; mean EDSS score during treatment, 2.6; P = 0.74). 
Rituximab was given as first-line treatment in 4 patients (with additional IVIG in 2), as second-
line treatment in 4 patients, and as third-line treatment in 1 patient. Of the patients treated 
with rituximab as first-line treatment, no additional immunotherapy was used after treatment. 
Six of 9 patients (66.7%) relapsed during treatment. Two of 3 patients who did not relapse were 
additionally receiving maintenance IVIG. One child had a severe life-threatening relapse while 
receiving therapeutic doses of rituximab and had depleted B cells. Rituximab was associated 
with a mean reduction in the ARR of 1.61 (mean ARR before treatment, 2.12; mean ARR during 
treatment, 0.67; P < 0.001), with no change in EDSS score (mean EDSS before treatment, 2.4; 
mean EDSS during treatment, 3.2; P = 0.23).
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Intravenous immunoglobulin (regular infusion every 4 weeks) was given as first-line 
maintenance treatment in 12 patients (2 received additional rituximab) and in 4 patients as 
a second-line treatment after revision of the diagnosis. All patients continued to receive IVIG, 
but in 2 the infusion was reduced to every 8 weeks. Four of 12 patients (33.3%) relapsed while 
undergoing treatment. The IVIG treatment was associated with a reduction in the ARR of 1.71 
(2.16 to 0.51, P < 0.001). The EDSS was also reduced (mean EDSS before treatment, 2.2; mean 
EDSS during treatment, 1.2; P = 0.01).
A total of 8 patients received oral prednisolone for more than 6 months; 5 (62.5%) relapsed 
while receiving treatment (3 while weaning from corticosteroids), and 1 patient relapsed 1 
week after treatment with corticosteroids was stopped. Two patients started treatment with 
cyclophosphamide and 1 with cyclosporine; all relapsed while receiving treatment. Overall, 
we did not identify any phenotype that was more responsive to any specific treatments (Figure 
3.6.3).
Fifty patients (49.0%) were not treated. The median number of relapses in the untreated group 
was 1.0 (range, 1.0-7.0), and the median EDSS score was 1.0 (IQR, 0-1.5). No differences 
were found in patient demographics and clinical symptoms at onset and final demyelinating 
phenotype between the patients who were treated and those who were not (Table 3.6.2). Overall, 
the treated patients had more relapses (median, 3.0; range, 1.0-17.0) and higher EDSS scores 
(median, 1.5; IQR, 0-2.5) than the untreated patients (median number of relapses, 1.0; range, 
1.0-7.0; P = 0.009 and median EDSS score, 1.0; IQR, 0-1.5; P < 0.001).
DISCUSSION
Although MOG-IgG associated disease is now well recognized in children and adults, few 
comparative studies have been performed of their clinical and investigative features, treatment 
response, or outcomes. In this large multicenter study of 102 children with relapsing MOG-IgG 
associated disease, the original diagnoses were various, and overall the treated patients had a 
more severe disease. Although treatments were heterogeneous, injectable MS drugs were not 
associated with improvement, and maintenance IVIG was found superior to other treatments.
We observed an age-dependent phenotype, with brain manifestation in younger children and 
optic neuritis and/or transverse myelitis with normal intracranial imaging findings in the older 
child. This finding is in keeping with the physiologic, age-dependent white matter maturation 
that occurs from infancy to adulthood and may suggest susceptibility of the uncompacted 
myelin22 to an antibody that targets the outermost layer of the myelin sheath.23 A progressive 
loss of tissue integrity occurs over time in patients with recurrent brain demyelination, which is 
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likely to result in secondary neuro-axonal injury and could explain the poor cognitive outcome 
seen in this group and the reduced response to immunotherapies over time.
In this cohort, we observed the treatment paradox described in similar disorders,24,25 whereby 
the higher relapse rate and poorer outcome in the group receiving more therapy is simply 
reflected by the a priori threshold for initiating such treatments. In the 52 patients who were 
treated with DMT, treatment was associated with a reduction in the ARR in patients treated with 
regular IVIG, rituximab, mycophenolate mofetil, and azathioprine in descending order. Care 
is also required when interpreting the ARR, which is susceptible to artefactual elevation, for 
example, when there is a short time to first relapse and a short time to treatment (increasing 
pretreatment ARR). Although we ensured therapeutic DMT doses by including treatment 
length of at least 6 months, lag time to therapeutic effect of specific treatments may lead to an 
artefactually elevated posttreatment ARR.
The unresponsiveness to conventional MS therapy is reminiscent of a report26 in AQP4-IgG 
NMOSD, although none of these children were reported to have life-threatening relapses 
after MS therapy as reported in some patients with NMOSD. None of the patients received 
alemtuzumab, which was reported to cause disease worsening in patients with NMOSD27 and 
MOG-IgG associated disease.28 Interestingly, 6 of 7 patients (85.7%) who received rituximab 
alone continued to relapse despite B-cell depletion. 
A key finding of our study is that IVIG as maintenance therapy was associated with the 
greatest improvements in ARR and EDSS score. Intravenous immunoglobulin is the only 
treatment that does not induce immunosuppression. Its mechanisms of action may go beyond 
the known immunomodulatory effect and may also be beneficial in patients with secondary 
inflammation.29 Interestingly, in a recent study30 using organotypic cerebellar section cultures 
from transgenic mice and MOG-IgG–induced demyelination, treatment with IVIG was protective 
from demyelination in a dose dependent manner.
A major limitation of this study is that disease was not systematically managed in all patients, 
with possible biases in treatment initiation and/or escalation. Because testing for MOG-IgG 
has only recently become available, the patients described in this article were frequently 
misdiagnosed with MS, viral encephalitis (in view of the cerebrospinal fluid leukocytosis), and 
central nervous system vasculitis (in view of the increased erythrocyte sedimentation rate), 
which resulted in heterogeneous treatment and management regimens across the multiple 
centers. Because a significant number of cases were retrospectively tested, with diagnosis 
only considered at relapse and often many years later, this study could not provide information 
on the utility of serial measurements and/or antibody titers in predicting disease course or 
directing DMT. This cohort was not adequately powered to evaluate potential differences of 
immunotherapy responses across the different relapsing phenotypes and was not optimal for 
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a direct evaluation of an individual or sequence of treatment effect, which is better suited to a 
study design in which the lag phase of efficacy or washout period of specific therapies could 
be prospectively controlled. One particular treatment that deserves specific attention is the 
cumulative use of corticosteroids, often used in conjunction with DMT and at low doses but also 
during relapses. Prolonged corticosteroid maintenance, which appears to be effective in adults 
with NMOSD, is less commonly used in the pediatric population in view of the adverse effects.13
In conclusion, despite the limitations, this post hoc evaluation and analysis of data previously 
collected and published allowed us to make important observations about the treatment 
responsiveness of patients with relapsing MOG-IgG associated disease, which has to be 
carefully and pragmatically considered alongside the safety of many of these treatments. 
Importantly, because most children with MOG-IgGs remain monophasic, the data reported here 
do not evaluate treatment for patients with monophasic ADS; hence, these treatment strategies 
should not be applied to children after the first clinical event. The important questions our 
study raises are whether the treatment resistant group represents a selected group of patients 
who are biologically or immunologically different and whether earlier intervention with more 
specific maintenance immunotherapy would lead to a better neurologic outcome. However, 
to achieve this, studies must initially elucidate many key aspects of the MOG-IgG associated 
disorders, such as disease heterogeneity, early biomarkers of relapsing and/or severe disease, 
and optimal outcome measures, after which controlled trials could be performed
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ABSTRACT
Introduction
Acquired demyelinating syndromes (ADS) are immune-mediated demyelinating disorders of 
the central nervous system in children. A nationwide, multicentre and prospective cohort study 
was initiated in the Netherlands in 2006, with a reported ADS incidence of 0.66/100,000 per year 
and MS incidence of 0.15/100,000 per year in the period between 2007 and 2010. In this study, 
we provide an update on the incidence and the long-term follow-up of ADS in the Netherlands.
Methods
Children <18 years with a first attack of demyelination were included consecutively from January 
2006 to December 2016. Diagnoses were based on the International Paediatric MS study group 
consensus criteria. Outcome data were collected by neurological and neuropsychological 
assessments, and telephone call assessments. 
Results
Between 2011 and 2016, 55/165 of the ADS patients were diagnosed with MS (34%). This 
resulted in an increased ADS and MS incidence of 0.80/100,000 per year and 0.26/100,000 per 
year respectively. Since 2006 a total of 243 ADS patients have been included. During follow-up 
(median 55 months, IQR 28-84), 137 patients were diagnosed with monophasic disease(56%), 
89 with MS(37%) and 17 with multiphasic disease other than MS (7%). At least one form of 
residual deficit including cognitive impairment was observed in 69% of all ADS patients, even 
in monophasic ADS. An Expanded Disability Status Scale(EDSS) score of ≥5.5 was reached in 
3/89 MS patients (3%). 
Conclusion
The reported incidence of ADS in Dutch children has increased since 2010. Residual deficits 
are common in this group, even in monophasic patients. Therefore, long-term follow-up in ADS 
patients is warranted. 
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INTRODUCTION
Acquired demyelinating syndromes (ADS) are immune-mediated demyelinating disorders of the 
central nervous system (CNS) in children.1,2 ADS encompass a wide spectrum of neurological 
symptoms depending on the location of inflammation and the severity of demyelination. As 
the clinical symptoms overlap in this spectrum, international consensus criteria have been 
proposed in 2007 to aid in diagnosis and distinction between subtypes.3 These criteria were 
revised in 2012.4 In addition, new findings in the past few years added valuable insights in 
paediatric ADS and its subtypes, including the identification of new biomarkers such as anti-
myelin oligodendrocyte glycoproteins antibodies (MOG-IgG)2,5 and the identification of new 
clinical subtypes as acute disseminated encephalomyelitis followed by optic neuritis (ADEM-
ON).6
ADS may remain monophasic after the first event. Yet, 15-32% of these children will fulfil the 
diagnostic criteria for paediatric MS within five years after the initial attack.1,2,7,8 Multiple aspects 
of outcome of paediatric MS patients have been described before, including the rate of disease 
progression in Expanded Disability Status Scale (EDSS) scores 9,10, cognitive performance11-13, 
decreased motor performance14,15, and neuropsychiatric complaints like fatigue and mood 
disorders.14,16 However, studies describing the long-term outcome of other ADS subtypes are 
scarce. 
In the Netherlands, a multicentre and prospective study was established in 2006 with national 
coverage for children with a first demyelinating event. Incidence estimates of paediatric ADS 
and multiple sclerosis have been reported in our prior work for the period between 2007-
2010.17 However, the number of patients who will be diagnosed with MS will likely increase 
with longer follow-up time. Furthermore, an increasing MS incidence in children has been 
reported in specific regions.18,19 Therefore, we aim to re-assess the incidence and presenting 
characteristics of ADS and its subtypes in the Netherlands. Second, we aim to provide long-
term follow-up data of the patients included in our prospective and multicentre cohort in the 
Netherlands. 
METHODS
Study participants
Children younger than 18 years, residing in the Netherlands, and experiencing a first 
inflammatory demyelinating event of the CNS in the period from 2006 to 2016 have been 
included in this study. All patients are participants of the PROUD-kids study (PRedicting the 
OUtcome of a Demyelinating event in children), a prospective, multicentre and observational 
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cohort study. Paediatric neurologists of the eight Dutch academic hospitals and of ten non-
academic hospitals took part in this study and included patients to reach nationwide coverage. 
Diagnoses were made using the revised criteria proposed by the International Pediatric 
Multiple Sclerosis Study Group (IPMSSG).4 Patients with alternative diagnoses were excluded 
(e.g. systemic autoimmune diseases, infectious diseases or metabolic diseases). Patients 
were classified as neuromyelitis optica spectrum disorder (NMOSD) as presenting phenotype 
if either patients were tested seropositive for anti-aquaporine 4 antibodies (AQP4-IgG), or when 
AQP4-IgG negative patients presented with simultaneous optic neuritis (either unilateral or 
bilateral) and transverse myelitis (TM) with at least three segments. 
Baseline parameters
At inclusion, demographic and clinical information of each patient was gathered. Demographic 
characteristics consisted for example of ethnic background, date and place of birth and family 
history on familial autoimmune diseases. Clinical characteristics consisted of presenting 
symptoms, reported infection or vaccination in the preceding four weeks, acute treatment and 
hospitalization. MRI images, serum and CSF parameters were also reviewed when available 
for diagnostics or evaluation. 
Follow-up parameters 
If patients were not referred to the paediatric MS centre for follow-up, the follow-up data of 
the patients were provided by the treating physician (f.e. clinical letters) and by interviewing the 
parents through telephone every 2 years after disease onset. 
Cognitive impairment (CI) and residual neurological deficits were assessed using the 
most recent neuropsychological assessment (NPA) performed by a paediatric clinical 
neuropsychologist, and neurological examination by a paediatric neurologist. NPAs were being 
performed appropriately for age. During the NPA, at least six of the following cognitive domains 
were being assessed for the presence of cognitive deficits: behaviour, language, intelligence, 
attention and concentration, memory, executive control functions and visuospatial abilities. 
Children were classified as cognitive impaired if at least one of these domains was affected. 
If data on neurological examination or NPA were not available, a standardised questionnaire 
was administered asking parents or patients about the presence of sensory complaints, motor 
deficits (e.g. complaints regarding paresis, ataxia, balance problems), bladder complaints (e.g. 
urge incontinence), maximum walking distance and cognitive impairment (including negatively 
affected school performance).
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The Expanded Disability Status Scale is widely used to express disability of patients with MS 
diagnosis.20 EDSS 5.5 stands for a walking distance of maximum 100 metres, without aid or 
rest. 
Antibody testing
Serum AQP4-IgG and MOG-IgG were tested with cell-based assays (CBA) provided in a 
central laboratory as described previously.21,22 Patients were tested for regular diagnostics, or 
retrospectively when serum of the patient was still available. 
Ethics approval
This study was approved by the Medical Ethical Committees of the Erasmus MC in Rotterdam 
and the other participating centres. Written informed consent was obtained from parents and 
also from patients if aged >12 years at presentation.
STATISTICAL ANALYSIS 
Demographic data of the general Dutch population were provided by Statistics Netherlands.23 
These data were used to calculate the incidence of ADS and its subtypes in the period of 2011-
2016 in the Netherlands. Statistical analyses were performed using IBM SPSS 21. Figures were 
made using Graphpad Prism 5.
Chi-square and when appropriate Kruskal-Wallis tests, were used to test differences in 
demographic and clinical characteristics between the different subtypes. For differences in 
numerical data between subtypes the ANOVA test was used, and when necessary the Mann-
Whitney U test. To compare the ethnic background of the patients with the Dutch population 
we used a Z-test, with data provided by Statistics Netherlands.23 Results were considered 
significant if p < 0.05. Missing data was removed from the analyses in all subgroups. 
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Figure 3.7.1: Incidence of acquired demyelinating syndromes (ADS) and multiple sclerosis (MS) in the 
Netherlands in 2007-2010 and 2011-2016
RESULTS
Incidence
From January 1 2011 to December 31 2016, 165 ADS patients were reported of which 55 
received an MS diagnosis during FU. In this period, the incidence of ADS was 0.80/100,000 per 
year, ADEM incidence was 0.23/100,000 per year and MS incidence was 0.26/100,000 per year. 
An overview of the calculated incidences is shown in Figure 3.7.1.
First presentation of ADS
From January 1 2006 to December 31 2016, 353 patients were eligible. Of these patients, 243 
patients with a first demyelinating event were included in the study (Figure 3.7.2). Presenting 
phenotypes consisted of optic neuritis (ON; n=55, 23%; from which 16/55 bilateral ON, 29%), 
transverse myelitis (TM; n=23, 9%); other monofocal clinically isolated syndromes (CIS; n=37, 
15%), polyfocal CIS (n=47, 19%), acute disseminated encephalomyelitis (ADEM; n=70, 29%) and 
NMOSD (n=11, 5%).
Regarding the age of onset, children with ADEM were significantly younger than the other 
presenting phenotypes (p<0.001) and presented more often after a reported preceding infection 
(p<0.001). The latter also applied to children who experienced a TM as first event (p=0.01). 
The ratio between females and males in all ADS patients did not differ significantly between 
the presenting phenotypes. When the ADS patients are divided in a group aged < 11 years 
(n=104) and a group > 11 years (n=139), the female:male ratio differed significantly (1.02:1 
versus 1.76:1, p=0.04). 
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Figure 3.7.2: Flowchart describing the patient selection process
Seventy-eight patients (32%) were of non-Caucasian origin. This proportion was significantly 
higher than the proportion of children of non-Caucasian origin (17%) in the general paediatric 
population in the Netherlands (Z = 5.1, p<0.001) 23. Most of the non-Caucasian patients were of 
African (29%) or Middle-eastern (23%) ethnicity. 
Forty-eight percent of all patients had a positive familial history of autoimmune diseases 
(first and second grade family members). Forty-eight (20%) patients reported the presence of 
rheumatoid arthritis in their family, 40 (16%) reported thyroid diseases, 35 (14%) the presence 
of other autoimmune diseases (e.g. Wegener’s disease and Crohn’s disease), 15 (6%) the 
presence of MS, 14 (6%) diabetes mellitus type 1 and 4 (2%) the presence of optic neuritis (ON). 
No significant difference was observed between the presenting phenotypes considering the 
familial history (p=0.3).
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In all ADS patients disease onset in winter was most prevalent (32%), compared to spring 
(28%), summer (22%) and autumn (17%). MOG antibodies were found positive in 31 of the 146 
tested patients (21%). When comparing the presenting phenotypes, MOG antibodies were most 
frequently found in patients who presented with ADEM and NMOSD (p<0.001). 
Detailed patient characteristics are displayed in Table 3.7.1. 
Follow-up
For the follow-up analysis, we divided all patients into the following categories: monophasic 
disease, MS and multiphasic non-MS disease (Table 3.7.2). The median follow-up time of all 
patients was 55 months (IQR 28-84). 
Monophasic patients
One hundred thirty-seven patients remained monophasic (137/243, 56%), including ADEM 
(n=62, 45%), ON (n=27, 20%; from which 11/27 bilateral ON, 41%), TM (n=17, 12%), CIS (n=7, 
5%), polyfocal CIS (n=16, 12%), and monophasic NMOSD (n=8, 6%). Of these NMOSD patients, 
three were tested seropositive for AQP4-IgG and four were seropositive for MOG-IgG. Seven 
monophasic patients received chronic immunosuppressive therapy: this was initiated in all 
AQP4-IgG positive patients, and in one of the MOG-IgG positive patients due to the disease 
severity at onset (Table 3.7.2). Two CIS patients received disease modifying treatment (DMT) 
because of suspected risk of future MS. One patient had a LETM that required ICU admission 
and ventilation, and was therefore given chronic immunosuppressive therapy for 1 year. 
MS patients
Eighty-nine patients were diagnosed with MS in our cohort (37%), of which 87 received the 
diagnosis within 5 years of follow-up. Of the 89 MS patients, 70 individuals developed a second 
attack during follow-up, and were thus diagnosed with clinically definite MS (CDMS). 
In these patients, the median time to CDMS was 9 months (IQR: 4-27). After 2 years of follow-up, 
74 percent of the MS patients developed CDMS. No patients with MS had a primary progressive 
disease course. Only one MS patient had an ADEM as first presentation.
After dividing the MS patients into two groups, aged over or below 11 years, the sex ratio 
showed a trend towards significance (p=0.07), with more girls in the older MS group. 
Compared to monophasic ADS, patients who received MS diagnosis during follow-up were 
more often of non-Caucasian origin (p<0.001) (Table 3.7.2). The calculated MS incidence for 
patients of non-Caucasian origin was 0.78/100,000 per year in the period from 2011 to 2016, 
compared to 0.16/100,000 per year in children of Caucasian origin.
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Figure 3.7.3: Distribution clinical subtypes of patients diagnosed with multiphasic non-MS (n=17). 
Abbreviations: acute disseminated encephalomyelitis (ADEM), optic neuritis (ON), neuromyelitis optica 
spectrum disorder (NMOSD), multiphasic acute disseminated encephalomyelitis (MDEM)
At last follow-up, 73/89 MS patients were on DMT for the duration of at least 1 year and in 28 
patients second-line treatment was started (Table 3.7.2). Of these 28 patients, 22 started using 
second-line treatment because of high MS activity, either on MRI or clinically, five because of 
side effects of first-line treatment and one due to the participation in an international paediatric 
MS drug trial. 
Multiphasic non-MS patients
The patients with multiphasic non-MS disease consisted of five patients who were diagnosed 
with ADEM-ON, five with NMOSD (AQP4: n=2, MOG: n=1), four with recurrent ON, two with 
multiphasic disseminated encephalomyelitis (MDEM) and one with ON followed by seizures 
(once secondary generalized convulsion, once focal epilepsy) (Figure 3.7.3). Of these 17 patients, 
12 used chronic immunomodulatory treatment > 1 year. Seven remained on first-line treatment 
(e.g. azathioprin, myfocenolate) and five patients were switched to second-line treatment (f.e. 
rituximab n=3, monthly intravenous immunoglobulins (IVIG) n=2).
Residual neurological deficits
Overall, physicians or parents reported at least one form of residual deficit at the last follow-up 
in 162 (69%) ADS patients, including 71 (83%) of the MS patients, 76 (57%) of the monophasic 
patients and 15 (94%) of the multiphasic non-MS patients. Residual neurological deficits were 
significantly more observed in MS patients compared to monophasic patients (p<0.001).
In the mono-ADS group, residual deficits were most often present in patients with TM and 
NMOSD (p=0.02). From the monophasic patients with a TM and residual deficits 11/14 had 
suffered from a longitudinal extended transverse myelitis. In MS and multiphasic non-MS 
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patients, no significant difference was found in residual deficits between the presenting 
phenotypes. 
Specific differences between the three categories were observed: MS patients reported 
significantly more sensory deficits and motor deficits compared to monophasic patients (p<0.05) 
(Figure 3.7.4). Yet in multiphasic non-MS patients visual deficits and cognitive impairment were 
most reported at last follow-up. 
Figure 3.7.4: Residual deficits of ADS patients at last follow-up. 
Definition: patients were classified as cognitive impaired if they had a deficit in at least one cognitive 
domain, tested by a neuropsychological assessment. EDSS: expanded disability status scale of 5.5 stands 
for a walking distance of about 100 metres, without aid or rest
Cognitive deficits
Thirty-two percent of all included patients (78/243) underwent an NPA (32/137 mono-ADS, 
38/89 MS and 8/17 multiphasic non-MS). 
At least one of the cognitive domains was affected in 65 of the tested patients (83%), respectively 
in 29/32 (91%) monophasic ADS, 29/38 (76%) MS and 7/8 (88%) multiphasic non-MS. Three or 
more cognitive domains were affected in 18/32 (56%) monophasic patients, 22/38 (58%) MS 
patients and in 6/8 (75%) multiphasic non-MS patients. The three most commonly affected 
domains in monophasic patients were intelligence, attention and concentration and memory, 
in MS patients language, attention and concentration and memory and in multiphasic non-MS 
UPDATED INCIDENCE AND OUTCOME OF ADS IN THE NETHERLANDS
197
3.7
patients attention and concentration, memory and executive control functions. Median time till 
NPA from disease onset was 15 months (IQR 6-32). In monophasic patients the median time 
was 25 months (IQR 11-62), in MS patients 11 (IQR 6-24) and in multiphasic non-MS patients 
10 (IQR 3-22). 
Data on school performance was available in 216/243 patients (monophasic patients n=124, MS 
n=76, multiphasic non-MS patients n=16). Negatively affected school performance was reported 
by 63/216 (29%) of the participants: 37/124 (30%) of the monophasic patients, 16/76 (21%) of 
the MS patients and 10/16 (63%) of the multiphasic non-MS patients. This included children 
to require academic accommodations, for instance extra assistance at school, extra time to 
complete examinations and change to special education. Of those who reported negatively 
affected school performance, 19/37 (51%) of the monophasic patients had CI assessed through 
an NPA, 7/16 (44%) of the MS patients and 6/10 (60%) of the multiphasic non-MS patients. 
Furthermore, a total of 122/243 patients reported attention deficits in the standardized 
questionnaire.
Disease progression in MS patients 
Three of the MS patients had an EDSS of 5.5 or above at the last moment of follow-up. All 
three patients received acute treatment at presentation. They all presented with a polyfocal 
CIS at the first event, including brainstem as well as spinal involvement (n=3). These patients 
had a follow-up time of 24, 52 and 96 months and reached EDSS 5.5 at 6, 48 and 66 months 
respectively. The first patient declined DMT. DMT was commenced in the other two patients, 
and both were escalated to second-line treatment (natalizumab) because of high MS disease 
activity.
DISCUSSION
We showed that the incidence of ADS and MS is higher in the period of 2011-2016 than of 2007-
2010 17. Thirty-seven percent of the patients received a diagnosis of MS during follow-up, which 
is in line with previous reports about the proportion of MS diagnosis in ADS. Residual deficits 
are often reported not only in MS, but in all ADS subtypes at last follow-up, irrespective of the 
presenting phenotype. 
The improved awareness of ADS in The Netherlands, aided by a more stable and extended 
referral network, likely attributed to the increase in incidence compared to 2007-2010. Notably, 
the small increase in ADS incidence was mainly driven by the rise in MS incidence. Our extended 
follow-up may have contributed to this higher MS incidence. We cannot exclude that the true 
incidence of paediatric MS is increasing in the Netherlands, as has been reported on overall 
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MS incidence in other regions 18,19. Prolonged assessment of the incidence will be necessary to 
answer this question. Our new ADS incidence estimates are comparable to previous prospective 
studies that reported ADS and MS incidence in children 1,24. Moreover, our study confirms the 
skewed ethnic distribution in paediatric MS patients towards non-Caucasian ethnicities 1,17,25,26. 
A non-MS multiphasic disease course was observed in a minority of the patients (17/243, 7%).
Remarkably 78% of these patients were tested seropositive for MOG-IgG, in line with previous 
findings that MOG-IgG positivity pleads against MS diagnosis and that these patients tend to 
have a relapsing disease course 27,28. 
MOG-IgG and AQP4-IgG seropositivity may be underestimated in this cohort, as the CBAs for 
both antibodies were developed and validated after the start of our prospective study. Serum 
was not retrospectively available of every patient who was included before the CBAs were 
implemented in routine diagnostics. 
Over a median follow-up time of 61 months, only three MS patients reached an EDSS of 5.5 or 
above. However, residual neurological deficits are common in patients with MS (83%), in line 
with previous studies 11-16. Cognitive deficits are commonly encountered in MS, but are also 
described in ADEM 29,30. Our results show similar results, as 34% of the ADEM patients show 
CI assessed by an NPA. A limitation here is that only one-third of our patients underwent an 
NPA in a standardised way. As part of the nationwide epidemiological orientation of our study 
testing all patients was not feasible. Still, every patient who underwent an NPA had at least 
six cognitive domains tested. Furthermore, since 2013 all ADEM and MS patients who were 
presented in the paediatric MS centre in Rotterdam, have been consecutively referred for an 
NPA. Therefore, any selection bias within these two groups would have been minimal, leading 
to a more representative view on cognitive impairment in these patients. Also the multiphasic 
non-MS patients reported cognitive impairment and visual problems. These findings can be 
explained by the relatively high proportion of ADEM-ON patients in this group 6. 
Our data further feed the impression that one single hit of ADEM can leave considerable 
intracerebral damage and may be considered less benign than previously thought 31-34. A recent 
study showed reduced age-expected brain growth in monophasic ADS patients, especially 
ADEM, indicating irreversible and continuing changes occurring in the CNS even in absence of 
chronicity 35. Furthermore, recent studies have shown long-term residual deficits in ADEM and 
monophasic patients, such as a higher prevalence of motor problems, lower physical activity 
and fatigue 14,15. 
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The high number of children with long-term residual deficits in the total group is concerning 
in relationship with school performances and psychomotor development, especially taking into 
account the cumulative nature of acquired disabilities after a longer disease duration in chronic 
demyelinating syndromes 9,36. Future participation in society, including work-related activities, 
is likely to be affected. Indeed, in a large proportion of adult patients, MS had negatively 
affected their employment situation 36,37. These effects could even be worse in paediatric onset 
ADS. Therefore adequate detection and guidance of ADS patients is important to preserve and 
improve societal functioning, and is essential during follow-up of these patients into adulthood.
There are some limitations to this study. Despite our quite unique and extensive national 
paediatric MS network with full geographical coverage, it is still possible that we have missed 
a few cases and thus have an underestimation of our incidence figures. Adolescents with CIS 
may have been assessed and followed-up by an adult neurologist and therefore have not been 
referred to take part in our study. In addition, the negatively affected school performance in 
ADS patients may be correlated with other problems than CI. Fatigue, mood disorders, anxiety 
and negative coping strategies could correlate with a negative school performance in these 
patients, and may interact with cognitive impairment as well 14-16. 
In conclusion, the reported incidence of ADS and MS in the Netherlands has increased during 
the previous years. Across all ADS subtypes the observed residual neurological deficits are 
considerable. Long-term follow-up studies of ADS patients will be needed to provide more 
insight into the risks involved and to identify possibilities for timely intervention.
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Fatigue and physical functioning 
in children with multiple sclerosis and 
acute disseminated encephalomyelitis
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ABSTRACT 
Background and objective
Fatigue and physical impairments are a major concern in children with multiple sclerosis (MS) 
and after acute disseminated encephalomyelitis (post-ADEM). We here aimed to evaluate the 
interaction between fatigue, exercise capacity, motor performance, neurological status and 
quality of life (HRQoL).
Methods
In this cross-sectional study, data of thirty-eight children (MS n=22, post-ADEM n=16), aged 
4-17 years attending our national pediatric MS-center, were studied. Fatigue was measured 
with the Pediatric Quality of life-Multidimensional Fatigue Scale, exercise capacity with the 
Bruce-protocol, motor performance with the Movement-Assessment-Battery-Children-II, 
HRQoL with the Pediatric Quality of Life questionnaire and extent of disability with the Expanded 
Disability Status Scale (EDSS). 
Results
Children with MS and post-ADEM experienced more fatigue (p<0.001), reduced exercise 
capacity (p<0.001) and impaired motor performance (p<0.001), despite low scores on the EDSS. 
Fatigue, but not the other parameters, was significantly correlated with HRQoL. Fatigue was 
not correlated with exercise capacity.
Conclusion
We confirm the major impact of fatigue on quality of life in children with MS and post-ADEM. 
Fatigue was not explained by reduced exercise capacity or impaired motor performance. 
An important finding for clinical practice is that the low EDSS score did not reflect the poor 
physical functioning.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous 
system. It is generally considered as a disease of young adults in their twenties and thirties, 
although 2-10% of all MS patients experience their first attack before the age of 18.1-3 Pediatric 
onset MS (POMS) shows parallels with adult MS, but runs a more severe course because the 
relapse rate is higher, next to a higher lesion load on MRI.4,5 Despite time to the secondary 
progressive phase in POMS is longer, patients are disabled at a younger age than patients with 
adult onset MS.1,6. In addition to mental and cognitive problems, many patients struggle with 
physical impairments and fatigue.7,8 These problems do not limit themselves to chronic forms 
of demyelinating disease like MS, but are also reported in children after acute disseminated 
encephalomyelitis (post-ADEM), although rapid motor function recovery after the acute phase 
in most of the patients seems to be the case.9-11. The Expanded Disease Status Scale (EDSS) 
is commonly used to evaluate disability of adult and pediatric patients with demyelinating 
disorders.12 However, it is originally intended for adult MS patients. 
As mentioned above, fatigue is a frequently occurring problem in patients with POMS and post-
ADEM. The cause of fatigue still remains unclear. In a Canadian study of children with MS and 
monophasic acquired demyelinating syndromes (mono-ADS), a correlation was found between 
fatigue and physical activity.13 POMS patients were less physically active and scored higher on 
fatigue scales than patients with mono-ADS. Possibly, due to complaints of fatigue, patients 
become less physically active and this may lead to decreased exercise capacity. 
We assume that physical disturbances as motor problems, fatigue and decreased exercise 
capacity affect a child’s physical and psychosocial development and hence their quality of life. 
To the best of our knowledge, there is no data available of motor development in children with 
POMS and ADEM and maximal exercise capacity in children with ADEM.
Therefore, we primarily aimed to evaluate whether children with MS and ADEM have a reduced 
exercise capacity and whether this correlates with fatigue. Second, we analyzed the possible 
relations between quality of life and fatigue, exercise capacity or motor performance. Lastly, we 
aimed to investigate whether the EDSS is an optimal measurement to determine disabilities in 
daily life in these children. 
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METHODS
Study participants
Children under the age of eighteen were eligible for this cross-sectional study when diagnosed 
with POMS or ADEM in consensus with the International Pediatric Multiple Sclerosis Study 
Group 2012 diagnostic criteria.14 Patients with other demyelinating syndromes (e.g. clinically 
isolated syndromes, neuromyelitis optica) were excluded. All children were evaluated in our 
national-multidisciplinary-pediatric-MS-center as part of routine medical care between 2013 
and December 2015. Assembled clinical parameters consist of patient history and neurological 
examination performed by a pediatric neurologist. Disability was expressed by the EDSS 
score.12 Measurements of exercise capacity, motor development, fatigue and quality of life 
were administered by a pediatric physical therapist. After the evaluation, tailor made advice 
concerning physical therapy and rehabilitation was given.
Written informed consent and permission to use the data for research purposes was obtained 
from all parents and/or children between 12 and 18 years of age.
Fatigue – Pediatric Quality of life Multidimensional Fatigue Scale (PedsQL-MFS)
The PedsQL-MFS was designed as a generic symptom-specific, and standardized instrument 
to measure fatigue in healthy children and in children with acute and chronic health conditions 
aged 2–18 years, also validated in Dutch children.15 The PedsQL-MFS comprises three 
subscales: general fatigue, sleep/rest fatigue and cognitive fatigue. A total fatigue score is 
calculated from the subscales. A scale score and total fatigue score of one standard deviation 
(SD) below the mean of healthy age-related reference norm was considered abnormal. 
Exercise capacity - Bruce-protocol
The Bruce-protocol was used to test maximal exercise capacity.16 Children were encouraged 
to perform to exhaustion. The maximal endurance time on the treadmill was used as criterion 
of exercise capacity. Before and during the test, heart rate (HR) and transcutaneous oxygen 
saturation were monitored (motion artifact system, type 2001, Respironics Novametrics, 
Murrysville, PA, USA). HR of ≥185 beats per minute or loss of coordination, because of 
excessive fatigue was taken as maximal performance.17 The standard deviation score (SDS) 
of the maximal endurance time is calculated using age-related reference values for healthy 
Dutch children.18,19
Motor performance - MABCII
Motor performance was examined with the Movement-Assessment-Battery-Children second 
edition (MABCII). The MABCII is a standardized and aged-related norm referenced test, 
validated for Dutch children, and developed to classify children according to degree of motor 
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performance.20 The MABCII has three domains: manual dexterity, ball- and balance skills. For 
each child, the raw item scores were transformed into a domain percentile score and a total 
percentile score. Scores ≤ fifth percentile denote a definite motor problem; scores between 
the sixth to 16th percentiles denote borderline performance; scores > 16th percentile indicate 
normal performance. 
Quality of Life - Pediatric Quality of Life Inventory (PedsQL) 4.0
Health related quality of life (HRQoL) data were collected using the PedsQL 4.0.21 Patients as 
well as one of their parents are asked to fill in the questionnaires. It encompasses 23 items on 
four Generic Core Scales: physical, emotional, social, and school functioning. A psychosocial 
functioning scale can be derived from the emotional, social, and school functioning items. All 
23 items together provide the total functioning score. The children indicate on a five-point scale 
the frequency in which they experience a problem and these scores are linearly transformed 
to a zero to 100 scale. Higher scores indicate better functioning. The Dutch version of the 
PedsQL has adequate psychometric properties.21 A scale score and total functioning score of 
one SD below the mean of healthy age-related reference norm was taken to indicate impaired 
HRQoL.22 
STATISTICAL ANALYSIS
Analyses were performed using SPSS 23.0 (IBM, Chicago, IL, USA). The Kolmogorov-Smirnov 
test was used to test whether the data was normally distributed. One sample T-test was used 
when comparing continuous data of each measurement to expected average of the reference 
group. A Chi-square test was applied to test whether the distribution of motor performance 
scores in our population differed significantly from that in the normative population. For 
correlation analyses Pearson correlation and Spearman correlation were used when 
appropriate. Mann-Whitney U test was used for group comparison. A p-value was considered 
significant <0.05. 
Body Mass Index (BMI) was calculated, and the Dutch Growth Analyzer version 3.5 served to 
calculate SDS for BMI on the basis of Dutch references.23
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RESULTS
Between June 2013 and December 2015, 40 children were diagnosed with MS( n=24) or ADEM 
(n=16). Two children with MS, had no standard assessment by the pediatric physical therapist, 
due to disability caused by serious ataxia (Figure 3.8.1). Thus, data of 38 children were eligible 
for analysis. The median age at time of assessment was 13.4 years (range 4.3-17.6). Fifteen 
children had disease activity within the sixth months before the FU visit. Twenty-two children 
were participating in sports activities.
Figure 3.8.1: Patient eligibility
Abbreviations: MS=Multiple Sclerosis, post-ADEM=after Acute Disseminated Encephalomyelitis, 
MABCII=Movement Assessment Battery for Children, second version; PedsQl=Pediatric Quality of Life 
Inventory, HRQOL=Health-related quality of life; EDSS= Expanded Disability Status Scale
Relevant baseline characteristics are listed in Table 3.8.1. None of the children had concomitant 
diagnosis influencing cardiopulmonary function.
Fatigue - PedsQL-MFS
The PedsQL-MFS was filled in by 37/38 of the children. One child could not fill in the questionnaire 
due to his young age (<5 years). All parents returned the questionnaire. Fifteen children and 
nineteen parents indicated fatigue (<-1 SD). Scores on all subscales were significantly lower 
than the reference group in both patients and parents (Table 3.8.2). Parents indicated more 
often and more severe fatigue for their children than the children themselves. Both children 
with MS as children post-ADEM experienced greater fatigue than healthy related peers: eight 
of 22 children with MS and seven of fifteen children post-ADEM. 
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Table 3.8.1 Baseline characteristics of participants.
Total group
n = 38
MS
n = 22
Post-ADEM
n = 16
Boys, n (%) 13 (34) 4 (18) 9 (56)
Age in years 13.4 (9.2 - 15.7) 14.0 (13.0 - 15.0) 4.5 (2.3 - 5.9)
SDS BMI 0.8 (0.3 - 1.4) 1.2 (0.3 - 1.6) -0.3 (-0.9 - 1.0)
Age first symptoms, years 11.8 (5.0 - 14.1) 14 (9.0 - 17.0) 4.5 (1.5 - 11.5)
Time from onset to assessment, months 16.3 (5.1 - 40.5) 10.2 (4.6 - 21.5) 40.1 (11.4 - 63.5)
DMT in MS at time of assessment, YES, n (%) 18 (47%) 18 (82%) -
Number of episodes within 12 months to 
assessment, n (%)
  0
  1
  2
  3
15 (40)
18 (47)
3 (8)
2 (5)
3 (14)
14 (64)
3 (13)
2 (9)
12 (75)
4 (25)
-
-
EDSS
  0
  1.0
  1.5
  2.0
  3.0
20 (53)
8 (21)
7 (18)
2 (5)
1 (3)
10 (46)
4 (18)
6 (27)
2 (9)
-
9 (56)
5 (31)
1 (6)
-
1 (6)
Sports participation at time of assessment, 
YES, n (%)
22 (58) 11 (50) 11 (69)
Data are presented as median (IQR) unless otherwise stated. MS = Multiple Sclerosis, post-ADEM = after 
Acute Disseminated Encephalitis, SDS = Standard Deviation Score, BMI = Body Mass Index, DMT = Disease 
Modifying Therapy, IQR = Interquartile Range.
Exercise capacity - Bruce-protocol
Exercise capacity data were analyzed for 36/38 children. Data of two children were not analyzed 
because they could not reach maximal performance (HR <185/min). The 36 children performed 
significantly below reference values (p<0.001) as shown in Table 3.8.2. Especially children with 
MS had a limited exercise capacity. Seventeen out of twenty (85%) children with MS and nine 
out of sixteen (56%) children with post-ADEM scored below average (<-1 SD).
Motor performance - MABCII
Thirty-seven children were tested with the MABCII. One child was not tested because of logistic 
reasons. Nineteen of these 37 children (51% vs 84% expected based on reference values) had a 
total impairment score (TIS) within the normal range, five children (14% vs 11% expected) were 
classified as borderline and another thirteen (35% vs 5% expected) as having a definite motor 
impairment. This distribution is significantly different from reference values (p≤0.001). 
Problems were encountered in all three subscales: manual dexterity, ball- and balance skills 
as well (p<0.001) as displayed in Table 3.8.2 and Figure 3.8.2. 
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Figure 3.8.2 MABCII - Total Impairment Score (TIS): Left bar ‘norm’: percentage of children from 
Dutch reference group. Total group: data of MS and ADEM children
MABCII - Total Impairment Score (TIS). 
When we added the two children who were excluded from analysis due to serious ataxia, fifteen 
of the 40 children (38%) had a definite motor problem.
Motor performance between the diagnosis groups differs: children with MS have more severe 
and more often motor impairments than children post-ADEM. Children with MS encountered 
most problems in balance skills, followed by ball skills and manual dexterity. Children post-
ADEM encounter problems in all three subscales, but these problems are more equally 
distributed over the three subscales.
Health-related quality of life - PedsQl-HRQoL
The PedsQl-HRQoL was completed by 37/38 of the children and 35/38 parents. One child could 
not fill in the questionnaire because of his age (<5 years) and three parents did not return 
the questionnaire. Fourteen children and twelve parents indicated an impaired HRQOL (<-1 
SD). Compared with the reference values, scores on all PedsQL-scales, except emotional 
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functioning, were significantly lower (Table 3.8.2). In contrast, the parental scores were 
significantly lower on all subscales. 
See Table 3.8.2 for descriptive results of children with MS and post-ADEM patients separately. 
Expanded Disability Status - EDSS
All of the children had an EDSS ≤3.0 (Table 3.8.2). Thirty-five patients (92%) did not have 
disabilities or were not aware of it in daily life (EDSS <2.0).See Table 3.8.2 for results of children 
with MS and post-ADEM separately.
Correlations between parameters
The mean SDS of the child reported PedsQL total fatigue score was significantly correlated 
with the mean SDS of the PedsQl-HRQoL total score reported by the child (r=0.704, p<0.001) 
and the parent (r=0.554, p=0.001). There was no significant correlation between the mean SDS 
of the PedsQL total fatigue score of the child and mean SDS exercise capacity, MABCII, BMI or 
sports participation. Furthermore, there were no correlations found between the subscales of 
the PedsQL fatigue and above mentioned parameters (data not shown).
No significant correlation was found between the EDSS and the mean SDS of the PedsQl fatigue 
total score of the child and parent, exercise capacity, MABCII, PedsQl-HRQoL total score of the 
child and the parent, BMI or sports participation (data not shown). 
A significance correlation was found between exercise capacity and sports participation (r= 
0.365, p=0.034).
Differences between children with and without fatigue
A significant difference in mean SDS of the PedsQl-HRQoL total score was found between 
children with and without fatigue (p<0.001). For the other parameters (exercise capacity, 
MABCII, BMI and sports participation), no significant difference was found (data not shown).
Impact of disease duration on outcome parameters
Disease duration differed for children with MS and post-ADEM (Table 3.8.1), therefore we 
analyzed the groups separately. Within both groups there was no significant correlation between 
any of the outcome parameters and disease duration (data not shown). Disease duration was 
calculated per group as beneath or above the median. 
Impact of disease activity on outcome parameters
The number of demyelinating events within the year to assessment was assessed to express 
disease activity. This did not correlate with any of the outcome parameters (data not shown).
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DISCUSSION
In this cohort of 38 children with MS and post-ADEM we found that a large proportion of the 
children experienced fatigue and had reduced exercise capacity. In addition many children had 
motor impairments and impaired HRQoL. However, the hypothesis that fatigue and exercise 
capacity are related in children with MS and post-ADEM was not confirmed. HRQoL was related 
with fatigue, but not with motor performance, the EDSS score or exercise capacity. Despite 
the physical impairments measured by the MABCII, in no more than three children (8%) the 
disability interfered with activities of daily living according to the EDSS results. 
Exercise capacity was reduced in both MS and post-ADEM patients. Durstine et al. describe 
that most individuals with a chronic disease or disability become less physically active.24 This is 
in line with Grover et al, who describe less physical activity in POMS and mono-ADS patients.13 
Physical inactivity can lead to a reduced exercise capacity, which in turn can lead to further 
inactivity and a decrease in participation in daily life activities. A negative spiral of reduced 
exercise and physical inactivity may arise.24 
In our study, sports participation served as a measure of physical activity and was found related 
with exercise capacity. This may suggests that exercise capacity and the level of physical 
activity of children with MS and post-ADEM can be improved with exercise interventions. In 
other studies of children with chronic systemic inflammatory conditions, exercise interventions 
indeed improved children’s exercise capacity and physical functioning.24 High intensity exercise 
programs appeared to be safe in adult MS patients, but need to be investigated in children with 
MS and post-ADEM.25,26 
We did not found a difference in exercise capacity between fatigued and not-fatigued patients, 
as initially hypothesized. This suggests that fatigue itself is not explained by reduced exercise 
capacity in our patients, and vice versa. The process of inactivity, decreased exercise capacity 
and fatigue probably involves a complex interaction including other factors as well. As Grover et 
al. not only found a correlation between physical activity and fatigue, but also with depression, 
we argue here that psychosocial factors and reduced psychosocial participation may play an 
important additional role in diminished physical activity and in turn decreased exercise capacity.
This is supported by our findings in HRQoL; children who experienced fatigue reported more 
problems in not only physical functioning, but also in emotional, social, scholastic, and 
psychosocial functioning. From clinical experience we observe that children with MS and post-
ADEM experience psychological distress and difficulties with coping with the diagnosis or 
residual deficits. It is described that chronic ill young adolescents feel their chronic condition 
as ‘disrupting normal life’ and they perceive ‘discomfort in their own body’.27 Literature of adult 
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patients with MS suggested that exercise could improve physical activity, depression, fatigue 
and HRQoL.25 In children without chronic illness literature shows a positive correlation between 
physical activity and HRQoL.28 Interventions for these problems in pediatric demyelinating 
disorders have not been evaluated to date. Disease perception, disease acceptance and coping 
might be potential areas in understanding the mechanism of fatigue, diminished physical 
activity and reduced exercise capacity. 
Physical ability in children with MS and post-ADEM is frequently evaluated with the EDSS. The 
EDSS contains items on different functional systems that reflect disability of adult patients 
with MS and includes for example sexual functioning.12 In our experience, administration of 
this scale requires the subject to have adequate language perception and expression, which 
may not always be the case in a pediatric ADS cohort. In this study we used the MABCII to 
measure motor functioning, including manual dexterity, ball- and balance skills. Children with 
MS showed motor impairments, particularly of balance skills. Children post-ADEM showed 
motor impairments as well, but these were more equally distributed over the three subscales. 
Forty-nine percent of all children showed severe or borderline deficits on the total impairment 
score, which is strikingly high. However, if compared to EDSS scores, only 8% of our cohort has 
a score ≥2, which reflects disability which the patient is aware of in daily life.12 Nine percent of 
the MS patients scored EDSS ≥2 versus 6% of the patients post-ADEM, which is low in contrast 
to the high total MABCII impairment scores (52% and 44% respectively). This discrepancy 
confirms that the EDSS is not an optimal measurement for motor deficits in pediatric MS 
patients, and especially not in young patients post-ADEM. The MABCII seems to be a more 
sensitive measurement for expressing motor deficits and its severity. 
In children it is important to acquire motor skills being able to participate in physical activities 
and therewith being able to participate with peers. Lack of participation in physical activity has 
contributed to a decrease in fitness, and an increased risk for disease.29 Monitoring of motor 
performance is important to enable timely intervention. 
Several limitations of this study need to be addressed. First, the sample size was relatively small. 
Second, only sports participation was taken as a measurement of physical activity. Physical 
activity includes not only sports, but also other activities which involve bodily movement, such 
as playing, home-school transfers, and recreational activities.30 Monitoring physical activity in 
children is difficult. As far as we know, reference values of activity trackers in Dutch children 
are not available yet. The use of questionnaires on physical activity is debated, because 
children and adolescents tend to overrate physical activities.31 Moreover, all children were 
evaluated in our national-multidisciplinary pediatric MS-center as part of routine medical care. 
Therefore, we did not have a healthy control group and used published age-related reference 
values of the healthy population instead. Another limitation of this study is the fact that due to 
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the small sample size it was not possible to correct for DMT in MS patients in the statistical 
analyses. However, 82% of the MS patients were on DMT, which indicates a relative high group 
homogeneity.
In conclusion, children with MS and post-ADEM in our study had significant problems on 
different domains of physical functioning. To further explore the associations between 
physical functioning (physical activity, exercise capacity, motor development) and psychosocial 
parameters such as fatigue, depression, anxiety and coping, larger (multinational) cohorts 
with longitudinal data are necessary. A possible next step would be to investigate whether an 
intervention with an exercise program can improve the physical and psychosocial functioning in 
children with MS and post-ADEM. Lastly, our data confirm that the EDSS lacks the sensitivity in 
children to reflect motor problems. This indicates that other measurements for the assessment 
of physical impairments, such as the MABCII, are needed. 
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ABSTRACT
Neurogenic lower urinary tract dysfunction (LUTD) in MS is highly prevalent in adults, but 
has not previously been described in paediatric MS. Twenty-four consecutive children with 
newly diagnosed MS were prospectively assessed for bladder and bowel problems early after 
diagnosis. Five of 24 children (21%) showed LUTD during assessment. One of these patients 
did not report voiding complaints. This high prevalence of LUTD indicates that all recently 
diagnosed patients with paediatric MS should be evaluated early in their disease and treated 
for urinary problems in order to prevent potential damage to the upper urinary tract.
LOWER URINARY TRACT DYSFUNCTION IN EARLY PEDIATRIC MS
225
3.9
INTRODUCTION
Neurogenic lower urinary tract dysfunction (LUTD) is common in adults with MS. At time of MS 
diagnosis 10% have LUTD and after a disease duration of ten years this percentage increases 
to around 80%.1,2 LUTD may not only lead to irreversible alterations and damage to the upper 
urinary tracts if left untreated, like vesicourethral reflux, hydronephrosis and potential renal 
impairment, but also causes a significant decrease in quality of life.3,4 As children with MS face 
a far longer disease duration, LUTD can potentially be extra worrisome in this young patient 
group. At this moment, little is known about the prevalence of LUTD in children with MS. The 
objective of this study is to evaluate the prevalence of bladder problems in children with MS 
already in the very early phase of their disease.
METHODS
Study participants
All children with newly diagnosed MS, aged under 18 and who were followed-up at our paediatric 
MS centre, were consecutively offered a structured urological assessment (UA) between July 
2012 and June 2015. We included children who had an UA within 18 months after diagnosis and 
who did not have a relapse during or at least two months before UA.
Paediatric MS was diagnosed in accordance with the latest International Paediatric MS Study 
Group (IPMSSG) criteria.5 Children with other acquired demyelinating syndromes such as acute 
disseminated encephalomyelitis, neuromyelitis optica and clinically isolated syndrome were 
excluded. Demographic and clinical data were collected, including the Expanded Disability 
Status Scale (EDSS) score6 at presentation, at time of assessment and at the most recent visit. 
The EDSS score obtained closest to the UA was used. The EDSS score was composed without 
the bladder/bowel functional score to prevent bias. This study was approved by the Medical 
Ethical Committee of the Erasmus MC in Rotterdam. Written informed consent was obtained 
from all guardians and/or children between 12-18 years old.
Urological assessment
All children were assessed by the paediatric urology team. The UA was standardised and 
contained a detailed medical history of voiding and bowel functions, a voiding and defecation 
diary, questionnaires about voiding and bowel habits, physical examination, uro-flowmetry 
and determination of post-voiding residue (PVR) with ultrasound. During uro-flowmetry 
simultaneous electromyographic (EMG) recordings of the pelvic floor muscles with surface 
electrodes were performed. Determinants of LUTD are PVR above 20 milliliters, increased 
pelvic floor muscle discharges on EMG during voiding and/or an abnormal flow-curve. 
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Magnetic resonance imaging
Most recent brain and spine MRI images (1.0 or 1.5 Tesla) were evaluated in consensus by 
two assessors (YYW and RFN). MRI spine was not available for every patient as this was not 
performed routinely. Available MRI were scored for hyperintense lesions on T2 or FLAIR 
weighted images for areas involved in micturition and MS predilection areas: periventricular, 
juxtacortical and infratentorial areas, pons, periaqueductal grey, cerebellum, cervical spinal 
cord (SC), thoracic SC and conus.
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS 21.0. Chi-square and Fisher’s exact test were 
used for categorical data. Mann-Whitney U test was used for continuous data. Results were 
considered significant if p<0.05.
RESULTS
Twenty-six patients were eligible for this study and were offered an UA. Two patients declined. 
In total 24 children fulfilled the inclusion criteria and were included for analysis. Patient 
characteristics are summarised in Table 3.9.1. The median age at MS diagnosis was 13,4 years 
and the majority of children were females (79%). 
Five out of 24 children (four females and one male) showed signs of LUTD during assessment 
(21%). Only one of these patients did not report voiding complaints. A summary of the results 
of the UA of these five children is shown in Table 3.9.2. All symptomatic children received 
uro-therapy and measures for optimising defecation and eventually one patient received drug 
therapy for the urological complaints.
Children with LUTD more frequently had a preceding transverse myelitis (TM), although not 
significant. Patients with LUTD had however significantly more often pyramidal and sensory 
problems at time of their first clinical presentation (p=0.028 and p=0.041 respectively).
No differences were found between the location of MRI lesions in patients with and without 
urological symptoms. Longitudinally extended TM (≥ 3 segments) was not observed in any 
patient. 
Children with LUTD showed higher EDSS scores at baseline, at UA and at the most recent visit, 
as shown in Table 3.9.1. No significant differences were found in annualised relapse rate.
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Table 3.9.2: Results of urological assessment in patients with bladder dysfunction 
I II III IV V
Gender female Male female female Female
Age at screening 17 y 7 y 12 y 16 y 13 y
Questionnaire
Urgency - + - + +
Straining + - - - -
Start difficulties + - - - -
Incontinence (day) - + - + +
Incontinence (night) - - + - -
UTIsa - - 2 y ago 2 m ago -
Voiding diary
Voiding frequency (day) 8 5 3 10 10
Voiding frequency (night) 0 0 0 0 2
Voiding volume (min-max) 150-350 50-100 100-190 50-300 100-300
Flow
Volume 210 175 185 360 390
Q max (cm H2O)
b 11 15 33 24 32
Tc 32 19 9 25 20
PVRd (mL) 60 0 0 20 20
Shapee plateau Bell tower bell Bell
EMG increased Normal normal normal Normal
Constipation yes No yes yes No
a UTI: urinary tract infection, b Qmax; maximal uroflow [cm H2O], c T: flow time [sec], dPVR: post-voiding 
residual volume [ml]. eBell-shaped flow curve indicates normal voiding phase. Plateau-shaped or a 
staccato flow curve might indicate an anatomical of functional obstruction. A tower shaped flow curve 
might indicate bladder overactivity.
DISCUSSION
Five patients (21%) in our study population showed voiding problems within the first 18 months 
after their paediatric MS diagnosis. This high number is in sharp contrast to the data obtained 
from adult patients and is higher than numbers reported in healthy school aged children.1,7 
Contributing factors to this higher prevalence of LUTD may be that children with MS show a 
higher relapse rate, have a higher lesion load on first MRI and have more axonal damage in 
early disease, leading to dysfunction in an early stage.8,9 
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In order to detect patients with LUTD, questionnaires seemed sufficient for 80% of the patients. 
However, one patient did not have bladder functioning related complaints and would have 
been missed if patients were not systematically evaluated. As expected, we observed a higher 
frequency of LUTD in children with a preceding TM, although this was not significant. Almost all 
children had a spinal cord MRI. Notably, the proportion of patients with SC lesions on MRI was 
equally high in patients with and without LUTD. This is in line with an earlier study in adults, 
that showed that only one-third of SC lesions were symptomatic.10
We found that patients with confirmed LUTD had a higher EDSS score. This may indicate a 
potential role for LUTD as a prognostic factor for future disability and should be investigated in 
a larger cohort. Whether higher disability is an independent risk factor for LUTD in paediatric 
MS needs to be investigated as well.
In conclusion treating physicians should be aware of the high prevalence of urological symptoms 
in children with MS, even very early in their disease. Every newly diagnosed child with MS 
should be assessed for LUTD and should be treated accordingly to prevent irreversible damage 
to the urinary tracts. Longer follow-up studies in larger cohorts and optimizing standardized 
and validated questionnaires to increase their diagnostic properties are the necessary next 
step.
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ABSTRACT
Objective
Acute disseminating encephalomyelitis (ADEM) is an inflammatory demyelinating disease 
affecting the central nervous system and mainly occurs in young children. Children who 
initially presented with ADEM can be diagnosed with multiple sclerosis (MS) in case new non-
encephalopathic clinical symptoms occur with new lesions on MRI at least three months after 
onset of ADEM. We aim to study the timing of MRI abnormalities related to the evolution of 
clinical symptoms in our Dutch paediatric ADEM cohort. 
Methods
The Dutch database for acquired demyelinating syndromes (ADS) was screened for children 
under age eighteen fulfilling the international consensus diagnostic criteria for ADEM. Children 
were eligible when the first MRI was performed within the first three months after onset of 
clinical symptoms and at least one brain follow-up MRI was available for evaluation. Forty-two 
children with ADEM were included (median age four years two months). All available MRIs and 
medical records were assessed and categorised as ‘improved’, ‘deteriorated’ and ‘unchanged’. 
Results
We found that during clinical recovery, new lesions and enlargement of existing MRI lesions 
occurred in the first three months in about 50% of the performed MRIs. In contrast, this was 
rarely seen more than three months after first onset of ADEM.
Conclusion
We recommend to perform a brain MRI as a reference scan three months after onset. Follow-
up imaging should be compared with this scan in order to prevent an incorrect diagnosis of MS 
after ADEM. 
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INTRODUCTION
Acute disseminating encephalomyelitis (ADEM) is a rare immune-mediated demyelinating 
disease affecting the central nervous system.1 ADEM is mainly observed in young children and 
usually has a monophasic disease course. A previous diagnosis of ADEM with encephalopathy 
is shown to be a negative predictor of a future diagnosis of multiple sclerosis (MS).1-4 Several 
small studies have reported that MRI abnormalities may appear later than the clinical 
symptoms and progression of MRI lesions has been reported during clinical improvement.5-7 
This is a potential problem as the 2012 International Paediatric Multiple Sclerosis Study 
Group (IPMSSG) diagnostic criteria state that MS diagnosis can be made after ADEM, when 
new clinical symptoms occur with new MRI lesions at least three months after the onset of 
ADEM.8 Here we aim to study the timing of MRI abnormalities related to the evolution of clinical 
symptoms in our Dutch paediatric ADEM cohort. 
METHODS
Study participants
We included children less than 18 years old diagnosed with ADEM according to the IPMSSG 
criteria.8 Patients were identified by screening the Dutch database for children with acquired 
demyelinating syndromes (ADS) from January 1995 to October 2015.2,9 Children were eligible for 
this study when the first MRI was performed within the first three months after onset of clinical 
symptoms and at least one brain follow-up (FU) MRI was available for evaluation. Patients were 
excluded if the clinical data were incomplete. This study was approved by the Medical Ethical 
Committee of Erasmus MC in Rotterdam. Written informed consent was obtained from all 
patients and/or their families.
Demographic and clinical data
Demographical and clinical data, including the clinical status at every MRI scan, were collected. 
The clinical status was scored as ‘improved’, ‘deteriorated’ or ‘unchanged’ when compared 
with previous documentation of the neurological examination. FU duration was determined by 
the last visit or telephone contact with a neurologist or paediatrician. 
MRI data
Brain MRIs were performed at 1.0 or 1.5 Tesla scanners and consisted of T1, T2, and proton 
density 3–5 mm images. In most cases FLAIR images were available. The MRIs were evaluated 
for change in size of the lesions and presence of new T2 or FLAIR lesions by two assessors 
(YYW and EDvP). A third assessor (RFN) was consulted in case there was no consensus. Each 
FU MRI was compared with the previous MRI. The change was categorised as: 1) improved: 
decreased amount and/or size of the lesions 2) deteriorated: increase of size and/or amount 
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of lesions; 3) unchanged. In case of multiphasic disease course only MRI scans preceding the 
second episode were evaluated.
STATISTICAL ANALYSIS
We used SPSS, version 21.0, for statistical analysis. Categorical data were analysed by Chi 
square test and the Fisher’s exact test. Continuous data were analyzed with the Student’s 
T-test. A p-value <0.05 was considered significant. 
RESULTS
Patient characteristics
Sixty-three children with ADEM were identified of whom 42 met our inclusion criteria. In 30 
children at least two MRIs were performed in the acute phase. In 25 children FU imaging 
after three months was available. Demographic and clinical data are shown in Table 3.10.1. No 
significant differences were found in age, gender and FU duration. 
Acute treatment consisted of intravenous methylprednisolone (IvMP) for 3-5 days. In ten patients 
this was subsequently followed by intravenous immunoglobulins (IvIG) in case of insufficient 
clinical improvement. Three patients did not receive acute treatment because of mild disease 
severity. Eight patients were given oral prednisone taper (OPT) after acute treatment with a 
median duration of 2.4 months (range 0.8-5.1) 
MRI abnormalities and clinical features in the acute phase
Three of the 42 patients had a normal first MRI scan at presentation (performed 3 days, 7 days 
and 30 days after onset). In these children MRI abnormalities were observed at the second MRI 
at 26, 36 and 40 days after onset respectively. 
In the 30 children with multiple MRIs during the first three months, a total of 44 FU MRIs 
were performed. Twenty-one of the 44 FU MRIs showed deterioration (48%), of which 11 scans 
showed enlargement of the existing lesions and in 14 new lesions appeared. One MRI scan 
normalized in the acute phase. In total 16/30 patients showed radiological deterioration in the 
acute phase (53%). The delay of MRI abnormalities compared to clinical status is demonstrated 
in Table 3.10.2. 
In this group of 30 patients only five patients were given OPT directly after acute treatment. 
Three out of five showed improvement on FU MRIs while being treated with OPT after previous 
radiological deterioration. These three patients also had FU imaging after the acute phase and 
after discontinuation of OPT for at least four weeks, that showed further improvement of FU MRIs. 
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Two patients who also received OPT after acute treatment, showed deterioration of MRI. The 
first patient discontinued OPT three weeks before FU MRI in the acute phase. The second 
patient started OPT after the FU scan in the first three months was performed and no FU MRI 
after the acute phase was available.
Table 3.10.2: Comparison of clinical status and MRI evolution in the acute phase of ADEM. 
44 FU MRIs in the acute phase MRI improved, n (%) MRI unchanged, n (%) MRI deteriorated, n (%)
Clinically improved, n=29 20 (69) 1 (3) 8 (28)*
Clinically unchanged, n=7 0 2 (29) 5 (71)**
Clinically deteriorated, n=8 0 0 8 (100)***
Forty-four FU scans were obtained in the acute phase in 30 patients. When patients were clinically worse 
compared to their clinical status at the previous scan, MRI was also worse in 100% of the scans. On the 
other hand when patients were clinically improving at time of FU scans, MRI status was congruent in only 
69% of the imaging. Twenty-eight percent showed deterioration (either enlargement of existing lesions 
or new lesions or both) despite of clinical improvement. The proportion of deteriorating scans with new 
lesions is as following: * 4/8 new lesions, ** 3/5 new lesions, *** 7/8 new lesions. 
MRI abnormalities and clinical features after the acute phase
In 25 patients FU imaging was performed after the acute phase of three months. Twenty-three 
patients showed improvement of their MRI abnormalities. However, only one normalized. Two 
patients showed deterioration of MRI lesions during FU after the acute phase. The first patient 
was given OPT after acute treatment at onset and ceased OPT six months before FU MRI 
was obtained. No MRI was made between the first brain MRI and FU imaging. The second 
patient showed new lesions without new clinical symptoms 7 months after onset. These two 
children had evident encephalopathy and were 2 and 7 years old at presentation. Extensive 
testing was performed and these patients did not fulfill diagnostic criteria for other differential 
diagnosis than ADEM. During follow up of respectively 8 years and 2 years they did not fulfill 
the diagnostic criteria for MS. 
In this group of 25 patients six were prescribed OPT. Except for the one patient mentioned 
above, five out of six showed improvement of MRI during FU after the acute phase. FU MRIs 
were all obtained after cessation of OPT for at least 4 weeks. 
Patients with both MRIs in the acute phase and after the acute phase
Due to the observations made in the results shown in the previous paragraphs, a subanalysis 
was performed in patients who had MRIs in both the acute and post-acute phase for better 
comparison of the MRI-scan evolutions within each patient. For this subanalysis patients were 
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eligible when at least two MRIs in the acute phase and at least one FU MRI after the acute 
phase were available. Thirteen of the initial 42 patients were included.
A total of 24 FU MRIs were performed during the acute phase. Fourteen of these showed 
deterioration (58%), of which 12 showed enlargement of previously observed lesions, and 8 with 
observed new lesions. In total 10/13 patients showed radiological deterioration in the acute 
phase (77%). 
When observing the MRIs after the acute phase, all patients showed radiological improvement 
compared to the last scan in the acute phase except for one patient. This concerned the patient 
with new observed lesions at 7 months after onset as previously described. 
Three patients received OPT after acute treatment. These patients showed radiological 
improvement on FU MRIs while being treated with OPT after previous deterioration in the acute 
phase. The FU MRIs after the acute phase and after discontinuation of OPT were improved in 
all three patients.
DISCUSSION
This study confirms that evolution of MRI abnormalities in children with ADEM can be delayed 
compared to the evolution of clinical symptoms, as suggested by some case reports.5-7 Also, a 
normal MRI in the first days after symptom onset does not rule out a diagnosis of ADEM.
The lack of a strict FU MRI protocol limited the evaluation of the exact timing of MRI 
abnormalities and clinical features. Due to the young age of our patients the decision to 
perform or not perform a FU MRI was based on individual circumstances, i.e., the need for 
sedation and clinical features.
It is likely that timing of discontinuation of corticosteroid treatment can potentially influence 
the FU MRI results. In our study this did not play a large role as only a small group received an 
OPT. Furthermore in most of these children FU imaging was performed at least 4 weeks after 
OPT was stopped.
We observed that MRI deterioration occurs often in the acute phase and rarely occurs more 
than three months after ADEM onset. This observation was further confirmed in the performed 
subanalysis of patients who had images available in both the acute and post-acute phase. The 
proportion of patients showing radiological deterioration is higher in the subanalysis compared 
to all patients who had multiple MRIs in the acute phase (77% and 53% respectively). This 
might be explained due to the selection bias of performing FU MRIs more often in children who 
showed deterioration on last MRI in the first three months.
CHAPTER 3.10
240
The message that MRI deterioration rarely occurs three months after onset is important, 
because the latest revised diagnostic criteria for ADS including MS in children allow MS 
diagnosis when a first episode of ADEM is followed by a new non-encephalopathic episode with 
new MRI abnormalities.8 Therefore it is important to critically assess the patient whether new 
clinical symptoms are truly present in case of new MRI abnormalities. 
In conclusion, our study shows that new MRI abnormalities may occur in the first three months 
even when clinical symptoms are improving, and this rarely occurs after 3 months. Therefore 
we recommend to perform a brain MRI three months after onset as reference scan. Further 
FU imaging should be compared with this reference scan in order to avoid false positive results 
and as a consequence an incorrect diagnosis of MS after a first episode of ADEM.
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4.
General discussion 
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Acquired demyelinating syndromes (ADS) encompass a broad spectrum of inflammatory 
demyelinating disorders of the CNS. Accurate diagnosis and prediction of disease course is 
imperative for accurate counselling and treatment opportunities. This underlines the need to 
improve the diagnostic process by further investigating the diagnostic and prognostic value 
of existing biomarkers, such as anti-myelin oligodendrocyte glycoprotein antibodies (MOG-
IgG), but also the need to find new biomarkers to predict the disease course accurately and 
early after onset. This thesis focuses on two rare groups of patients in the ADS spectrum: 
neuromyelitis optica spectrum disorders (NMOSD) in adults and the spectrum of childhood 
onset ADS. We aimed to move forward on delineating the spectrum of ADS, and investigating 
the disease course and outcome in children with ADS and in adults with NMOSD. Here we 
outline and discuss our main findings. Future directions are discussed after each specific topic 
and at the end of this Discussion. 
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PART ONE - NEUROMYELITIS OPTICA SPECTRUM DISORDERS 
Clinical comparison between AQP4-IgG, MOG-IgG and seronegative NMOSD
After the discovery and validation of anti-aquaporin 4 antibodies (AQP4-IgG), the AQP4-IgG 
serostatus is implemented in the diagnostic criteria for NMOSD (Table 1.1).1 This broadened 
the clinical spectrum of NMOSD and enabled to study the differences between AQP4-IgG 
seropositive and AQP4-IgG seronegative patients.1–3 In our study (chapter 2.1), we confirmed 
that about one third of the AQP4-IgG seronegative NMOSD patients have MOG-IgG1, 
including limited forms of NMOSD-like phenotypes.4 In addition we assessed the brain MRIs 
of our seropositive patients for the presence of NMO-specific brain lesions, which typically 
occur at sites with high aquaporin-4 expression.5,6 These lesions were not present in MOG-
IgG seropositive NMOSD patients, which is likely due to the different underlying disease 
mechanisms. Patients with MOG-IgG are more often males in contrast to AQP4-IgG positive 
patients and more often have a monophasic disease course.7–11 Despite the seemingly benign 
course, a proportion of patients still relapses and shows accumulation of disability. A recent 
retrospective cohort study showed that with a longer follow-up (FU), about 80% of the patients 
with MOG-IgG will develop a relapsing disease course.12 These findings need to be validated 
in the future. Chronic immunosuppressive agents should be considered in MOG-IgG patients 
with relapsing disease, with caution of overtreatment considering the potential long disease 
intervals. 
Epidemiological data on AQP4-IgG and MOG-IgG related disorders
In the Netherlands, AQP4-IgG and MOG-IgG are diagnostically tested in one central reference 
laboratory (Sanquin Diagnostic services) with specific cell-based assays. Therefore we were 
able to calculate the nationwide incidence figures for AQP4-IgG and MOG-IgG in the Dutch 
population. Chapter 2.2 presented the Dutch incidence of AQP4-IgG associated NMOSD of 
0.09 per 100.000 persons, which is about one in a million. This is within the range of previously 
described incidence rates from 0.05-0.4 per 100.000 people.13–16 Differences can be explained 
by study design and inclusion criteria. For example two studies from comparable western 
countries in Denmark and the United Kingdom did not achieve nationwide coverage and also 
included AQP4-IgG negative NMOSD patients.14,16
MOG-IgG were described in demyelinating disorders including NMOSD in adults and children, 
and other ADS subtypes in children. In chapter 2.3 we calculated the mean incidence for MOG-
IgG seropositive ADS in the Dutch population of 0.16 per 100.000 persons per year (almost 
two in a million), with a higher incidence in children (0.31 per 100.000 children per year) than 
in adults (0.13 per 100.000 persons per year). We also observed differences in distribution 
of clinical phenotypes in adults and children, possibly influenced by the different impact of 
inflammation on myelin that is still maturing. Clinicians should be aware that a minority of 
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the patients have an extended time-to-first-relapse of more than 200 months. Even though we 
did not have a standardized serological follow-up (FU) in these patients, we observed that the 
majority of the patients who turned seronegative during FU, did not show further relapses. Well 
set-up prospective studies are needed to further investigate the association between disease 
course and MOG-IgG serostatus. 
It should be noted that for both antibodies, the incidence estimates are minimum incidence 
figures, since mild cases and forme fruste types of the disease could have been missed. Yet, the 
longer both assays are used in clinical practice, it is likely that more rare clinical presentations 
will be observed, leading to a further broadening of the antibody associated clinical spectrum. 
One example is already given in chapter 2.3, where it seems that a cortical manifestation with 
seizures is described in a handful of MOG-IgG seropositive patients in current literature. 
 
Future research concerning NMOSD
In NMOSD no predictive biomarkers for relapses and prognosis of disease course are identified, 
other than the AQP4-IgG and MOG-IgG serostatus. As disability accumulation is correlated 
with relapses, accurate prediction of treatment response and thus selecting the right agent 
to start with is essential. This is particularly important when chronic treatment options are 
expanding and practicing personalized medicine is desired.17 One of the possibilities is further 
investigating B-cell subsets (for example surface biomarkers) or T-cell subsets.18 Collection 
of paired blood and CSF in this group of patients will create opportunities to better understand 
the pathophysiology of NMOSD, and aid in finding new biomarkers for disease course. In 
addition, despite MOG-IgG can be found in one-third of the AQP4-IgG seronegative patients, 
the other 2/3 of patients are still unaccounted for with a double seronegative status. Some 
patients in this latter group might still be seropositive for one of these antibodies, but are not 
detected with the current CBA due to low antibody levels. The search for new antibodies in this 
group can provide insight in pathophysiology, customize treatment for individual patients and 
determine their prognosis. 
The presented epidemiological figures are not only of importance for care and counselling, 
but also for the design potential future clinical trials. Due to the low incidence of AQP4-IgG 
and MOG-IgG seropositive patients, a stepwise initiation of clinical trials and international 
collaboration is warranted to guarantee successful enrollment of patients. Treatment agents 
for AQP4-IgG seropositive patients are under research in ongoing clinical trials.19 
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Main findings & Clinical implications Part ONE:
ADULT ACQUIRED DEMYELINATING SYNDOMRES, FOCUS ON NEUROMYELITIS OPTICA 
SPECTRUM DISORDERS
Main findings 
The incidences of AQP4-IgG seropositive NMOSD and MOG-IgG associated ADS in the 
Netherlands are 0.09/100.000 persons and 0.16/100.000 persons per year respectively, with a 
higher MOG-IgG incidence in children than adults. 
•  About one-third of the Dutch AQP4-IgG seronegative patients with a clinical NMOSD 
phenotype are tested positive for MOG-IgG. 
•  Although MOG-IgG seropositive patients generally have a more favorable outcome than 
AQP4-IgG positive NMOSD patients, caution must be taken in relapsing MOG-IgG patients 
who are at risk of accumulation of disability. 
Clinical implication: 
MOG-IgG should be tested in parallel with AQP4-IgG in patients with suspected (limited forms 
of) NMOSD as part of the routine diagnostic work-up.
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PART TWO – CHILDHOOD ONSET ACQUIRED DEMYELINATING SYNDROMES 
SECTION TWO-A: EARLY and ACCURATE DIAGNOSIS FOR PEDIATRIC MS 
Multiple sclerosis (MS) is a chronic variant of ADS and the most well-known amongst the 
different ADS subtypes. At the time of a first attack, it can be a challenge to distinguish MS from 
non-MS patients, especially in children due to a more extensive list of differential diagnoses.20 
In addition, determining the disease course after MS diagnosis can be difficult. We aimed to 
investigate biomarkers for an early and accurate MS diagnosis and for identification of patients 
with a clinically active disease. 
MS diagnosis at first attack of ADS
The International Pediatric MS study group (IPMSSG) proposed the first set of diagnostic 
consensus criteria for children in 2007 and these were revised in 2012.21,22 The IPMSSG 2012 
consensus criteria implemented the McDonald 2010 criteria for pediatric MS, with provisions 
for children <12 years and patients with acute disseminated encephalomyelitis (ADEM).23 
Recently, the international panel on diagnosis of MS proposed the McDonald 2017 criteria, 
by reviewing and revising the prior 2010 McDonald criteria.23,24 These revised criteria include 
important modifications with re-introducing CSF oligoclonal bands (OCB) into the criteria and 
allowing symptomatic lesions to contribute to dissemination in space (DIS) and dissemination 
in time (DIT). The McDonald 2017 criteria need validation before being implemented in clinical 
practice. The McDonald 2010 and revised McDonald 2017 criteria are displayed in Table 1.1. 
Implications of the novel McDonald 2017 criteria 
We evaluated the diagnostic accuracy of the revised 2017 criteria in 164 children (110 ADS 
without encephalopathy, ADS-; 54 ADEM, ADS+) with a first attack of ADS compared to the 
former 2010 criteria (chapter 3.1). Clinically definite MS (CDMS), defined as two attacks with 
different neurological localizations, was used as the endpoint to compare the McDonald 2010 
and 2017 criteria. The 2017 criteria were more sensitive (83% vs 49%) and less specific (73% 
vs 87%), but the overall diagnostic accuracy was higher (77% vs 70%) than the 2010 criteria. 
The differences in test characteristics of the revised and former criteria are mainly caused by 
allowing OCB to be a substitute for DIT. Our data shows that more children will be diagnosed 
with MS at baseline (2017 n=48 vs 2010 n=27). Yet, the specificity decreased with the new 
criteria, which was caused by 7 patients. These 7 patients all have a high-risk MS profile and 
will likely be diagnosed with CDMS during longer FU. It is important for clinicians to realize 
that more children will be identified at baseline who are likely to have a less clinically active 
disease course. 
Our data shows that the test characteristics are similar (even somewhat better) in children 
under age 12, and pleads for the applicability of these new criteria across the whole age-span, 
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in line with previously published studies.25–27 About 10% of the ADEM patients would have been 
diagnosed with MS using the new MS criteria. However, no ADEM patient was diagnosed with 
CDMS. In order to prevent erroneous diagnosis in this group of patients, the provision to not 
apply these criteria on children with ADEM should be kept. Our data is in line with Fadda et 
al, however the figures can vary due to difference in study design, including the difference in 
endpoint (either CDMS or new T2 lesions on MRI).27 Validation of these criteria in other cohorts 
are needed. 
Biomarkers for MS at first attack of childhood-onset ADS
Predictive value of CSF soluble CD27
Soluble CD27 (sCD27) is an immunological marker that is secreted by activated T-cells, and 
is introduced as a potential biomarker for T-cell mediated inflammation.28 CSF sCD27 is 
validated as a biomarker for intrathecal T-cell activation in MS, after using an extensive battery 
of biomarkers for CNS inflammation.29 In a recent study executed in adults by our research 
group, high levels of sCD27 in CSF independently associate with MS diagnosis and disease 
course in adults with clinically isolated syndrome (CIS).30 The predictive value of this promising 
biomarker in children with ADS was not investigated before.
In chapter 3.2, we compared the sCD27 levels in CSF of ADS subgroups sampled at time of 
first attack. Our data is in line with the study performed in adults showing higher levels in MS 
than in monophasic clinically isolated syndromes (CIS) with the highest levels among ADS- 
patients who were diagnosed with CDMS during FU. In addition, high sCD27 levels at baseline 
are predictive for CDMS diagnosis and show a shorter time to second attack in MS. This 
validation strengthens the conclusions from both studies. Moreover, the sCD27 levels found in 
pediatric MS are higher than in adult MS, which support existing data that children have a more 
inflammatory disease course than adults.31–34 In contrast to the conclusions made in adult 
MS, we did not find a correlation between sCD27 levels and relapse rate. This finding might 
be explained by a ceiling effect, as the overall relapse rate is high in the pediatric MS cohort. 
Despite the higher disease burden in pediatric MS, the time to disease progression is slower 
in children than in adults.33,35,36 A longer FU is needed to investigate a possible relationship 
between sCD27 levels and chronic disease progression.
Predictive value of CSF and serum neurofilament light chain 
As indicated above, disease progression is slower in children than in adults.33,35,36 Yet, 
neurodegeneration seems to be present early in the disease course of pediatric patients, 
indicated by a high proportion of T1 hypointense lesions on baseline MRI, and reduced brain-
expected brain growth at baseline as reported in literature.37,38 Axonal damage is considered 
one of the major causes for persisting neurological disability in MS.39 A promising biomarker for 
axonal damage is neurofilament light chain (NfL), a component of the neurocytoskeleton that 
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is released in the extracellular space after axonal death.40 NfL increases with age in healthy 
individuals, reflecting neurodegeneration as part of the physiological aging process.41 In adults 
with CIS, high levels of NfL in CSF are associated with future MS diagnosis.42 
We first investigated NfL in CSF in both adults and children (chapter 3.3). CSF NfL levels 
at first attack of ADS predicted a second attack (CDMS) both in children and adults without 
encephalopathy (CIS), even better than currently used markers such as asymptomatic T2 
lesions on MRI and OCBs in CSF. We compared the NfL levels in children and adults, and 
the levels were even higher in children, implying that children not only have signs of more 
inflammation but also, in line with existing literature, seem to have more axonal damage than 
adults.37,38 Moreover, in our pediatric MS cohort, more T1 hypointense lesions were found at the 
baseline scan compared to their adult counterparts. The fact that we did not find a correlation 
between EDSS and NfL levels is not surprising in this prospective cohort, as children with 
MS have a slower disease progression than adults.33,35,36 Longer FU is needed in order to re-
investigate this association. 
Subsequently, we investigated NfL in serum, as serological biomarkers are more easily 
assessable than CSF and are likely to be preferred in the future. We show in chapter 3.4 that 
CSF and serum NfL (sNfL) at baseline correlate well in the overall ADS group and correlate 
even better in the ADS patients without encephalopathy (ADS-) with future CDMS. The sNfL 
levels were highest in ADEM patients, followed by ADS- patients future CDMS diagnosis and 
the lowest in monophasic ADS- patients. Serum NfL was positively correlated with multiple 
MRI parameters, including T1 hypointense lesions, as a sign for axonal loss. This further 
supports sNfL as a validate marker for axonal damage. Higher levels of sNfL at baseline are 
associated with a shorter time to CDMS diagnosis in ADS- patients, after adjusting for age, 
OCB and MRI parameters. 
A paradox seems to exist between the signs of more neuroaxonal loss in pediatric MS compared 
to adults early in the disease and yet, the rate of progression is slower in children.33,35,36 Yet, 
biological differences at different ages can influence this observation, including the myelination 
process: this continues into early adulthood, and may cause a difference in lesion composition 
and in repair capacity along the myelin maturation.43 In addition, functional compensatory 
mechanisms may play a role, but need to be further explored with functional MR imaging.44
To our surprise, ADEM patients showed rather high NfL levels in CSF and the highest among the 
patient subgroups in serum, as shown in chapter 3.3 and 3.4. These two studies complement 
each other and seem to indicate that neuro-axonal damage is a prominent feature in ADEM. The 
association between CSF/serum NfL levels and cognitive and radiological outcome measures 
of ADEM patients need to be investigated in the future. 
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Main findings & Clinical implications Part Two – SECTION TWO-A: 
EARLY and ACCURATE PREDICTORS FOR PEDIATRIC MS 
Main findings 
• McDonald 2017 criteria can be applied in children across the age-span with a first attack 
of non-encephalopathic demyelination. Keeping in mind that the new criteria are more 
sensitive but less specific than the former 2010 criteria, mainly impacted by the inclusion of 
CSF OCBs as substitute for dissemination in time. 
• With the McDonald 2017 criteria applied at baseline, more patients can be diagnosed with 
MS who likely have a less active disease course. 
• Soluble CD27 in CSF have predictive value for future diagnosis MS at the first attack of 
pediatric demyelination. 
• NfL in CSF at baseline predicts MS diagnosis in both adults and children. Higher levels are 
found in children than in adults. 
• Serum NfL in children correlates well with CSF NfL and is also predictive of MS diagnosis 
after correction for existing predictive factors. 
• High CSF and serum NfL levels in ADEM patients indicate that neuro-axonal loss is a 
prominent feature in in ADEM. 
Clinical implication: 
• McDonald 2017 criteria may be used in clinical practice for MS diagnosis in children across 
the whole age-span, but not in children with ADEM. 
• Prompt initiation of chronic treatment in pediatric MS is supported by the presence of high 
levels of inflammatory and neurodegenerative biomarkers at the first attack.
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SECTION TWO-B: DISEASE COURSE AND OUTCOME OF CHILDHOOD ONSET ADS 
Disease course and Treatment of MOG-IgG associated relapsing disorders
MOG-IgG can be found in the spectrum of ADS in children and adults, in children up to 50% at 
first presentation.45–47 The presence of MOG-IgG pleads against MS diagnosis, but is associated 
with a higher risk of relapsing non-MS disease.45,46 In clinical practice these relapsing patients 
tend to accumulate residual deficits, sometimes despite the use of immunosuppressive 
treatment. Due to the rarity of MOG-IgG relapsing disorders, we collaborated with multiple 
European countries to increase the sample size to study the clinical spectrum, given treatments 
and outcome in this MOG-IgG associated relapsing demyelinating syndromes. 
In chapter 3.5, we described the disease course, treatment response and outcome of 17 
young patients presenting with ADEM followed by optic neuritis (ADEM-ON). The disease 
course was heterogeneous and no predictors could be found between patients with high and 
low relapse rates. Immunosuppressive agents were given to 59% of these patients, including 
azathioprine, mycophenolate and potent therapies like Rituximab, maintenance IvIG therapy 
and cyclophosphamide. Despite the heterogeneity in treatment, we observed that a total of 
54 relapses occurred on all treatments, including more potent therapies such as Rituximab 
or intravenous IvIG. On the contrary, children were highly sensitive to steroids and 27/54 
relapses occurred while weaning-off oral prednisone or within 4 weeks after discontinuation 
of prednisone. This indicates a certain degree of corticosteroid dependence in these children 
and may be typical of relapsing MOG-IgG associated ON.48 However, the worrisome side effects 
of prednisone in these developing children49 and the unpredictable disease course of patients 
warrant against long-term use of prednisone. 
In chapter 3.6 we retrospectively collected 102 children with MOG-IgG associated relapsing 
disorders. Above mentioned immunosuppressive agents or MS disease modifying drugs 
(interferon beta, glatiramer acetate) were initiated in 52/102 (51%) of these children. Despite 
treatment, 127 relapses still occurred in these 52 children. No difference was found in 
demographics between patients who did and did not relapse after initiating immunosuppressive 
drugs. We observed an age-dependent phenotype, with brain manifestations in younger 
children, and optic neuritis and/or transverse myelitis with normal brain MRI in older children. 
This finding may reflect the differences in white matter composition during physiologic, age-
dependent maturation of the brain in childhood.50 
In both chapter 3.5 and 3.6, we observed that treatments were administered heterogeneously 
and made it difficult to fairly compare treatment responses. Treatment consensus guidelines 
are urgently needed in order to make better comparison possible. As the data collection was 
retrospective for both studies, we were precluded from investigating the prognostic relevance 
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of MOG-IgG levels on disease course. Longitudinal serological FU of MOG-IgG will be important 
for future studies. More studies are needed to investigate the disease heterogeneity, early 
biomarkers for relapsing disease and optimal outcome measures for MOG-IgG associated 
disorders. After elucidating these aspects of MOG-IgG related disorders, clinical trials can be 
performed. 
Outcome of childhood-onset ADS
The potential cognitive and physical sequelae of pediatric MS are mentioned in different 
studies.51–53 Even though outcome studies of monophasic ADS and non-MS chronic disorders 
are emerging, the evidence is not as extensive as in pediatric MS patients. Additional studies 
on the outcomes and FU of pediatric ADS are needed. 
Update on incidence and outcome of ADS
In chapter 3.7 we provided the updated Dutch incidence of ADS and MS and is increased 
compared to our previous work.52 This increase can be partially explained by increased 
awareness and our well-established referral network. However, we cannot exclude that the 
true incidence of pediatric MS is increasing in the Netherlands. Prolonged assessment of the 
incidence will be necessary to answer this question. 
Furthermore, we studied the clinical characteristics of 243 children included in the PROUD-
kids study at presentation and at last FU with a median FU time of 5 years. During FU, 37% 
of the ADS patients was diagnosed with MS, in line with other studies.51,53,54 A few findings 
are noteworthy: In our cohort, an Expanded Disability Status scale score (EDSS) of 5.5 is only 
reached in 3% of the MS patients after a median of 61 months. However, the overall proportion 
of physicians or parents reporting residual deficits is high in our ADS patients (69%), including 
83% in MS patients. This may mean that the disability measurement with EDSS, which was 
originally designed for adults, does not reflect disability well in the pediatric population.55 This 
will be further discussed in the next section ‘Fatigue and physical functioning’.
One-third of the included ADEM and MS patients who were followed in the National Pediatric 
MS center underwent a neuropsychological assessment in a consecutive manner. In this 
tested group, cognitive impairment was observed in the majority of children (>75%). The high 
percentage of cognitive deficits in the monophasic group (overrepresented by ADEM patients) 
feeds the impression that one single hit of ADEM can leave considerable intracerebral damage. 
As mentioned earlier, reduced age-expected brain growth is also shown in monophasic ADS 
patients, especially ADEM, indicating irreversible and continuing changes occurring in the 
CNS even in the absence of chronicity.56 Moreover, negatively affected school performance 
was reported by parents in one-third of our ADS cases, some even requiring adjustments at 
school including extra time to complete examinations and change to special education. In a 
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major proportion of adult MS patients, MS negatively impacted their employment situation.57 
The effect on participation in society could even be worse in pediatric onset ADS. Adequate 
detection of disability and guidance of ADS patients in collaboration with other specialists, 
such as (pediatric) rehabilitation specialists, is important to preserve and improve societal 
functioning, and is essential during FU of these patients into childhood. 
Fatigue and physical functioning 
Fatigue is a frequently reported complaint in pediatric MS.58,59 However, fatigue does not limit 
to chronic forms of demyelinating disease such as MS, but is also reported in children with 
ADEM.59–61 The cause of fatigue in ADS is unclear. In a Canadian study, a correlation is found 
between fatigue and physical activity, where MS children were less physically active and scored 
higher on fatigue scales than patients with monophasic ADS.62 We assumed that physical 
disturbances such as motor problems, fatigue and decreased exercise capacity affect a child’s 
quality of life. 
In the Dutch Pediatric MS center, children with ADEM and MS were consecutively referred to 
the pediatric physical therapist to screen for motor function, quality of life (including fatigue 
scales) and exercise capacity. In chapter 3.8, two main findings need to be discussed: 
First, that children with MS and ADEM are more fatigued, have reduced exercise capacity 
and impaired motor performance compared to their healthy related peers. Unexpectedly, we 
found no correlation between these parameters. Yet, fatigue was correlated with a reduced 
quality of life. We hypothesize that a complex interaction exists in the process of inactivity, 
decreased exercise capacity and fatigue and might involve other factors, such as depression 
and psychosocial factors. This is supported by our finding that patients who were more 
fatigued, not only had more problems with physical functioning, but also in emotional, social, 
scholastic and psychosocial functioning. In our experience, psychological distress is often 
observed in ADS patients in coping with the diagnosis and residual deficits. Disease perception, 
disease acceptance and coping might be potential areas to investigate in order to increase our 
understanding of the underlying mechanisms involving fatigue, diminished physical activity 
and reduced exercise capacity. Future research projects in this area will need to cover all these 
different aspects in order to draw conclusions. Furthermore, a positive correlation was found 
between sports participation and exercise capacity. In adult MS patients, exercise seems to 
improve physical activity, depression, fatigue and quality of life.63 The effect of high-intensity 
exercise programs appeared to be beneficial in adult MS patients, and are yet to be tested in 
children.63,64 
Second, we found that 49% of all children showed severe or borderline deficits, which is 
strikingly high. Especially because only 9% of the MS patients and 6% of the ADEM patients 
had a EDSS score of ≥2, which reflects disability where the patient is aware of in daily life. This 
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discrepancy confirms that the EDSS is not an optimal metric for motor deficits in pediatric 
patients65 and that the MABCII may be a more sensitive alternative. The lack of sensitivity of 
EDSS in the pediatric population may be explained by the requirement of adequate language 
perception and expression of the patient, which may not always be the case in children and 
young adolescents. Other metrics and tools that are sensitive to detect subtle disability in 
patients with pediatric MS and ADS are needed. 
Bladder function in pediatric MS
Neurogenic lower urinary tract dysfunction (LUTD) is common in adults with MS with a 
prevalence of 10% at time of MS diagnosis, but the figures for children are unknown.66,67 In 
chapter 3.9, we observed that 21% of our pediatric MS patients already have voiding problems 
in the first 18 months after initial MS diagnosis, and this figure is higher than in adults. We 
found that patients with confirmed LUTD had a higher EDSS score at baseline, at urological 
assessment and at last visit. This may indicate a potential role for LUTD as a prognostic 
factor for future disability. More patients with LUTD had a preceding TM, even though this 
was not statistically significant. Whether LUTD is an independent risk factor for disability 
after correction for preceding TM should be investigated in a larger cohort. Other contributing 
factors to the higher prevalence of LUTD may be the higher disease activity in pediatric MS, 
including a higher relapse rate, higher lesion load on baseline MRI and more axonal damage 
early in the disease.43,68 Clinicians treating pediatric MS patients should be aware of the high 
prevalence of LUTD very early in the disease course. Optimizing standardized and validated 
questionnaires are necessary to improve LUTD detection.
MRI in children with acute disseminated encephalomyelitis
In ADEM patients, the MRI abnormalities can be very extensive.69 The evolution of MRI lesions 
during FU is rarely studied, except for a few case reports.70–72 In chapter 3.10, 42 children 
with ADEM were included for evaluation. We found that deterioration of MRI abnormalities 
(i.e. enlargement of existing lesions or appearance of new lesions) rarely occurs after the first 
three-month period. This finding is important as the latest revised diagnostic criteria for ADS 
including MS in children allow MS diagnosis when a first episode of ADEM is followed by a new 
non-encephalopathic episode with new MRI abnormalities.22 Therefore performing a new MRI 
three months after symptom onset is warranted to establish a new reference point for further 
FU. This in order to prevent unjust confusion about potential MS diagnosis and unjustified 
initiation of disease modifying therapies.
Future research concerning childhood ADS 
For MS risk stratification, the clinical profile, MRI, blood and CSF parameters are used 
in clinical practice, including MOG-IgG.73 Finding more biomarkers and risk factors to 
differentiate between MS and non-MS patients is needed and has therapeutic implications. 
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In addition, predictive factors for future disease course in MS and other chronic forms of ADS 
are necessary, especially as the therapeutic possibilities will likely expand in the near future. 
With this in mind, a logical next step is to find easily assessable metrics for treatment response 
and disease progression (such as neurodegeneration). Two potential metrics for further 
exploration are retinal optical coherence tomography (OCT) and serum neurofilament. The 
inner layer of the retina is known as the retinal nerve fiber layer (RNFL) and can be measured 
with OCT. Thinning of the RNFL may lead to thinning of the macular ganglion cell layer (MCGL) 
and are both reflective for neurodegeneration in adults with MS.74 OCT is non-invasive and can 
be of value for longitudinal monitoring of neurodegeneration in pediatric ADS. The first results 
of serum NfL in pediatric ADS patients are presented in this thesis, but needs validation and 
requires further study for clinical relevance.
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Main findings & Clinical implications Part Two – SECTION TWO-B: 
DISEASE COURSE and OUTCOME OF CHILDHOOD ONSET ADS
Main findings 
• Treatment regimens used in MOG-IgG associated relapsing disorders are heterogeneous.
•  MOG-IgG associated disorders are sensitive to corticosteroids and show a certain degree of 
corticosteroid dependence. 
• Physical and cognitive sequelae are common across all subtypes of ADS, including 
monophasic ADS. 
• EDSS is an insensitive metric to express physical disability in pediatric ADS, MABC II might 
be a better alternative. 
• Neurogenic bladder dysfunction is common in children with MS even early in the disease 
course. 
• In ADEM patients, a delay is observed in MRI lesions, for example enlargement and new 
lesions in <3 months after onset while patient is improving.  
Clinical implications 
• Treatment guidelines need to be established for MOG-IgG positive patients to facilitate 
systematic evaluation of treatment responses. 
• In MOG-IgG relapsing disorders, oral corticosteroids should be tapered off very slowly, 
while keeping in mind that patients are prone to a relapse on low dose prednisone. 
• Extra attention should be paid to long-term physical and cognitive sequelae in pediatric 
ADS in collaboration with pediatric rehabilitation specialists, physical therapists and 
neuropsychologists. 
• Physicians treating pediatric MS patients should actively ask for symptoms that are related 
to neurogenic bladder dysfunction in order to start timely interaction. 
• In ADEM patients, an MRI brain needs to be repeated after 3 months to establish a new 
reference point for follow-up, in order to prevent misdiagnosis of MS. 
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GENERAL DIRECTIONS FOR FUTURE RESEARCH
Important steps have been made in the research of NMOSD in adults and ADS in children, 
but additional work is needed to further explore the underlying pathophysiology of ADS, 
and find predictive factors for accurate diagnosis, disease course and outcome. Specific 
recommendations for future research regarding results presented in this thesis are described 
in previous paragraphs. Here are a few general suggestions for moving forward. 
The value of existing cohorts with long-term follow-ups
The chapters in this thesis were made possible by the two prospective cohort studies that 
are currently ongoing in the ACE ErasMS center Rotterdam, including the National NMOSD 
and Pediatric MS expert center. The longer the FU time, the more valuable these cohorts 
will become, especially in children because of the long time to disease progression in this 
group.33,35,36 Furthermore, collaboration between the PROUD and PROUD-kids study in 
Rotterdam is valuable, as both prospectively include patients with first demyelination in adults 
and children, respectively. Research in both adult and pediatric patients can improve our 
understanding of ADS in general by studying the similarities and differences, and may help in 
finding clues for the underlying pathophysiology. 
Moving forward on the ‘why’ and ‘when’ in ADS
MS has a multifactorial etiology with an interplay between genetics and environmental 
factors.75 Yet, a larger gap is present in our knowledge regarding this interplay in other ADS 
subtypes. Due to the rarity of ADS, including NMOSD in adults, international collaboration will 
allow for larger sample sizes which are required in both genetic and environmental research. 
Also, this collaboration may increase our knowledge on the ethnical differences in the clinical 
presentations of ADS subtypes. Identification of contributing (modifiable) risk factors are not 
only valuable for insight in pathophysiology, but also for potential prevention strategies, for 
example weight loss in children with increased BMI and subscribing vitamin D supplements 
in vitamin D deficiency in children with MS.73,76 In addition, the role of the gut microbiome in 
disease pathogenesis in MS and other ADS subtypes need to be explored and might lead to 
complementing therapeutic strategies in the future.77–79 
The difficulty of investigating environmental factors in general is that the relevant research 
parameter is often identified in a retrospective and non-population based setting, which is 
prone to recall-bias and is difficult to quantify. For pediatric ADS, collaboration with longitudinal 
prospective population-based studies in the healthy pediatric population, like the Generation R 
study in Rotterdam, may provide crucial insights in the effect of environmental and genetic MS 
risk factors on the pediatric brain development.80,81 This provides an unique opportunity to study 
whether the genetic and environmental interplay generates a vulnerability in the individual 
GENERAL DISCUSSION
259
4
patient for future MS diagnosis. This collaboration is recently established and data shall be 
presented in the future. 
As discussed in the first chapter of this thesis (General Introduction), the putative window of 
disease susceptibility is shorter in children and starts counting from birth. Yet, it is possible 
that the accumulation of MS risk already starts as early as in the perinatal or even in the 
prenatal period, as displayed in Figure 4.1. Despite conflicting results on the effect of prenatal 
maternal smoking on MS risk in the offspring, there are suggestions about increased MS 
risk after maternal illness and prenatal exposure to pesticides.82–84 As the development of the 
immune system already starts in the embryonic phase, it will be worthwhile to set up large 
epidemiological studies in pregnant women (and even in the preconceptional phase) and have 
prospective longitudinal FU of the offspring after delivery. Knowledge on these risk factors can 
open up a new window for disease prevention strategies. 
Figure 4.1: The extended putative window of disease susceptibility. The putative window of disease 
susceptibility might even start  before or since the moment of conception. Investigating environmental 
factors before and during pregnancy adds to the knowledge on the pathophysiology of MS, and creates a 
new window for disease prevention strategies. 
PROUD-kids 2.0: our next step 
Recently, the PROUD-kids 2.0 study has been launched of children with a first attack of ADS. 
This study is a new and elaborated version of the current PROUD-kids study, not only aiming 
at identifying prognostic factors for disease course at disease onset, but also improve the 
(long-term) understanding of ADS including the temporal dynamics of biomarkers (such as 
sequential MRI parameters and biomaterial sampling like serum antibody-status and changes 
in immunological cell phenotypes and functionalities). Control subjects, like blood-related 
siblings, age-matched friends in the same environment and patients with other neurological 
diseases, are being included. 
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Acquired demyelinating syndromes (ADS) are a group of auto-immune mediated CNS 
inflammatory demyelinating syndromes, of which multiple sclerosis (MS) is the most common 
subtype. ADS may occur as a transient illness or may represent the first attack of a chronic 
demyelinating disorder. At first attack it can be difficult for physicians to differentiate between 
the ADS subtypes due to overlapping clinical features. Yet, accurate diagnosis, prediction of 
disease course and outcome of different subtypes are imperative for accurate counselling and 
to initiate the right treatment. This thesis focuses on two rare groups of patients in the ADS 
spectrum: neuromyelitis optica spectrum disorders (NMOSD) in adults and the spectrum of 
childhood onset ADS. We aimed to move forward on delineating the spectrum of ADS, and 
investigating the disease course and outcome of ADS in children and in adults with NMOSD.
In Chapter 1 the spectrum of ADS and its heterogeneity is described, and the current 
knowledge of NMOSD and childhood-onset ADS. The spectrum of childhood-onset ADS is 
outlined, including the disease course and risk factors for MS, and the treatment regimens 
and outcome of pediatric ADS. NMOSD was previously considered as a rare and severe subtype 
of MS, with predominant involvement of the optic nerves and spinal cord. Nowadays it is 
acknowledged as a rare subtype of ADS, and a distinct entity different from MS. The majority 
of patients are seropositive for the pathognonomic anti-aquaporin 4 antibodies (AQP4-IgG). In 
addition, the current knowledge on anti-myelin oligodendrocyte glycoprotein antibodies (MOG-
IgG) associated ADS is described. 
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PART ONE: ACQUIRED DEMYELINATING SYNDOMRES, FOCUS ON 
NEUROMYELITIS OPTICA SPECTRUM DISORDERS
The first part of this thesis focuses on NMOSD in adults. In chapter 2.1 we studied the presence 
of MOG-IgG in AQP4-IgG seronegative NMOSD, and compared the clinical features of MOG-
IgG seropositive patients with AQP4 seropositive and ‘double seronegative’ patients. We found 
that one-third of the AQP4-IgG seronegative NMOSD patients have MOG-IgG antibodies (20/61 
patients). MOG-IgG seropositive patients were more frequently males and were more often 
from Caucasian origin than AQP4-IgG patients. Moreover, MOG-IgG seropositive patients more 
frequently had a coincident presentation of optic neuritis and transverse myelitis. Overall, a 
monophasic disease course and favorable outcome were more frequently seen in MOG-IgG 
patients than AQP4-IgG seropositive patients. NMOSD patients can be classified by their 
serological antibody status for AQP4-IgG, MOG-IgG, or seronegativity for both antibodies. 
As both antibodies are diagnostically tested in one central reference laboratory (Sanquin 
Diagnostic services) we had a unique opportunity to assess the nationwide incidence figures 
of these two antibody-associated demyelinating disorders in the Netherlands. Chapter 2.2 
reports that about 15 AQP4-IgG seropositive NMOSD patients are currently being identified 
per year in the Netherlands. The mean incidence of AQP4-IgG associated NMOSD of 0.09 per 
year per 100.000 persons, nearly one in a million. In chapter 2.3, the mean overall incidence 
of MOG-IgG seropositive ADS of 0.16 per year per 100.000 persons, with a higher incidence in 
children (0.31/100.000 persons per year) than in adults (0.13/100.000 persons per year). These 
epidemiological figures can aid in care and counselling, and the design of potential future 
clinical trials. In chapter 2.3, we additionally we studied 61 MOG-IgG seropositive patients 
who were known at the NMO expert center or pediatric MS center. We observed a different 
distribution of clinical phenotypes in children and adults. A long time-to-first-relapse >200 
months was observed in a minority of the patients, suggesting that relapse can occur many 
years later. Lastly, it seems that a great majority of patients, who turned seronegative during 
follow-up (FU), do not relapse. 
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PART TWO – CHILDHOOD ONSET ACQUIRED DEMYELINATING SYNDROMES 
The second part of this thesis focuses on childhood-onset ADS. One of the main goals of our 
prospective study in Rotterdam is finding biomarkers that contributes to the differentiation 
between MS and other ADS, allowing the physician to diagnose the patient accurately and early 
in the disease course. This part of the thesis is divided in two sections. 
Section TWO-A: EARLY and ACCURATE PREDICTORS FOR PEDIATRIC MS 
Recently, the international panel on Diagnosis of Multiple sclerosis proposed new revisions 
to the McDonald 2010 criteria. The revised McDonald 2017 criteria include important 
modifications by re-introducing CSF oligoclonal bands (OCB) into the criteria and allowing 
symptomatic lesions to contribute to dissemination in space and time on MRI. In chapter 3.1 
we compared the diagnostic accuracy at the first attack of the revised McDonald 2017 criteria 
and the former McDonald 2010 criteria of 164 ADS children. We found that the McDonald 2017 
criteria were more sensitive (83% vs 49%) and less specific (73% vs 87%) for clinically definite 
MS (CDMS) diagnosis, but the McDonald 2017 criteria perform well across the age-span with 
a higher diagnostic accuracy than the 2010 criteria (77% vs 70%). Due to the higher sensitivity, 
the application of the 2017 criteria will lead to more MS diagnosis at baseline. But because of 
the decrease in specificity a subgroup of these identified children are likely to have a less active 
clinical disease course. In addition, these criteria should not be applied to acute disseminated 
encephalomyelitis patients who present with prominent encephalopathy. 
Soluble CD27 (sCD27) in CSF, a protein secreted by activated T-cells, is of predictive value for 
MS diagnosis and disease course at first attack in adult patients. In chapter 3.2 we evaluated 
this marker in 94 ADS children. High levels at baseline in patients without encephalopathy 
(ADS-) were predictive of CDMS diagnosis and are associated with a shorter time to a second 
attack of MS (hazard ratio (HR) 2.8 per 100 U/mL increase in sCD27 levels; p<0.001), after 
adjustments for age, oligoclonal bands and presence of dissemination in space on baseline MRI. 
No difference was seen between ADS children with encephalopathy (ADEM) and monophasic 
patients without encephalopathy. Moreover, the sCD27 levels found in pediatric MS are higher 
than in adults MS, which support existing data that children have a more inflammatory disease 
course than adults.
Neurodegeneration is present already early in the disease course in both adult and pediatric MS 
patients, despite the disease progression is still slower in children than adults. Neurofilament 
light chain (NfL) is a marker for neurodegeneration and high levels of NfL in CSF are associated 
with future MS diagnosis in adults with clinically isolated syndromes (CIS). In chapter 3.3, 
we studied the NfL levels in CSF of the first attack in 88 adult and 65 pediatric patients. We 
demonstrated that higher CSF NfL levels at first attack predict a second attack in both children 
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and adults without encephalopathy, after adjustments for currently used markers such as 
asymptomatic T2 lesions on MRI and OCBs in CSF (children HR 3.7; p=0.007, adults HR 2.1; 
p=0.032). CSF NfL levels were even higher in children than in adults, implying that children 
have not only signs of more inflammation but also seem to have more axonal damage than 
adults. This was supported by our finding that more T1 hypointense lesions were found at the 
baseline scan in children than in adults. We also saw high levels of CSF NfL in monophasic 
ADEM patients. 
In adult MS, CSF and serum NfL (sNfL) are highly correlated and the levels are associated with 
future disease activity. We aimed to explore these associations in pediatric ADS patients in 
chapter 3.4. In total, 102 children with a first attack of demyelination and 23 pediatric controls 
were included. Of the 102 patients, 47 (46%) were also tested for CSF NfL. CSF and serum NfL 
were positively correlated in the total group (ρ 0.532, p<0.001) and even better in the subgroup 
of patients with future CDMS diagnosis (ρ 0.773, p<0.001). Serum NfL was higher in patients 
than in controls. In the ADS group, the highest levels were found in ADEM, followed by patients 
without encephalopathy (ADS-) with future CDMS diagnosis, and lowest levels were seen in 
ADS- who remained monophasic. High serum NfL levels at baseline are associated with a 
shorter time to CDMS diagnosis in ADS- patients (p=0.045). The HR for CDMS diagnosis was 
1.09 for each 10 pg/mL increase of sNfL, after correction for age, OCB, ≥9 T2 hyperintense 
lesions and gadolinium enhanced lesions (p=0.012). The strong correlation between CSF and 
serum NfL strengthens its reliability as a serum marker of neuroaxonal damage. Moreover, 
the high CSF and serum NfL levels in children with ADEM suggests that neuroaxonal damage 
is a prominent feature in ADEM. 
Section TWO-B: DISEASE COURSE AND OUTCOME OF CHILDHOOD ONSET ADS 
This section focuses on the disease course and outcome of childhood-onset ADS. 
Chapter 3.5 and 3.6 described the clinical phenotype and disease course of relapsing MOG-IgG 
seropositive children, identified by the European MOG consortium. Existing data shows that the 
presence of serum MOG-IgG pleads against MS diagnosis, but is associated with a higher risk 
for relapsing non-MS disease. In chapter 3.5, we described 17 patients with ADEM followed by 
optic neuritis (ADEM-ON); 16/17 patients were positive for MOG-IgG. The disease course was 
heterogeneous and no predictors could be found between patients high and low relapse rates. 
Twelve patients received oral prednisolone and 10 received maintenance immunosuppression 
(e.g. azathioprine, intravenous immunoglobulins (IvIG), Rituximab). During a FU of 5.3 years 
(IQR 1.8–10.2 years), 54 relapses occurred with a median of 3 relapses per patient (range 1–9 
per patient). The percentage of patients with cognitive and physical sequelae is high (47%). 
Patients relapsed on all maintenance immunosuppressive treatments. Patients were prone to 
relapses when being weaned off oral prednisone, but no relapses occurred on a prednisolone 
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dose >10 mg/day. This suggests a degree of steroid-dependency and physicians should be 
aware of the risks of long-term steroid exposure.Chapter 3.6 describes 102 children with 
MOG-IgG associated relapsing disorders. The observed clinical phenotype consists of 
NMOSD (43%), multiphasic ADEM (20%), ADEM-ON (20%) and relapsing ON (18%). Chronic 
immunosuppressive agents or MS disease modifying agents were given to 52 children (51%). 
Yet, 127 relapses still occurred in these treated children. Treated patients had more relapses 
(median 3.0; range 1.0-17.0) than untreated patients (median 1.0; range 0-7.0)(p<0.001) and 
had higher Expanded Disability Status Scales (EDSS) scores. IvIG, as a immunomodulatory 
treatment, seemed to have a better effect on disease activity than other immunosuppressive 
agents, and MS agents did not decrease the relapse rates. We observed an age-dependent 
phenotype, with brain manifestations in younger children, and optic neuritis and/or transverse 
myelitis with normal brain MRI in older children. 
Our research group reported a Dutch incidence of ADS and MS in children of 0.66/100.000 
per year and 0.15/100.000 per year in the period of 2007-2010. In chapter 3.7 we presented 
an updated and increased Dutch incidence of 0.80/100.000 for pediatric ADS and 0.26/100.000 
for pediatric MS per year (2011-2016). Since the start of the PROUD-Kids study, 243 were 
included and the long-term outcome was studied in this chapter. At the end of FU (median 55 
months), patients were classified into monophasic ADS (56%), MS (37%) and relapsing non-MS 
demyelination (7%). At least one form of residual deficit, including cognitive impairment, was 
found in 69% of the patients. Negatively affected school performance was reported by parents 
in one-third of our ADS cases, some even requiring academic adjustments. 
Fatigue is a frequently reported complaint in pediatric MS and is also reported in ADEM. The 
cause of fatigue in ADS is unclear. Children with ADEM and MS known in Erasmus MC were 
consecutively referred to the pediatric physical therapist to screen for motor dysfunction, 
fatigue and reduced exercise capacity by administering questionnaires and physical tests. In 
chapter 3.8, we showed that children with MS and ADEM are more fatigued, have reduced 
exercise capacity and impaired motor performance compared to their healthy related peers. 
Unexpectedly no correlation was found between these three parameters. Also, ADS children 
had more problems in the emotional, social, scholastic and psychosocial functioning than 
healthy peers. These findings imply that other factors, such as depression and psychosocial 
factors, may play a role in the process of inactivity, decreased exercise capacity and fatigue. In 
addition, we found a large discrepancy between the children with severe or borderline motor 
deficits measured by the MABCII (49%) and the proportion of children with EDSS score of 
≥2 (only 9% MS, 6% ADEM). This discrepancy confirms that the EDSS is not an optimal and 
sensitive metric for disability in pediatric MS and ADS patients. 
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Neurogenic lower urinary tract dysfunction (LUTD) is common in adults with MS. Little is 
known about the prevalence of LUTD in pediatric MS. In chapter 3.9, 24 newly diagnosed 
pediatric MS patients underwent an extensive urological assessment including uroflowmetry 
with simultaneous (non-invasive) electromyography recordings of the pelvic floor muscles. We 
observed a high proportion of voiding problems (21%) already in the first 18 months after initial 
MS diagnosis. Questionnaires about voiding seemed sufficient to detect LUTD in 80% of the 
patients. One patient would have been missed if patients were not systematically evaluated. 
Clinicians treating pediatric MS patients should be aware of the high prevalence of LUTD very 
early in the disease course. 
The evolution of MRI lesions during FU in ADEM children is rarely studied. In chapter 3.10, 42 
ADEM children were included for evaluation. When analyzing patients ≥2 MRI scans during 
the acute phase (first 3 months after symptom onset), and who had ≥1 scan after this period, 
we found that the evolution of MRI abnormalities in children with ADEM can be delayed 
compared to the evolution of clinical symptoms: a normal brain MRI was present in 3/42 
patients (performed 3, 7, 30 days after onset) and MRI abnormalities were observed on scans 
made at day 26, 36 and 40 days respectively. In addition, deterioration of MRI abnormalities (i.e. 
enlargement of existing lesions or appearance of new lesions) occurs frequently in the acute 
phase, despite the clinical improvement of the patient. Deterioration of the scan rarely occurs 
after this three-month period. Therefore performing a new MRI three months after symptom 
onset is advised to have a new reference point for future clinical relapses. 
The main findings from our studies are summarized and discussed in Chapter 4, including the 
recommendations for future research. 

5.2
Samenvatting 
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Verworven demyeliniserende syndromen (Acquired Demyelinating Syndromes, ADS) zijn 
een groep auto-immuun gemedieerde inflammatoire demyeliniserende syndromen van het 
centrale zenuwstelsel. Multipele sclerose (MS) is hiervan de meest bekende. ADS kunnen 
een monofasisch of chronisch beloop hebben. Door overlappende klinische presentaties kan 
het voor de artsen uitdagend zijn om tijdens een eerste aanval onderscheid te maken tussen 
verschillende ADS subtypes. Echter is accurate diagnose, voorspelling van ziektebeloop en 
uitkomst van verschillende subtypes onmisbaar voor voorlichting en start van de juiste 
behandeling. Dit proefschrift focust zich op twee relatief zeldzame groepen van patiënten in 
het ADS spectrum: neuromyelitis optica spectrum ziekten (NMOSD) in volwassenen en het 
spectrum van ADS op de kinderleeftijd. We streven ernaar een stap vooruit te zetten door 
onderzoek te doen naar subtypen, ziektebeloop en uitkomsten in kinderen met ADS en in 
volwassenen met NMOSD.  
In hoofdstuk 1 wordt het heterogene spectrum van ADS beschreven en de huidige kennis van 
NMOSD en ADS op kinderleeftijd samengevat. Het spectrum van ADS op de kinderleeftijd is 
uiteengezet, met onder andere het ziektebeloop en risicofactoren voor diagnose MS. Tevens 
zijn de behandelopties en uitkomsten van kinder-ADS beschreven. NMOSD werd eerder gezien 
als een ernstige vorm van MS, waarbij vooral de oogzenuwen en ruggenmerg zijn aangedaan. 
Inmiddels wordt het erkend als een zeldzaam ADS subtype wat geheel losstaat van MS. 
Merendeel van deze patiënten zijn seropositief voor de pathognomonische anti-aquaporine 4 
(anti-AQP4) antistoffen. In dit hoofdstuk wordt daarnaast de huidige kennis over anti-myeline 
oligodendrocyt glycoproteine (anti-MOG) antistoffen geassocieerde ADS beschreven. 
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DEEL 1: VERWORVEN DEMYELINISERENDE SYNDROMEN – FOCUS OP 
NEUROMYELITIS OPTICA SPECTRUM ZIEKTEN  
Het eerste gedeelte van dit proefschrift focust zich op NMOSD in volwassenen. In hoofdstuk 
2.1 hebben we de aanwezigheid van anti-MOG antistoffen onderzocht in NMOSD patiënten 
zonder anti-AQP4 antistoffen en ook vergeleken we de klinische kenmerken van anti-MOG 
seropositieve met anti-AQP4 seropositieve en ‘dubbel seronegatieve’ patiënten. We hebben 
gevonden dat 1/3 van de anti-AQP4 seronegatieve NMOSD patiënten anti-MOG positief zijn 
(20/61 patiënten). Anti-MOG positieve patiënten zijn vaker man en van Kaukasische afkomst 
vergeleken met AQP4-IgG positieve patiënten. Daarnaast hebben anti-MOG positieve NMOSD 
patiënten vaker tegelijkertijd een neuritis optica en myelitis transversa. In het algemeen 
hebben patiënten met anti-MOG antistoffen vaker een monofasisch beloop en gunstigere 
uitkomst dan anti-AQP4 patiënten. 
Omdat zowel de anti-MOG als anti-AQP4 antistoffen in Nederland worden getest in een 
centraal diagnostisch laboratorium (Sanquin Diagnostiek), hadden we de unieke kans om 
de nationale incidentie van deze twee antistof geassocieerde demyeliniserende syndromen 
in Nederland te onderzoeken. In hoofdstuk 2.2 rapporteren we dat er in Nederland jaarlijks 
gemiddeld 15 anti-AQP4 positieve NMOSD patiënten worden gediagnosticeerd. Hiermee is 
de gemiddelde incidentie van anti-AQP4 geassocieerde NMOSD 0.09 per jaar per 100.000 
personen; wat neerkomt op bijna 1 op de miljoen personen. In hoofdstuk 2.3 hebben we de 
gemiddelde incidentie voor anti-MOG seropositieve ADS in Nederland berekend, dit was 0.16 
per jaar per 100.000 personen, wat afgerond neerkomt op 2 personen per miljoen. Hierbij zagen 
we een hogere incidentie in kinderen (0.31/100.000 personen per jaar) dan in volwassenen 
(0.13/100.000 personen per jaar). Deze epidemiologische cijfers kunnen niet alleen bijdragen 
aan  de voorlichting van patiënten, maar ook aan het opzetten van toekomstige klinische trials.
 
In hoofdstuk 2.3 hebben we tevens de 61 anti-MOG positieve patiënten, die bekend waren in 
het nationale NMO en kinder MS centrum, bestudeerd. We zagen dat het klinische fenotype van 
kinderen en volwassenen verschillend is. Een minderheid van de patiënten had een relapse na 
meer dan 200 maanden na de eerste aanval. Dit laat zien dat een nieuwe relapse zelfs mogelijk 
is na een dergelijk lange periode. Ten slotte observeerden we dat bij de meerderheid van de 
patiënten die tijdens follow-up seronegatief werden, er geen nieuwe aanvallen meer optreden. 
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DEEL 2 – VERWORVEN DEMYELINISERENDE SYNDROMEN OP DE 
KINDERLEEFTIJD 
Het tweede deel van dit proefschrift focust zich op ADS op de kinderleeftijd. Een van 
de hoofddoelen van de prospectieve PROUD-kids studie in Rotterdam is het vinden van 
biomarkers die bijdragen aan het differentiëren tussen MS en andere vormen van ADS. Dit kan 
artsen helpen om vroeg in het ziektebeloop een accurate diagnose te stellen. Deel 2 van dit 
proefschrift is verdeeld in 2 secties. 
 
Sectie 2A – Vroege en accurate voorspellers voor diagnose MS op de kinderleeftijd 
De internationale werkgroep voor het diagnosticeren van MS (International Panel on Diagnosis 
of MS) heeft de voormalige McDonald 2010 criteria aangepast. De belangrijkste aanpassingen 
in de gereviseerde McDonald 2017 criteria zijn de re-introductie van de oligoclonale banden 
(OCB) in liquor en de toevoeging dat symptomatische lesies kunnen bijdragen aan spreiding in 
tijd en plaats op de MRI-scan. In hoofdstuk 3.1 vergelijken we de diagnostische accuraatheid 
van de McDonald 2010 en 2017 criteria in 164 kinderen met een eerste aanval van ADS. De 
McDonald 2017 criteria zijn sensitiever (83% vs 49%) en minder specifiek (73% vs 87%) voor 
‘clinically definite MS’ (CDMS; c.q. een tweede aanval van MS). De McDonald 2017 criteria zijn 
toepasbaar op kinderen van alle leeftijden. Door de hogere sensitiviteit identificeren we meer 
kinderen met diagnose MS ten tijde van de eerste aanval. Maar door de lagere specificiteit 
zal er een subgroep MS patiënten zijn die een minder actief ziektebeloop heeft. De McDonald 
2017 criteria niet accuraat voor kinderen met de diagnose ADEM (acuut gedissemineerde 
encephalomyelitis). 
Soluble CD27 (sCD27) in liquor wordt uitgescheiden door geactiveerde T-cellen en is 
voorspellend voor MS diagnose en ziekbeloop op het moment van een eerste aanval in 
volwassen patiënten. In hoofdstuk 3.2 hebben we deze biomarker bekeken in 94 ADS kinderen 
op het moment van de eerste aanval. Hoge levels ten tijde van de eerste aanval bij ADS kinderen 
zonder encefalopathie (ADS-) waren voorspellend voor de diagnose CDMS. Tevens zijn hoge 
levels in deze groep geassocieerd met een kortere tijd tot een tweede aanval van MS (hazard 
ratio (HR) 2.8 per 100 U/mL toename in sCD27 levels; p<0.001), na het corrigeren voor leeftijd, 
OCB en aanwezigheid van spreiding in plaats op de eerste MRI-scan. We zagen geen verschil in 
de levels bij kinderen met encefalopathie (ADEM (of evt ADS+) en monofasische ADS- kinderen. 
Daarnaast viel op dat sCD27 levels bij kinderen met MS hoger waren dan bij volwassenen met 
MS. Dit gegeven ondersteunt de bestaande literatuur dat kinderen een meer inflammatoir 
ziektebeloop hebben dan volwassenen. 
Neurodegeneratie lijkt al vroeg in het ziektebeloop aanwezig te zijn bij zowel volwassenen als 
kinderen met MS, ondanks dat de ziekteprogressie bij kinderen over het algemeen trager is 
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dan bij volwassenen. Neurofilament light chain (NfL) is een marker voor neurodegeneratie 
en hoge NfL levels zijn geassocieerd met MS diagnose in patiënten met een CIS (clinically 
isolated syndrome). In hoofdstuk 3.3 hebben we de NfL levels in liquor vergeleken tussen 88 
volwassenen en 65 kinderen op het moment van een eerste aanval van demyelinisatie in het 
centraal zenuwstelsel. We tonen aan dat hogere NfL levels in liquor  ten tijde van de eerste 
aanval, een tweede aanval voorspellen in patiënten die zich presenteren zonder encefalopathie; 
dit is ook het geval na correctie voor asymptomatische T2 lesies op de MRI-scan en oligoclonale 
banden in liquor (HR bij kinderen 3.7, p=0.007; HR bij volwassenen 2.1, p=0.032). De liquor NfL 
levels zijn zelfs hoger bij kinderen dan bij volwassenen. Dit zou kunnen betekenen dat kinderen 
niet alleen een meer inflammatoire ziekte hebben, maar ook dat kinderen meer axonale schade 
hebben dan bij volwassenen vroeg in het ziektebeloop. Dit wordt verder ondersteund door een 
groter aantal T1 hypointense lesies op de baseline MRI, die geassocieerd zijn met hogere NfL 
levels, in kinderen dan in volwassenen. Tevens zagen we opvallend hoge liquor NfL levels in 
kinderen met een monofasisch ADEM.
In volwassen MS patiënten zijn liquor en serum NfL sterk met elkaar gecorreleerd en zijn 
de levels geassocieerd met toekomstige ziekteactiviteit. In hoofdstuk 3.4 hebben we deze 
correlatie en associatie onderzocht bij ADS kinderen. In totaal zijn er 102 kinderen met een 
eerste aanval van ADS en 23 symptomatische kindercontroles geïncludeerd die allen werden 
getest voor NfL in serum (sNfL). Van de 102 patiënten hebben we van 47 (46%) ook NfL in 
liquor gemeten. Er was een correlatie tussen NfL in liquor en NfL in serum in de totale groep 
(correlatie coëfficiënt Pearson rho 0.532, p<0.001). In de subgroep van patiënten met CDMS 
diagnose tijdens follow-up was deze correlatie sterker (ρ 0.773, p<0.001). Serum NfL was hoger 
in patiënten dan in controles. Binnen de ADS patiëntengroep zijn de hoogste levels gevonden 
in kinderen met ADEM, gevolgd door kinderen die zich presenteerden zonder encefalopathie 
(ADS-) én CDMS diagnose kregen tijdens follow-up, en ten slotte gevolgd door ADS- patiënten 
die monofasisch bleven. Hoge sNfL levels ten tijde van de eerste aanval zijn geassocieerd met 
vaker diagnose CDMS en een kortere tijd tot CDMS diagnose in ADS- patiënten (p=0.045). De 
HR voor CDMS was 1.09 voor elke 10 pg/mL stijging van sNfL, dit was na correctie voor leeftijd, 
OCB, >9 T2 hyperintense lesies en aankleurende lesies na gadolinium op de baseline MRI-scan 
(p=0.012). 
De sterke correlatie tussen NfL in liquor en serum versterkt de betrouwbaarheid van serum 
NfL als een marker voor neuro-axonale schade.  Daarnaast wijzen de hoge levels in zowel 
liquor als serum in ADEM op neuro-axonale schade bij deze aandoening. 
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Sectie 2B: Ziektebeloop en uitkomsten bij ADS op de kinderleeftijd
In hoofdstuk 3.5 en 3.6 beschrijven we de klinische fenotypen en het ziektebeloop van 
recidiverende anti-MOG seropositieve kinderen, die geïdentificeerd zijn door het Europese 
MOG consortium. Uit bestaande literatuur blijkt dat de aanwezigheid van anti-MOG tegen MS 
diagnose pleit en dat de aanwezigheid van anti-MOG is geassocieerd met een hoger risico op 
een recidiverende aandoening anders dan MS. In hoofdstuk 3.5 beschrijven we  17 kinderen 
die na een ADEM recidiverend een of meerdere neuritis optica hebben doorgemaakt (ADEM-
ON); 16/17 patiënten zijn positief getest voor anti-MOG. Het ziektebeloop is heterogeen en 
er zijn geen voorspellers gevonden voor patiënten die veel of weinig relapsen hadden tijdens 
follow-up. Twaalf patiënten werden behandeld met  oraal prednison en 10 patiënten met 
prednison-sparende immuunsuppressie (o.a. azathioprine, intraveneuze immunoglobulines 
(IvIG), Rituximab. Tijdens een follow-up van 5.3 jaar (IQR 1.8-10.2), deden zich  54 aanvallen 
voor, met een mediaan van 3 aanvallen per patiënt (range 1-9). Een groot percentage patiënten 
had last van cognitieve en fysieke problemen (47%). Geen van de prednison-sparende 
immuunsuppressiva was  effectief genoeg om patiënten aanvalsvrij te houden. Daarentegen 
zijn er geen relapsen waargenomen tijdens prednisongebruik  van meer dan 10 mg per dag, 
maar zijn patiënten bij het afbouwen van prednison onder deze dosering gevoelig voor een 
relapse. Dit wijst op enige mate van prednison-afhankelijkheid, waarbij men bewust dient te zijn 
van de risico’s van lange termijn blootstelling aan corticosteroïden bij kinderen.  In hoofdstuk 
3.6 beschrijven we 102 kinderen met een anti-MOG geassocieerde recidiverende ziekte. De 
klinische fenotypen bestonden uit NMOSD (43%), multifasisch ADEM (20%), ADEM-ON (20%) 
en recidiverende neuritis optica (18%). Totaal werden 52 kinderen (51%) behandeld met 
chronische immunosuppressiva of MS medicatie.  Desondanks traden er in deze behandelde 
kinderen  127 aanvallen op. Behandelde patiënten hadden meer relapsen dan onbehandelde 
patiënten (mediaan 3.0, range 1-17 vs mediaan 1.0, range 0-7.0)(p<0.001) en hadden daarnaast 
een hogere score voor invaliditeit (EDSS). IvIG, dat een immunomodulatoir effect heeft, leek 
een beter effect te hebben op ziekteactiviteit dan andere immunoosuppressiva. MS middelen 
lieten geen effect op de ziekteactiviteit zien. We observeerden een leeftijdsafhankelijk fenotype, 
waarbij jongere kinderen vaker een klinische presentatie met betrokkenheid van de hersenen 
hadden. Oudere kinderen daarentegen hadden juist vaker een neuritis optica en/of een myelitis 
transversa met een normale MRI hersenen.
Onze onderzoeksgroep heeft eerder een Nederlandse incidentie voor ADS en MS bij kinderen 
gerapporteerd van respectievelijk 0.66 per 100.000 per jaar en 0.15 per 100.000 per jaar in 
de periode van 2007-2010. In hoofdstuk 3.7 presenteren we een update van de toegenomen 
Nederlandse incidentie van 0.80/100.000 voor kinderen met ADS en 0.26/100.000 voor kinderen 
met MS (2011-2016). Sinds de start van de PROUD-kids study zijn 243 kinderen geïncludeerd 
en zijn de lange termijn uitkomsten bestudeerd. Bij een mediane follow-up van 55 maanden 
zijn patiënten onderverdeeld in monofasisch ADS (56%), MS (37%) en recidiverende non-
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MS aandoeningen (7%). Van de patiënten heeft  69% ten minste één vorm van restklachten, 
inclusief cognitieve beperkingen. Negatieve impact op schoolprestaties is gerapporteerd in 
een derde van de ADS patiënten, waarbij soms schoolaanpassingen nodig waren. 
Vermoeidheid is een frequent gerapporteerde klacht in kinderen met MS en ADEM. De oorzaak 
voor vermoeidheid is onbekend. Kinderen met ADEM en MS die werden behandeld in het 
Erasmus MC zijn systematisch verwezen naar de kinderfysiotherapeut voor een screening 
van motore dysfunctie, vermoeidheid en verminderde conditie door middel van het afnemen 
van vragenlijsten en fysieke testen. In hoofdstuk 3.8 laten we zien dat kinderen met MS en 
ADEM meer en vaker vermoeid zijn en daarnaast een slechtere conditie en motore functie 
hebben vergeleken met gezonde leeftijdsgenootjes. We hebben geen correlatie gevonden 
tussen deze drie parameters. Bovendien hadden kinderen met ADS meer problemen in zowel 
het functioneren op emotioneel, sociaal en psychosociaal gebied als in het functioneren op 
school. Daarnaast hebben we een grote discrepantie waargenomen tussen het percentage 
kinderen met ernstige of borderline motorische dysfunctie bij de MABCII test (49%) en het 
percentage kinderen dat een EDSS score van twee of hoger heeft (9% MS, 6% ADEM).  Deze 
discrepantie bevestigt dat de EDSS schaal geen optimaal en sensitief meetinstrument is voor 
het uitdrukken van beperkingen in kinderen met MS en ADS. 
Neurogeen blaaslijden komt vaak voor bij volwassenen met MS. Er is weinig bekend over 
deze klachten bij kinderen met MS. In hoofdstuk 3.9 hebben 24 nieuw gediagnosticeerde 
kinderen met MS een uitgebreide urologische screening gekregen inclusief uroflowmetrie, 
waarbij tegelijkertijd een (niet-invasieve) elektromyografie van de bekkenbodemspieren werd 
verricht. Een groot aantal kinderen had reeds mictieproblemen in de eerste 18 maanden 
na diagnose(21%). Mictievragenlijsten waren voldoende om 80% van de patiënten met een 
neurogene blaas te detecteren; één patiënt zou gemist zijn wanneer deze kinderen niet 
systematisch werden doorverwezen voor de urologische screening. Artsen die kinderen met 
MS behandelen dienen alert te zijn op het voorkomen van neurogeen blaaslijden vroeg in het 
ziektebeloop. 
De verandering van MRI lesies tijdens follow-up van ADEM patiënten is weinig onderzocht. 
In hoofdstuk 3.10 werden 42 kinderen met een ADEM geïncludeerd voor analyse. Bij ADEM 
kinderen die ≥2 MRI scans hadden in de acute fase (eerste 3 maanden na het ontstaan van 
klachten) en ≥1 scan na de acute fase zagen we dat de veranderingen van MRI afwijkingen 
achterloopt ten opzichte van de klinische symptomen: in 3/42 patiënten was de MRI normaal bij 
debuut (MRI verricht 3, 7 en 30 dagen na onset) en werden MRI afwijkingen zichtbaar op follow-
up scans gemaakt op respectievelijk dag 26, 36 en 40. Daarnaast zagen we dat verslechtering 
van MRI afwijkingen (e.g. toename in grootte van bestaande lesies of ontstaan nieuwe lesies) 
vaak voorkomt in de acute fase, ondanks verbetering in de kliniek. Toename van afwijkingen 
(in grootte en/of aantal) gebeurt zeer zelden na de eerste drie maanden. Derhalve adviseren 
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we 3 maanden na het ontstaan van symptomen een nieuwe MRI te verrichten als nieuwe 
uitgangswaarde voor eventuele nieuwe aanvallen. 
De belangrijkste bevindingen van onze studies zijn samengevat en bediscussieerd in hoofdstuk 
4. Hier worden ook aanbevelingen gedaan voor toekomstig onderzoek. 
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DANKWOORD
Allereerst wil ik graag alle patiënten (en hun familieleden) van het Kinder MS centrum en NMO 
centrum danken voor hun bereidheid om deel te nemen aan de lopende onderzoeken. Zonder 
jullie zou dit proefschrift nooit tot stand zijn gekomen! 
Niet te vergeten alle collega’s (kinder)neurologen en kinderartsen voor alle verwijzingen 
om deze twee zeldzame cohorten uit te breiden door de jaren heen. Met name wil ik graag 
alle onderzoekers danken van de Nederlandse MS en ADEM studiegroep bij kinderen: veel 
dank voor jullie jarenlange trouwe inzet door verwijzingen, medebehandelingen en inclusies. 
Ongetwijfeld zal het aankomende PROUD-kids 2.0 een enorm succes worden in samenwerking 
met jullie. 
En nu, mijn promotor: prof. dr. R.Q. Hintzen, beste Rogier, ik wil je heel erg bedanken dat 
je deze Nijmeegse 4.5 jaar terug zo openhartelijk hebt ontvangen en mij de kans hebt 
geboden om dit promotietraject in te gaan. In deze jaren heb ik de vrijheid gekregen om dit 
proefschrift te kunnen afleveren met deze diversiteit aan projecten. Ik waardeer je scherpe 
blik zowel op de inhoud als de tekstuele aspecten van een stuk, en ik bewonder dat je zó snel 
samenwerkingskansen kunt spotten en grijpen, met mooie projecten als resultaat. Niet alleen 
heb ik me kunnen ontwikkelen op wetenschappelijk gebied, maar ook op persoonlijk vlak door 
alle kansen die mij zijn aangereikt. Mijn dank aan jou is groot. 
Mijn co-promotor: dr. R.F. Neuteboom, beste Rinze, het begon allemaal bij jou in 2013, toen 
ik me meldde per email bij de kinderneurologie voor een onderzoeksstage. Wat een korte en 
krachtige 3 maanden van onderzoek waren dat, waarbij ik met veel plezier op de polikliniek 
van de kinderneurologie heb gezeten. Ik ben je dankbaar dat je me hebt aangedragen om als 
opvolger van Daniëlle terug te komen naar het Erasmus MC, met dit boekje als eindresultaat. 
Hoop in de toekomst nog veel met je samen te kunnen werken en van je te leren. 
De kleine promotiecommissie: dr. C.E. Catsman Berrevoets, beste Coriene, dank voor alle 
bemoedigingen die je hebt gegeven bij het (soms keer op keer) (re-)submitten van papers (vooral 
wanneer de moed is weggezakt). Ben blij dat je in deze commissie hebt willen plaatsnemen. Prof. 
dr. M.A.A.P. Willemsen, beste Michèl: in 2013 beoordeelde je als onafhankelijke beoordelaar 
mijn master thesis voor de geneeskunde opleiding, en nu ook dit proefschrift! Veel dank voor je 
jarenlange nauwe betrokkenheid, je kritische blik op manuscripten en nu het plaatsnemen in 
deze commissie. Dr. M. Lim, dear Ming: thank you for coming all this way from the UK and your 
willingness to take place in this thesis committee. I look forward to our future collaborations. 
Overige leden van de commissie : prof dr. P.A.E. Sillevis Smitt en prof. dr. E.H.H.M. Rings wil ik 
graag danken voor hun bereidheid om plaats te nemen in de promotiecommissie. 
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Many thanks to all co-authors of the European MOG consortium. I hope this collaborative effort 
will be a stepping stone towards an expansion in knowledge on MOG associated demyelinating 
syndromes. I look forward to the future projects!  
Collega’s van het Kinder MS centrum: Anke, Femke, Jetty, Jeroen, Leontien, Margreet, Margreet 
A, Marjolein, Monique, Roelie en Yannick. Het was super om met jullie gewerkt te hebben in 
dit topcentrum! Leontien, Jeroen en Roelie: wat leuk dat we samen papers hebben kunnen 
schrijven. Het was leerzaam interdisciplinair bij te dragen aan kennis over kinderen met ADS! 
Collega’s van het ErasMS: Arlette, Beatrijs, Daniëlle, Dorine, Hanne, Immy, Jacqueline, Josje, 
Julia, Leonieke, Louk, Mascha, Naghmeh, Naziha, Roos, Sjoukje, Tessel, Wendy en Yvonne. 
Dank voor de samenwerking in de afgelopen jaren. 
Immy en Daniëlle, mijn voorgangers: ik stapte in op een soepel lopende trein dankzij jullie 
jarenlange inzet. Wat een mooi cohort is de PROUD-kids 1.0 geworden! Daniëlle, wat fijn dat 
we een tijd overlap hebben gehad en dat we allebei een sprint hebben kunnen trekken in ons 
traject! 
Louk, mijn voormalig student en nu volwaardige collega-onderzoeker: je inzet (en vooral je 
humor) is onmisbaar geweest in het laatste traject van mijn promotie. Jouw gedrevenheid 
heeft zich geresulteerd in een promotietraject die je over 4 jaar ongetwijfeld met vlag en 
wimpel af gaat leveren. Dank voor het uitbreiden van mijn woordenschat, het was spang! Onze 
werkoverleggen blijf ik graag voortzetten in de KFC!
Roos, lieve Roossie: samen zijn we begonnen aan ons promotietraject, en rond dezelfde tijd 
eindigen we. Heb zo genoten van onze (relativerende) gedachtewisselingen op de 22e, zowel 
over het onderzoek als privé zaken. Ik bewonder je positiviteit en je nuchtere blik op het leven. 
Met veel plezier kijk ik terug naar alle congressen en leuke dingen die we samen hebben 
gedaan. Ik hoop in de komende jaren nog veel met je samen te werken.. let’s roll!
Arlette, wat ben ik blij dat je mijn opvolgster bent geworden! Vanaf het begin heb ik vertrouwen 
gehad dat je binnen no-time je weg zou vinden in dit promotietraject. Bovenal ben ik blij voor 
de patiënten, dat ze met een kundige en leuke dokter verder zullen gaan. Ik wens je alle succes 
toe en dat je mooie vruchten mag plukken van de PROUD-kids 1.0 en de 2.0. 
Alle polidames: veel dank voor jullie hulp bij het inplannen van patiënten. Elise, aan jou speciaal 
veel dank voor je flexibiliteit en hulp bij het inplannen van de NMO poli en jongeren met MS.
Collega’s van de immunologie en virologie: Annet, Gijs, Jamie, Liza, Malou, Marie-José, Marvin, 
Steven. Veel dank voor jullie geduld bij de soms onverwachte (en late!) bloedbuizen ;) Speciale 
dank aan MJ en Annet voor alle pipetteerhulp bij de biomarker-projecten!
Collega’s op de genetica en epidemiologie, met name Andy, Andrea, Jeanette, Michael, Pascal, 
Ramazan: dank voor het rapen, pipetteren en shippen van samples! 
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Een speciaal bedankje voor Dörte Hamann en het auto-immuun laboratorium in Sanquin 
Amsterdam, met name Erna Schuurman en Jan de Jong: Dörte, veel dank voor je jarenlange 
trouwe samenwerking en het delen van je expertise op het gebied van de anti-AQP4 en anti-
MOG CBA’s. Jullie waren altijd laagdrempelig bereikbaar voor overleg en inzetten van samples, 
wat voor de zorg van deze patiënten ten goede is gekomen. 
Dank aan alle collega-onderzoekers op de 22e en met name de kamergenoten in Ee-2230 voor 
de gezelligheid op de kamer: Agnes, Alex, Amaia, Bianca, Danielle B, Carina, Christa, Christine, 
Esther, Farren, Harmke, Joyce, Julia, Kim, Krista, Laurike, Marienke, Marieke, Melissa, Merel 
en Sonja. De koffie- en taartmomenten worden zeer gemist! Leden van ‘the Cosy Table’, daar 
linksachter in de hoek bij het raam (zowel nieuwere als oudere leden: Julia, Joyce, Farren, 
Louk en Sonja): wat een lol hebben we gehad samen aan die tafel (en vooral véééél en lekker 
gesnackt). Veel dank voor jullie begrip wanneer mijn geheugen als een gatenkaas was door 
het parallelle werk in mijn hoofd, op de momenten dat ik halverwege in (of juist uít) gesprekken 
viel, en de relatief lange momenten waar ik met mijn koptelefoon op en de ‘me, myself and I’ 
manier achter de computer zat. Laurike: dank voor het bijdragen aan de voorpret naar mijn 
promotie toe met het uitproberen van restaurantjes! 
Mijn vrienden wil ik bedanken die mijn promotie hebben meegemaakt en die me het nodige 
perspectief hebben geboden dat er meer bestaat dan werk! Een aantal van jullie wil ik 
persoonlijk noemen: Joy, zo dankbaar als sisters dat we zoveel kunnen delen met elkaar, je 
enthousiasme op mijn hoogtes en je steun in de dalen hebben mij deze 4 jaar op persoonlijk 
vlak zo opgebeurd! Ik toost graag snel weer met je bij Kwiezien! Hanshi en Wenya: 20 jaar 
vriendschap en tof dat jullie deze mijlpaal met me kunnen vieren. Mc: mijn halve buurvrouw, 
je bent altijd trots op wat ik aan het doen ben en zo fijn dat we altijd lekker kunnen kletsen. 
Kaman en Michelle: thanks for our nice dinners and sharings about the PhD life! Daniëlle K, 
je bent de nuchtere dokter-vriendin die mij met mijn beide benen op de grond houdt. Hoop je 
ondanks alle drukte vaker te zien! Danny, zonder jouw bemoedigende woorden zou ik dit traject 
niet eens zijn ingegaan. Dank voor je oneindige vertrouwen in mijn kunnen (ook al  heb ik die op 
vele momenten niet) en je enthousiasme over wat er ook op mijn pad komt. 
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Mijn paranimfen:  
Saar, mijn collega en goede vriendin. Wat een eer dat je naast me wilt staan: je bent de beste 
verpleegkundige die ik ken, met een hart van goud en zoveel passie voor je patiënten! Mijn 
promotietraject zou ik me niet kunnen voorstellen zonder jou, en nu promoveren we ook nog 
eens een beetje samen!  Ik wens je het beste in je carrière en alle liefde van de wereld!
Jen, mijn reismaatje, ex-huisgenoot, medechristen en lieve vriendin: wat een eer dat jij naast 
mij wilt staan vandaag. Dank dat je er altijd bent tijdens de diepe dalen en tijdens hoge hoogtes, 
met geduld, begrip en vertrouwen! Ik kijk uit naar alle mooie reizen in de toekomst en het 
bereiken van onze toekomstige mijlpalen, inclusief het vinden van onze prinsen! 
En nu, mijn basis, mijn familie: papa en mama, ik ben zo dankbaar voor al het vertrouwen,  de 
onvoorwaardelijke liefde en de stimulans om het beste uit mezelf te halen. Zonder jullie heb ik 
me niet kunnen ontwikkelen tot wie ik ben! Ik hou van jullie!
Yu Lun, Yu Kee en Vicky, my future sister-in-law: (vrijwel) elk weekend reis ik met alle plezier 
weer richting het oosten van het land, omdat het altijd zó gezellig is thuis! Weet dat ik altijd 
trots op jullie ben en voor jullie klaar sta! 
Tot slot, mijn grootste dank wil ik uiten door omhoog te kijken.. alle eer aan U!
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6.4
PhD training
Courses Year Workload (ECTS)
Expanded Disability Status scale training 2014 0.2
Introduction into Data analysis (NIHES) 2014 0.7
Excel basic workshop (MolMed) 2014 0.3
Basic genetics (MolMed) 2014 0.6
Basic SNPs course (MolMed) 2014 2.0
Research Integrity 2015 0.3
Introduction in GraphPad Prism 2015 0.3
Basiscursus Regelgeving Klinisch onderzoek (BROK) 2016 1.4
Survival Analysis (MolMed) 2016 0.6
Microbiome (MolMed) 2016 0.5 
Advanced Immunology (MolMed) 2017 1.5
Biomedical English writing and communication 2017 4.0
Oral presentations
Childhood-onset MS; Regionaal MS symposium; Maasstad ziekenhuis, 
Rotterdam 
2014 1.2
Neuromyelitis optica spectrum disorders; ErasMS Rotterdam 2014, 2017 1.2
Disease course and outcome of children with ADEM followed by optic neuritis; 
International Child Neurology Congress, Amsterdam
2016 1.2
Prediction of pediatric MS: bands do aid; Meeting of the Dutch MS Research 
Foundation 
2016 1.2
Disease course and outcome of children with ADEM followed by optic neuritis; 
Meeting of the Dutch MS Research Foundation
2016 1.2
Soluble CD27 in pediatric ADS; Voorjaarsvergadering NVKN 2017 1.2
Validation of the McDonald 2017 criteria for MS in children; 
Voorjaarsvergadering NVKN
2018 1.2
Poster presentations
ECTRIMS (5 posters) 2015-2017 5.0
International Child Neurology Congress, Amsterdam 2016 1.0
Meeting of the Dutch MS Research foundation, Amsterdam 2016 1.0
Wetenschappelijke vergadering, Nunspeet 2017 1.0
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(Inter)national conferences
Congress of the European Committee of Treatment and Research in MS 
(ECTRIMS); Boston (2014), Barcelona (2015), London (2016), Paris (2017)
2014-2017 4.0
Meeting of the Dutch MS Research foundation 2015, 2016 1.0
International Child Neurology Congress, Amsterdam 2016 1.0
MS symposium VUMC, Amsterdam 2016, 2017 1.0
Wetenschappelijke vergadering NVN 2017 0.5
Voorjaarsvergadering NVKN 2017, 2018 1.0
2. Teaching
Lecturing
Lectures ‘Acquired demyelinating syndromes in childhood’ and 
‘Treatment of childhood-onset MS’, medical students, minor in pediatric 
neurology, Erasmus MC, Rotterdam 
2014, 2015, 2017 1.0 
Supervising/guiding (master) students
Guiding pre-university students in their final school year with their research 
paper on pediatric MS (Aleid Bax, Sammie Yam)
2015 1.0
C. Louk de Mol, January 2017-May 2018, Clinical Research Master (NIHES), 
Rotterdam 
2017-2018 10.0
3. Other
International investigators meeting PARADIGMS (Fingolimod vs Avonex) trial, 
Frankfurt, Germany 
2014 1.0
Organizer of the ‘Symposium for neuroimmunological disorders in children’, 
Rotterdam 
2016 1.5
Sub-investigator in clinical trials for pediatric MS 
Fingolimod (PARADIGMS), Teriflunomide (Aubagio)
2014-2018 2.0
Co-investigator in clinical trials for adult RRMS and PPMS (Fingolimod, 
Ocrelizumab, BIIB033)
2014-2018 1.5
Total ECTS 36.4
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6.5
LIST OF ABBREVIATIONS 
ACE    Academic centers of Excellence 
ADEM   acute disseminated encephalomyelitis 
ADEM-ON   acute disseminated encephalomyelitis followed by (recurrent) optic 
neuritis 
ADS    Acquired demyelinating syndromes
AID    Auto-immune disease 
AQP4   Anti-aquaporin 4
ARR   Annualized relapse rate 
CBA   Cell-based assay 
CDMS    Clinically definite multiple sclerosis 
CIS   Clinically isolated syndrome
CNS   Central nervous system 
CSF   Cerebrospinal fluid 
DIS    Dissemination in space 
DIT    Dissemination in time
DMT    Disease modifying therapy 
DMFI    Delta mean fluorescence intensity 
EDSS   Expanded disability status scale 
ELISA   Enzyme-Linked Immuno Sorbent Assay
FACS   Fluorescence activated cell sorting 
FLAIR    Fluid-attenuated inversion recovery 
FU   Follow-up 
HEK293    Human embryonic kidney cell line 
HR   Hazard ratio 
HRQoL   Health-related quality of life 
ICU    Intensive care unit
IgG / IgM  Immunoglobulin G and immunoglobulin M
IMT   Immunomodulatory treatment 
IPMSSG   International Pediatric Multiple Sclerosis Study Group 
IvIG   Intravenous immunoglobulins 
IvMP    Intravenous methylprednisolone 
LETM    Lontigudinally extensive transverse myelitis 
LN18    Human malignant glioma cell line
LP   Lumbar puncture 
LUTD   Lower urinary tract dysfunction
MDEM   Multiphasic ADEM 
MMF   Mycophenolate mofetil 
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MOG   Myelin oligodendrocyte glycoprotein 
Mono-ADS  Monophasic ADS 
MRI    Magnetic resonance imaging 
MS   Multiple sclerosis 
NfL    Neurofilament Light chain 
NMOSD   Neuromyelitis optica spectrum disorders 
NPA   Neuropsychological assessment 
OCB   Oligoclonal bands 
ON   Optic neuritis 
OND   Other neurological diseases 
OPT    Oral prednisone taper 
PROUD-kids    PRedicting the OUtcome of Demyelinating syndromes in children 
study 
SC   Spinal cord 
sCD27   Soluble CD27 
SD    Standard deviation 
SPMS   Secondary progressive multiple sclerosis 
RDS   Relapsing demyelinating disorder 
RTX   Rituximab 
RON   Relapsing optic neuritis 
RR   Relative risk 
RRMS   Relapsing remitting multiple sclerosis 
TM    Transverse myelitis 
TTFR   Time to first relapse 
VA   Visual acuity 
WBC   White blood count
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6.5
MOVING FORWARD ON ACQUIRED 
DEMYELINATING SYNDROMES
DIAGNOSIS, DISEASE COURSE AND OUTCOME
Acquired demyelinating syndromes (ADS) 
encompass a broad spectrum of inflammatory 
demyelinating disorders of the central nervous 
system. This thesis focuses on two rare groups 
of patients in the ADS spectrum: neuromyelitis 
optica spectrum disorders (NMOSD) in adults 
and the spectrum of childhood onset ADS. 
Accurate diagnosis and prediction of disease 
course is imperative for accurate counselling 
and treatment opportunities. We aimed to 
move forward on the spectrum of ADS by 
investigating predictive factors for an accurate 
diagnosis and by describing the disease course 
and outcome of these patients.
